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Abstract
The primary objective of these experiments was to examine the function and distribution of 
the a  1-adrenoceptor (ai-AR) subtypes in the mouse carotid artery. The aims were 
achieved by using wire myography for the functional studies and confocal microscopy for 
the studies of ai-A R  distribution. For both types of study, single and double knockouts of 
the a i “AR subtypes were employed, in addition to phaimacological analysis, to provide an 
insight into the ai-ARs in the wild type (WT) mouse.
The aim of the first two studies presented in this thesis (Chapters Three and Four) was to 
establish whether an aiA-AR-mediated and/or ais-AR-mediated conti'actile response exist 
in the mouse carotid artery, in addition to the predominant am-AR. It was found that the 
aiA-AR had a contractile role in this vessel based on phaimacological analysis in the WT 
mouse and knockout mice. Firstly, an ai-AR-mediated contractile response was identified 
in the aiB/o-KO. Secondly, the ocm-AR and another ai-A R subtype were identified as 
mediating the phenylepMne-induced response by employing subtype selective antagonists. 
Thirdly, the A-61603-induced response was found to be mediated by the aiA-AR and the 
aiD-AR using subtype selective antagonists. This also demonstrated that this au -A R  
selective agonist had an action on the am-AR, In the absence o f am-AR selective 
compounds, compaiison of the agonist responses in the WT mouse and knockout mice 
revealed that a minor a m-AR-mediated response was also present. Thus, the am-AR 
predominantly mediates the vasoconstriction of the mouse carotid artery but the aiA-AR 
and aiB-AR appear to contribute to the contractile response.
The aim of Chapter Five was to assess the effect of nitric oxide (NO) on the ai-AR- 
mediated contractile response in the mouse carotid artery. The contractile response to both 
phenylephrine and A-61603 was augmented by the nitric oxide synthase inhibitor L- 
NAME. This suggested that the ai-AR-mediated contractile response was suppressed by 
NO. An attempt was made to determine whether NO was released spontaneously in this 
vessel or in response to ai-A R stimulation. There was no evidence of constitutive NO 
release. The effect of L-NAME was greater with increasing concentrations of ai-AR 
agonist and a non-adrenergic response was shown to be unaffected by L-NAME. From 
these findings it is evident that in the mouse carotid artery activation of ai-ARs triggers 
NO release, which suppresses the ai-AR-mediated contractile response.
3
Chapter Six aimed to examine the distribution of the ai-AR subtypes in the media of the 
mouse carotid arteiy, A protocol was developed to determine optimum conditions to 
visualise the binding distribution of the fluorescent ai-AR ligand Quinazoline Piperazine 
Bodipy (QAPB) in the media of this vessel. Comparison of QAPB binding in the WT 
mouse with the ai-AR knockout mice demonstrated that the aio-AR was a major 
component of the ai-AR population. The use of non-fluorescent subtype selective 
antagonists to compete for QAPB binding sites revealed that the aiA-AR and am-AR also 
appeared to exist in the media of the WT mouse. Comparison of the QAPB subcellular 
binding distribution in the WT mouse and knockout mice suggested that the am-AR may 
be predominantly located on the cell surface, while, in the absence of the atB-AR, the aiA- 
AR and am-AR may be predominantly located at intracellular sites.
The final study in this thesis (Chapter seven) aimed to establish whether ai-ARs exist on 
the endothelium of the mouse carotid artery. Evidence of ai-ARs on endothelial cells (EC) 
was found both in the WT and knockout mice through the use of QAPB and non- 
fluorescent subtype selective antagonists. The proportion of EC with QAPB binding was 
reduced in the knockout mice indicative of the loss of an entire ai-AR population 
compared to the WT mouse. Comparing QAPB binding in the WT mouse and knockout 
mice in the presence of the non-fluorescent antagonists provided evidence that all three ai~ 
AR subtypes are present on the endothelium in the carotid artery of the WT mouse.
Collectively, the findings of the studies presented in this thesis demonstrate that all three 
ai-ARs are present and are functional in the mouse carotid artery. The am-AR is 
confirmed as being the predominant conti’actile ai-AR subtype but both the ajA“AR and 
aiB-AR do have minor contractile roles in this vessel. Furthermore, the activation of ai- 
ARs on the endothelium may result in the release of NO and subsequently cause the 
suppression of the a i-AR-mediated contractile response.
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Chapter 1 General Introduction
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Adrenoceptors regulate the actions of the endogenous catecholamines noradrenaline (a 
neurotransmitter) and adrenaline (a hormone) in many physiological processes in both the 
central and peripheral nervous system. In the peripheral nei-vous system adrenoceptors 
mediate a variety of processes, such as vascular tone, glycogenolysis and cardiac 
contraction. The role of adrenoceptors in vascular tone shall be examined in this thesis.
1.1. Adrenoceptor classification
In 1905, Dale reported that adrenaline produced vasoconstriction, which resulted in a rise 
in blood pressure and vasodilation. These early experiments were the first to associate 
adrenaline with the concept of a receptor and were the initial steps in the identification of 
adrenoceptors. In 1948, Ahlquist studied the effects of catecholamines on physiological 
responses in isolated tissues and proposed that two adrenoceptor subtypes existed, which 
were designated alpha (a) and beta ({3). This designation was based on different potency 
series for the catecholamines: the potency series for a-ARs was adrenaline = noradrenaline 
> isoproterenol, and for (3-ARs was isoproterenol > adrenaline > noradrenaline. This 
subdivision of adrenoceptors was later confirmed when phentolamine and ergotoxine were 
shown to selectively antagonise a-ARs, while dichloroisoprenaline (Powell & Slater, 
1958) and propranolol (Black et al, 1964) blocked p-ARs. Two p-ARs subtypes were 
then identified and classified as Pi and P2 (Lands AM et al, 1967;Furchgott, 1967). A 
study by Brown and Gillespie (1957) reporting that the a-AR antagonists dibenaraine and 
phenoxybenzamine increased noradrenaline release by nerve stimulation, together with a 
study by Starke (1972), lead to the identification of pre-junctional a-ARs. The a-ARs 
were subsequently subdivided into subgroups based on their anatomical location: ai-ARs 
were labelled post-junctional and az-ARs pre-junctional (Langer, 1974). An alternative 
classification designating a-ARs according to function was proposed, in which ai-ARs 
mediated the excitatory responses, while az-ARs mediated inhibitory responses 
(Berfhelsen & Pettinger, 1977). This classification was superseded by a classification 
based on the potency of agonists and antagonists for a-ARs (McGrath, 1982b;Bylund DB 
et al, 1994;Hieble et al, 1995). ai-ARs could be activated by rnethoxamine, cirazoline or 
phenylephrine and inhibited by prazosin, WB4101 or corynanthine. az-ARs could be 
activated by a-methylnoradrenaline, UK-14304, B-HT920 or B-HT933 and inhibited by 
yohimbine, rauwolscine or idazoxan az-AR. It later became evident that heterogeneous 
subgroups existed within both the ai-AR and az-AR subtypes.
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The ai-ARs were the first to be subclassified. Based on functional studies, McGrath et a l 
(1982a) proposed that the ai-ARs be further subdivided on the basis of agonist selectivity. 
Furthermore, Morrow and Creese (1986) proposed two ai-AR subtypes: aiA-ARs and aiB- 
ARs based on differences in affinity for WB4101 and phentolamine in radioligand binding 
assays. The existence of these ai-AR subtypes was supported by subsequent studies, 
which identified antagonists showing selectivity for what was then considered to be the 
aiA-AR over the am-AR (Gross et al, 1988;Minneman et al, 1988).
From the late 1980s, the development of molecular cloning techniques and drugs with 
improved selectivity aided the subclassification of adrenoceptors. Molecular cloning 
techniques were used to identify four ai-AR subtypes which were designated aia, am, aic 
and aid. Uppercase and lowercase are used to designate the ai-AR subtypes defined by 
pharmacological and molecular techniques, respectively. The am-AR was the first ai-AR 
cloned (Cotecchia et al, 1988) and has since been shown to conespond to the 
pharmacologically defined am-AR (Heible JP et al, 1995b). However, the other subtypes 
cloned were inconsistent with those that had been characterised pharmacologically or by 
radioligand binding. The cloned am-AR was thought to be a novel subtype (Schwinn et 
al, 1990) but subsequent studies showed it was a homologue of the existing am-AR 
subtype (Perez et al, 1994;Rokosh et al, 1994;Price et al, 1994a;Pimoule et al, 1995;Laz 
et al, 1994) and was reclassified as aiA-AR (Heible JP et al, 1995a). It was determined 
that the clone initially identified as am-AR was a novel subtype (Ford et al, 1994;Perez et 
al, 1991;Lomasney et al, 1991) and was classified as the am-AR (Bylund DB et al,
1994). In addition, ai-ARs showing low affinity for prazosin were identified and 
classified as am-AR (Flavahan & Vanhoutte, 1986). It has been proposed that the am-AR 
may be a different conformational state of the a^-A R  (Ford et al, 1998;Marti et al, 
2005).
The az-ARs were subdivided into azA-AR, azs-AR and azc-AR largely based on 
radioligand binding assays (Bylund et al, 1988), corroborated by molecular cloning 
(Regan et al, 1988;Bylund DB et al, 1994). Molecular cloning also revealed an azo-AR 
subtype in rodents, which was later found to be a species homolog of the human azA-AR 
and is now referred to as the azA/o-AR (Bylund DB et al, 1994).
The pharmacological subdivision of the p-ARs into pi-ARs and pz-ARs was also verified 
by molecular cloning (Frielle et al, 1987;Dixon et al, 1986). A new subtype termed the
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Ps-AR was also cloned (Arch et al, 1984). In addition, the P4-AR subtype was proposed 
(Bylund DB et al, 1994) but was not cloned. Consequently, it is now recognised that the 
p4-AR is a novel state of the Pi-AR (Granneman, 2001).
Adrenoceptors have now been characterised as three major subtypes, each containing 
heterogeneous subgroups: ai-AR (a^-AR, am-AR and am-AR), az-AR (azA-AR, azB- 
AR and azc-AR) and P-AR (pi-AR, pz-AR and P3-AR). The ai-AR subtypes are of key 
interest to this thesis.
1.2. ai-AR compounds
1.2.1. ai~AR agonists
The catecholamine noradrenaline is classed as a non-selective adrenoceptor agonist as it 
activates ai-ARs, az-ARs and P-ARs with similar potencies (Knepper et al., 1995). 
However, it has been demonstrated using radioligand binding assays that noradrenaline had 
20-times higher affinity for am-ARs compared to a;A-ARs and am-ARs (Minneman et 
al, 1994).
Phenylephrine is a non-selective ai-AR agonist, which can enable the ai-AR response to 
be studied in isolation. It should be noted that in some studies phenylephrine was more 
potent for the am-AR than the other ai-AR subtypes (Knepper SM et al, 1995;Perez et 
al, 1991;Lomasney et al, 1991;Minneman et al, 1994). It has been suggested that the 
variations in the potency of phenylephrine may be due to differences in receptor 
populations in different tissues and species (Minneman et al, 1994).
The development of selective compounds for the aiA-AR subtype has proved more 
successful than for the am-AR or am-AR subtypes, which do not have any effective 
selective agonists at present. There are a limited number of aiA-AR selective agonists 
available, including A-61603 (Knepper SM et al, 1995).
The potential use of A-61603 as a potent a  1 a-A R  selective agonist was first reported by 
Knepper and colleagues (1995), who studied A-61603 in a variety of tissues believed to 
have a predominance of a  1 A-ARs: the rat submaxillary gland (Michel et al, 1989); the rat 
vas deferens (Honner & Docherty, 1999;Aboud et al, 1993); the canine prostate (Goetz et
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al, 1994); and the cloned bovine am-AR (Schwinn et al., 1990). This was compared to the 
A-61603~induced response in am-AR sites(cloned hamster am-AR (Cotecchia et al., 
1988)) and am-AR sites (cloned rat am-AR (Perez et al., 1991)). Radioligand binding 
suggested A-61603 had increased affinity for the aiA-AR sites by 35-125-times compared 
to am-AR sites and 45-150-times than the am-AR. Similarly, radioligand binding 
experiments showed that A-61603 had 20 times increased affinity at the canine prostate 
a  1 A-AR than the am-AR of the rat spleen and had over 300 times higher affinity compared 
to the am-AR of the rat aorta (Knepper et al., 1995). Furthermore, in functional 
experiments, for instance, at the rat vas deferens aiA-AR indicated A-61603 was 60 times 
more potent than the am-AR of the rat spleen and over 1000 times more potent than the 
am-AR of the rat aorta (Knepper et al., 1995). The decreased potency of A-61603 at both 
am-AR and am-AR sites, reported by Knepper et al. (1995), has been supported by 
several other studies. For instance, a recent study using the mouse myocardium, which is 
believed to have aiA-ARs and am-ARs but no am-ARs, the lack of response to A-61603 
in the trabeculae from the aiA-KO provided evidence that A-61603 did not stimulate the 
am-AR (McClosskey et al., 2002). Similarly, despite producing a pressor response in the 
wild type (WT) mouse, A-61603 did not alter the baseline heart rate and mean arterial 
pressure in the aiA-KO (Rokosh and Simpson, 2002), in agreement with A-61603 having 
minimal effect on the am-AR and am-AR. In addition, in the aiBo-KO, where the only 
possible ai-AR is the aiA-AR, the pressor response to A-61603 was comparable to the WT 
mouse verifying selectivity for the a  % A-AR (Hosoda et al., 2005).
In radioligand binding studies, the affinity of A-61603, compared to phenylephrine and 
noradrenaline, at the aiA-AR sites, revealed that A-61603 had 30-100-fold higher affinity 
than phenylephrine and 15-25-times higher affinity than noradrenaline (Knepper et al., 
1995). The increase in affinity identified in the radioligand binding data was also observed 
in functional experiments, which showed that A-61603 was 160-300-fold more potent than 
phenylephrine and 130-200-fold more potent than noradrenaline at the aiA-AR sites 
(Knepper et al, 1995). In a study of the rat vas deferens, Honner and Docherty (1999) 
reported potency values for A-61603, noradrenaline and phenylephrine that support those 
obtained by Knepper et al. (1995). Additional functional studies also showed that A-61603 
was more potent than noradrenaline and phenylephrine in various vessels where the aiA- 
AR was considered to be dominant. For instance, in human subcutaneous resistance 
arteries, A-61603 demonstrated ten-fold higher potency than noradrenaline and was 54- 
fold more potent than phenylephrine (Jarajapu et al., 200Id).
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Rnepper et al. (1995) also reported that the potency of A-61603 compared to noradrenaline 
and phenylephrine was less substantial at the aie-AR and the aip-AR. For instance, A- 
61603 was only 40 times more potent than phenylephrine at am-AR sites, compared to 
160-300 at aiA-AR sites, and only 30 times more potent than noradrenaline, as opposed to 
130-200 times higher potency at aiA-AR sites. Furtheiraore, at the am-AR in rat aortic 
rings A-61603 was 30-fold less potent than phenylephrine and over 500-times less potent 
than noradrenaline. Thus, there is considerable evidence that A-61603 shows higher 
potency than noradrenaline and phenylephrine at aiA-AR sites and lower potency at am- 
AR and am-AR sites.
There is, therefore, substantial evidence for the effectiveness of A-61603 as an aiA-AR 
agonist. However, it should be noted that A-61603 is an imidazoline and can act through a 
non-adrenoceptor-mediated mechanism in some vessels (Willems et al, 2001). The A- 
61603-induced contiactile response in the carotid arteriovenous anastomes of the pig was 
not characterised despite the activation of ai-ARs, az-ARs, 5-HTib/d receptors, 5-HTz 
receptors and eicosanoid receptors being excluded.
1.2.2. a^AR selective antagonists
Prazosin is a non-selective ai-AR antagonist (Hanft & Gross, 1989;Ford et al, 1994). In 
the vast majority of studies prazosin acts as a competitive reversible antagonist. However, 
agonist curves with depressed maximum responses and nonparallel shifts have been 
reported in the rat aorta (Alosachie & Godffaind, 1988;Doggi*ell, 1992) and murine aorta 
(Yamamoto & Koike, 2001b). In addition, although being classed as a non-selective 
antagonist, there is evidence from IP accumulation experiments that prazosin shows some 
selectivity for the am-AR and am-AR over the aiA-AR (Williams et al, 1999).
WB 4101 was the first compound classed as an aiA-AR selective antagonist (Morrow & 
Creese, 1986) and showed 20-fold selectivity for what was then termed the aiA-AR over 
the aiB-AR. However, the ai-AR subtype referred to in this study as the aiA-AR was 
redesignated as the am-AR. In fact, subsequent studies have demonstrated that WB 4101 
has high affinity at both the aiA-AR and the aio-AR (Perez et al, 1991;Schwimi et al, 
1995;Weinberg et al, 1994). Since the identification of WB 4101, several other œia-AR 
selective antagonists became available, such as 5-methylurapidil (Gross et al, 1988), 
KMD-3213 (Shibata et al, 1995), RS 17053 (Ford et al., 1996), tamusolin (Foglar et al.,
1995), Rec 15/2739 (Leonardi et al., 1997) and RSlOO 329 (Williams et al, 1999). The
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selectivity of 5-methylurapidil and RSI00 329 has been examined in more detail for the 
puiposes of this thesis.
5-methylurapidil has been used as an aiA-AR selective compound in both radioligand 
binding assays (Gross et at, 1988;Yoshio R et al, 2001) and functional experiments 
(Kong et al, 1994;Daniel et al, 1999;Yang et al, 1998;Argyle & McGrath, 2000;Perez et 
al, 1994). 5-methylurapidil displayed approximately 100-fold higher affinity for œia-ARs 
in the rat hippocampus, heart and vas deferens over aie-ARs in the rat liver and spleen 
(Gross et al, 1988). It has also been shown that 5-methylurapidil has intermediate affinity 
for the aiD-AR (Kenny et al, 1995;Perez et al, 1991;Schwinn et al, 1995). In the 
literature, in rat and mouse vessels in which the aiA-AR is predominant, affinity estimates 
for 5-methylurapidil ranged from 8.0 to 9.2 (Daly et al, 2002a;Buckner et al, 
1996;Gisbert et al, 2003;Shibano et al, 2002;Zacharia et al, 2004;Kamikihara et al, 
2005;Lachnit et al, 1997). In vessels of these rodents in which the aio-AR predominates, 
affinity estimates ranged from 7.5 to 8.3 (Daly et al, 2002a;Kenny et al, 1995;Aboud et 
al, 1993;Buckner et al, 1996;Testa et al, 1997;Gisbert et al, 2003). With the overlap in 
affinity estimates it is clear that 5-methylurapidil does not clearly differentiate the aiA-AR 
from the am-AR.
An alternative œia-AR selective antagonist, RSI00329, has been reported to have 126-fold 
increased selectivity for the aiA-AR over the am-AR and 50-fold over the am-AR in 
radioligand binding studies (Williams et al, 1999) and has been increasingly used in recent 
studies. The reported affinity of RSI00 329 in the mouse vas deferens, in which the aiA- 
AR predominates was 9.6 (Cleaiy et al, 2003), while in the rat aorta, in which the am- 
predominates an affinity estimate of 7.9 was reported (Williams et al, 1999).
Only one antagonist is available that is selective for the a^-A R  over the œia-AR and the 
aiB-AR. BMY 7378 has been shown to competitively antagonise am-ARs with 100-fold 
higher selectivity over both the aiA-AR and aie-AR (Goetz et al, 1995;Saussy et al,
1996). Affinity estimates ranging from 8.3 to 9.6 have been reported from vessels in the 
rat and mouse which are predominantly am-AR (Daly et al, 2002a;Iiosoda et al, 
2005b;Tanoue et al, 2002b;Yamamoto & Koike, 2001b). In comparison, in the rat and 
mouse affinity estimates for BMY 7378 in vessels where the aiA-AR predominates ranged 
from 5,8 to 6.7 (Shibano et al, 2002;Gisbert et al, 2003;Lachnit et al, 1997;Kamikihara et 
al, 2005;Zacharia et al, 2004). It should be noted that BMY 7378 acts as a partial agonist 
at the 5-HTiA receptor . Furthermore, a recent study reported that at concentrations greater
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than 0.3 pM BMY 7378 acted as an antagonist at the azc-AR (Cleary et al, 2005). 
Nevertheless, BMY 7378 is widely used to identify aio-ARs (Hosoda et al, 2005b;Daly et 
al, 2002a;Tanoue et al, 2002b;Yamamoto & Koike, 2001b).
There is a distinct lack of am-AR selective antagonists. Chloroethlyclonidine was initially 
classified as an am-AR selective antagonist (Han et al, 1987), showing approximately 5- 
fold higher affinity for the am-AR over what was then considered to be the aiA-AR in 
radioligand binding and functional experiments, and 3-fold higher affinity for the am-AR 
over the am-AR (Kenny et al, 1995;Michel et al, 1989;Schwinn et al, 1995). However, 
there is substantial evidence that chloroethlyclonidine alkylated all of the ai-AR subtypes 
and could not be classed as an am-AR antagonist (Perez et al, 1994;Lomasney et al, 
1991;Schwiim et al, 1990;Hirasawa et al, 1997). Several other compounds have been 
proposed as potential am-AR selective antagonists, based on radioligand binding studies, 
such as spiperone (Bylund et al, 1994), respiperone (Sleight et al, 1993), cyclazosin 
(Giardina et al, 1996) and AHlll lOA (Saussy et al, 1996). However, these compounds 
proved to be only moderately selective for the am-AR over the aiA-AR and am-AR, or 
discrepancies were found between binding and functional studies (Stam et al, 
1998;Giardina et al, 2003;Eltze et al, 2001;Giardina et al, 2003;Schwinn et al, 1995).
It is clear that agonists and antagonists with clear selectivity for the individual aj-AR 
subtypes are still required. Despite the current attempts to develop new compounds, the 
lack of subtype selective compounds hinders the pharmacological characterisation of ai- 
ARs. The subtype selectivity of the compounds used will be assessed throughout the 
studies described in this thesis.
1.3. ai-AR signalling
Adrenoceptors are G-protein coupled receptors, which consist of seven transmembrane 
spanning domains and are connected by three intracellular and three extracellular loops. 
The tiansmembrane domains are highly conserved between ai-AR subtypes, but the C- 
terniinus and N-terminus differ (Graham et al, 1996;Faure et al, 1994a). Stimulation of 
ai-ARs produces cellular responses by initiating multiple signalling pathways, which can 
vaiy depending on the guanine nucleotide binding protein (G protein) that the ai-AR 
subtype couples to.
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The Gq/ii family is the predominant G-protein for all three ai-AR subtypes (Wu et al, 
1992). Upon stimulation, the ai-ARs couple to the Gq/n, which usually results in the 
activation of phospholipase C. Once activated, phospholipase C catalyses the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate, producing the second messengers inositol-1,4,5- 
tiisphosphate (IP3) and diacylglycerol (DAG). IP3 stimulates the release of intracellular 
calcium ([Ca^’^ Ji) from internal stores and DAG activates protein kinase C. Differences in 
the coupling of the ai-AR subtypes to this signalling pathway are apparent. For instance, 
Schwinn et al. (1991) showed that the aiA-AR activates IP3 formation more efficiently than 
the aiB-AR. Furtheniiore, subsequent studies reported that the aiA-AR is efficiently 
coupled to IP3, while the am-AR is poorly coupled (Schwinn et al, 1995;Theroux et al, 
1996;Taguchi et al, 1998;Gisbeit et al, 2000;Garcia-Sainz & Villalobos-Molina, 2004). 
Interestingly, this contrasts with native cells in which the am-AR appears to be particularly 
well coupled relative to the am-AR.
In addition to phospholipase C, ai-ARs have been shown to activate phospholipase Az 
(Perez et al, 1993), phospholipase D (Ruan et al, 1998), voltage-dependent and 
independent Ca^^-channels leading to Ca^  ^ influx (Minneman, 1988) and mitogen- 
activated protein kinase (Williams et al, 1998).
1.4 . ai-AR subcellular localisation
1.4.1. Unstimulated cells
The development of antibodies specific to the ai-AR subtypes have enabled the 
localisation of ai-AR proteins to be identified. One of the first studies to use this approach 
was performed in unstimulated Chinese hamster ovary (COS-7) cells and reported a 
difference in the localisation of the am-AR and am-AR: a predominance of the am-AR 
intracellularly and the am-AR on the cell surface (Hirasawa et al, 1997). A later study in 
rat-1 fibroblasts and cells cultured from the femoral and renal arteries, identified all three 
ai-ARs on both the cell surface and inside the cell (Hrometz et al, 1999). However, the 
am-AR was most visible on the cell surface, while the localisation of the am-AR and am- 
AR was less clear. McCune et al. (2000) agreed that the am-AR was predominantly 
located on the cell surface in unstimulated rat-1 fibroblasts. This study also reported that 
the am-AR was mainly intracellular. A more recent study employed ai-AR antibodies in 
transfected human embryonic kidney (HEK-293) cells to investigate the effect of ai-AR
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heterodimers on subcellular localisation (Uberti et al, 2003). It was found that the am-AR 
could dimerise with the am-AR and am-AR. In particular, the am-AR/am-AR dimer 
resulted in a reduction in the intracellular expression, and an increase in the cell surface 
expression, of the am-AR.
Green fluorescent protein (GFP) is an autofluorescent protein that can be attached to 
recombinant receptors to examine receptor localisation. The use of ai-AR-GFP-tagged 
receptors in COS-7 transfected cells revealed that the ato-AR was predominantly found on 
the cell surface and that am-ARs were predominantly located at intracellular sites 
(Hirasawa et al, 1997). This was in agieement with the findings of the studies using ai- 
AR antibodies. However, a subsequent study using transfected HEK 293 cells reported the 
predominance of both the am-AR-GFP and am-AR-GFP on the cell surface and found 
that the am-AR-GFP was intracellular (Chalothom et a l, 2002). Hague et û/.(2004a) also 
demonstrated that the am-AR was mainly intracellular in HEK 293 cells, as well as in rat 
aortic smooth muscle cells and CHO cells. This study suggested that the limited cell 
surface expression of the am-ARs-GFP in HEK 293 cells was due to a long N-tenninus. 
This was demonstrated by a reduction in the binding site density of the am-AR and am- 
AR when the N-terminus of these subtypes was replaced with that of the am-AR. 
Furthermore, the cell surface expression of the am-AR was improved when the am-AR N- 
terminus was shortened or substituted with the N-terminus of the am-AR (Hague et al, 
2004a).
BODIPY fluorescent prazosin (Quinazoline Piperazine Bodipy (QAPB)) is a usefril tool 
for the study of the subcellular localisation of ai-ARs as it is a green fluorescent ligand 
with high affinity for ai-ARs. Using QAPB in rat-1 fibroblasts transfected with the aw- 
AR, ai-ARs have been detected both intracellularly and on the cell surface (Daly et al, 
1998). This was also demonstrated in a subsequent study in live rat basilar SMCs 
(McGrath et a l, 1999). Furthermore, in human SMCs the population of intracellular ai- 
ARs detected at intracellular sites was quantified as approximately 40% of the total 
population of ai-ARs (Mackenzie et a l, 2000). A subsequent study using QAPB in 
transfected COS-7 cells reported that the aia-AR was predominantly inside the cell and the 
aib-AR mostly localised on the cell surface, although some evidence of intiacellular am- 
ARs was reported (Sugawara et a l, 2002). This supports previous results by that gioup 
using GFP-tagged ai-ARs (Hirasawa et a l, 1997). A recent study in the mouse mesenteric 
arteiy found that the am-AR was located on both the cell surface and intracellularly
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(McBride et al Submitted for publication) in agreement with findings in isolated cells 
(Sugawara et a l, 2002). At present, no other studies have examined the subcellular 
location of ai-ARs in whole blood vessels.
The findings of the localisation studies using ai-AR antibodies, GFP-tagged ai-ARs and 
fluorescent ai-AR ligands are in general agreement. Collectively, they suggest that in 
unstimulated isolated cells the a^-AR is predominantly located on the cell surface and the 
aiA-AR and am-AR are predominantly located at intiacellular sites. However, all three 
aj-AR subtypes do appear to be present both on the cell membrane and inside the cell of 
most cell types.
1.4.2. Receptor cycle
The receptor cycle has been visualised using GFP-tagged receptors (Kallal & Benovic,
2000). Like other G-protein coupled receptors, ai-ARs are synthesised in the Golgi 
apparatus, where they are inserted into the cell membranes of intracellular vesicles. The 
intracellular vesicles transport the receptors to the cell surface and the vesicles fuse with 
membrane. At the cell surface, the receptors can be activated by agonists to produce 
functional responses. Subsequently, the receptors become phosphoiylated, resulting in 
inactivation. This is followed by internalisation, with the vesicles moving back to the 
perinuclear region, and recycled by dephosphoiylation or degraded in lysosomes.
There is evidence from immunohistochemishy to suggest that exposure to an agonist at the 
cell surface can stimulate the internalisation of the receptor and tianslocation to the 
perinuclear region. The majority of evidence is provided for the am-AR, which has been 
shown to internalise when exposed to noradrenaline (Fonseca et al, 1995;Hague et al, 
2004b), phenylephrine (McCune et a l, 2000) or adrenaline (Hague et a l, 2004b). 
However, Chalothom et a/.(2002) reported that upon stimulation, the proportion of am- 
ARs located inhacellularly increases, but there was little evidence of the am-AR 
undergoing agonist-induced internalisation. This study also found that internalisation was 
dependent on the stimulated receptors associating with aiTestin molecules and that the 
agonist-stimulated internalization of the am-AR was slower than the am-AR. It has been 
suggested that the lack of evidence for the agonist-induced internalisation of the am-AR 
may be due to a constitutively active am-AR resulting in the high proportion of am-ARs 
already being intracellular prior to agonist exposure (Chalothom et al., 2003).
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The fluorescent ligand QAPB has been used to study a i-A R  cycling in rat-1 fibroblasts 
and HEK 293 cells expressing the am -A R  (Pediani et al, 2005). It was found that QAPB 
bound the am -A R  on the cell surface, and was internalised with the receptor. However, 
the potential for QAPB acting as an agonist or inverse agonist has been discounted 
(Pediani et al, 2000). Therefore, the internalisation of QAPB bound to the am -A R  
appeared to be due to spontaneous endocytosis. It was shown that the bound QAPB was 
transported to perinuclear regions by vesicles and could be recycled back to the cell 
surface. In agreement with the subcellular localisation reported in previous studies 
(Hirasawa et a l, 1997;Sugawara et al, 2002), am -A R s were predominantly intracellular, 
consistent with the am -A R  moving between the cell surface and perinuclear 
compartments. Pediani et al. (2005) also reported that the internalisation of the am -A R  
relied on P-arrestins, which supports the study by Chalothom et a l (2002), since there was 
no evidence for the uptake of QAPB in P-arrestin deficient cells but there was evidence of 
QAPB and P-arrestin-2-GFP being colocalised.
In addition to examining the subcellular localisation of ai-ARs in unstimulated cells, ai- 
AR antibodies, GFP-tagged receptors for the ai-AR subtypes and ai-AR fluorescent 
ligands can be used to visualise ai-AR cycling. This evidence suggests that ai-AR 
intemalisation and the subsequent receptor cycling can be stimulated, by agonist binding, 
or can be spontaneous.
1.5. ai-AR tissue distribution
RT-PCR, RNase protection assays and Northern blotting can be used to study mRNA 
expression. Northem blotting and RNase protection assays can successfully detect mRNA 
for ai-AR subtypes in tissues (Garcia-Sainz et a l, 1994;Price et a l, 1994b;Price et a l, 
1994a), while RT-PCR can identify where the ai-AR subtypes are expressed as well as 
quantify the mRNA present (Scofield et a l, 1995). Radioligand binding is another 
common method to investigate receptor distribution. In contrast to Northem blotting and 
RNAse protection assays, radioligand binding detennines the distribution of ai-AR protein 
instead of mRNA.
ai -AR subtypes are distributed in a wide variety of tissues. The majority of evidence of 
ai-AR distribution has come from rats and humans. However, in recent years ai-AR 
expression has also been studied in the mouse (Cavalli et al., 1997; Alonso-Llamazares et 
al., 1995; Yang et al., 1998). In general, multiple subtypes are present in most tissues, but
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species heterogeneity is apparent in the distribution of ai-AR subtypes in some tissues. 
Therefore, an overview of the distribution of ai-ARs in the major organs and blood vessels 
of humans, rats and mice is described below.
1.5.1. Organs
The balance of evidence suggests that the human heart has a predominance of am-ARs 
(Price et a i, 1994a;Faure et al, 1995), while the rat heart has high levels of both am -A R  
and aiB-ARs expressed (Price et a l, 1994a;Garcia-Sainz et a l, 1994;Rokosh et a l, 
1994;Scofield et a l, 1995;Faure et a l, 1994b). Like the heart, the human liver appears to 
predominantly express the am -A R  (Price et a l, 1994a;Faure et a l, 1995;Garcia-Sainz et 
al, 1994). The rat liver has high levels of ais-AR expression (Garcia-Sainz et al, 
1994;Price et a l, 1994a;Rokosh et a l, 1994;Scofîeld et a l, 1995;Faure et a l, 1994b). 
While homogeneous populations of aiB-ARs have been identified in the mouse liver (Yang 
et al, 1998;Deighan et a l, 2004). It appears that am-ARs are expressed predominantly in 
the human spleen (Faure et a l, 1995;Price et al, 1994a;Scofield et al, 1995). Although a 
homogeneous population of am-ARs were detected in the rat spleen (Kong et al, 
1994;Michel et a l, 1993), Faure et al. (1994b) detected high levels of am-ARs. It has 
been shown that the human, rat and mouse lung have a predominance of am-ARs (Faure 
et al, 1995;Yang et al, 1998), however, high levels of am-ARs have also been detected 
in the rat lung (Faure et al, 1994b). Price et al. (1994a) reported that both the human and 
rat kidney had predominant am-AR expression. It has been reported that similar levels of 
am-AR and am-AR are expressed in the murine kidney (Yang et a l, 1998).
In general, expression of the ai-AR subtypes in the brain is high. It appears that, in 
humans, the cerebellum (Price et a l, 1994b;Faure et al, 1995) and the cerebral cortex 
(Price et al, 1994b;Faure et a l, 1995) have a predominance of am-ARs. In the rat, the 
cerebellum (Scofield et a l, 1995) has high levels of am-ARs. There are reports that the 
rat cerebral cortex shows a predominance of am -ARs (Perez et a l, 1991;Lomasney et al, 
1991), but Scofield et al. (1995) concluded that there was no dominant ai-AR subtype 
expressed in the rat cerebral cortex. The murine cerebellum has a predominance of am - 
ARs (Yang et a l, 1998;Papay et a l, 2004). While high levels of both the am -A R  and am 
-AR have been reported in the murine cerebral cortex (Yang et a l, 1998;Papay et al, 
2006;Papay et al, 2004).
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These studies demonstrate that the ai-ARs are distributed in a variety of tissues. Some 
differences do exist between species in the predominant ai-AR subtype expressed in some 
of the organs. However, in the human, rat and mouse, the balance of evidence suggests 
that the expression of the am-AR is higher than the am-AR and am-AR in the major 
organs.
1.5.2. Vascular smooth muscle
It has previously been established that all three a i-A R  subtypes are expressed in vascular 
smooth muscle (Miller et a l, 1996). However, approximately 90% of the total a% -A R  
m RNA expression in peripheral arteries appeared to be due to the am -A R  (Guarino et a l,
1996). Generally, expression of the am -A R  was highest, followed by the am -A R , and the 
am -A R  was lowest (Piascik et al, 1997). A  recent study in the rat demonstrated that the 
am -A R  was predominant in the thoracic aorta and mesenteric artery, the am -A R  was 
predominant in the tail and small mesenteric artery and the expression of the am -A R  was 
minimal (Marti et a l, 2005).
Blood vessels are composed of three layers: the adventitia, media and intima. The media 
consists of smooth muscle cells and elastic lamina, while the adventitia is made up of 
fibres, fibroblasts and nerve endings, and the intima is a single layer of endothelial cells. 
Recently, the relative distiibution of ai-ARs in the media and adventitia of the carotid 
arteiy and the aorta in the rat has been examined. In the aorta, the media and adventitia 
have been shown to express all three ai-AR subtypes (Faber et a l, 2001). The adventitia 
showed larger populations of am-ARs and am-ARs than the media, while am-ARs were 
in larger proportions in the media than adventitia. Faber and Yang (2006) reported similar 
findings in the carotid artery, in which greater proportions of am-ARs were detected in the 
media but the adventitia had greater proportions of am-ARs. However, in conhast to the 
thoracic aorta, the carotid artery had a greater proportion of am-ARs detected in the media 
than the adventitia. At present, there is no evidence of ai-AR expression on the 
endothelium of rat or mouse arteries.
The differing distr ibutions of the ai-subtypes suggest that the roles of the ai-AR subtypes 
in vasoconstriction differ. Nevertheless, the detection of the mRNA or protein cannot be 
taken as evidence that the ai-AR subtype is functional or point to that function.
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1.6. ai-AR vascular function
In most mammalian species, the contraction of vascular smooth muscle is principally 
mediated by ai-ARs (Guimaraes & Moura, 2001;Vargas & Gomian, 1995). Generally, a 
predominant ai-AR subtype has been assigned to each blood vessel but it appears that 
more than one ai-AR subtype can contribute to the contraction of a particular vessel. The 
ai-AR subtype mediating the contraction of a particular vessel is often comparable 
between species; though differences can exist (Buscher et a l, 1996). For this reason, the 
roles of ai-ARs in the arteries of both mice and rats are summarised below.
1 .6 .1 . cciA~AR
There is substantial evidence that am-ARs are the predominant subtype mediating the 
contraction of small, innervated resistance arteries. In the mouse, these vessels include 
mesenteric resistance arteries and tail arteries (Daly et a l, 2002a;Rokosh & Simpson, 
2002;Shibano et a l, 2002;Hedemann & Michel, 2002;Lachnit et a l, 1997). Similarly in 
rats, am-ARs appear to be the principal mediators of contraction in the tail arteiy (Ibarra et 
al, 2000) and small mesenteric arteries (Stassen et a l, 1998), as well as in the renal arteiy 
(Hrometz et a l, 1999). These findings suggested that the am-AR is a main mediator of 
vascular smooth muscle contraction. There is a lack of evidence for the am-AR being 
involved in the contraction of large, poorly inneivated conductance arteries in the mouse 
(Deighan C, 2002;Daly et a l, 2002a) and rat (Kenny et a l, 1995;Buckner et al, 1996). 
However, there is recent evidence to suggest that a minor am-AR-mediated response may 
exist in the thoracic aorta of the mouse (Hosoda et a l, 2005b;Lazaro-Suarez et a l, 2006) 
and the rat carotid artery (Chiba & Tsukada, 2002;Naghadeh, 1996 University of Glasgow 
PhD Thesis.). It is clear that evidence of an am-AR contractile response in conductance 
arteries is inconsistent and further investigation is required.
1.6 .2 . cxiD"AR
It appears that the predominant contractile receptor in large, non-inneivated conductance 
arteries is the am-AR. For instance, there is substantial evidence that in the mouse, am- 
ARs regulate the contraction of the thoracic aorta, carotid artery, femoral artery, iliac artery 
and superior mesenteric arteiy (Yamamoto & Koike, 2001b;Piascik et a l, 1997;Hrometz et 
a l, 1999;Daly et al, 2002a;Martinez L et a l, 1999;Tanoue et al, 2002c;Ali,
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2004;Deighan C, 2002;Jarajapu et a l, 2001a;Jarajapu et a l, 2001b;Lachnit et al, 
1997;Stasseii et a l, 1997). Similarly am-ARs mediate the contraction of the rat iliac 
artery, carotid artery, thoracic aorta, mesenteric artery, and renal artery (Hedemann J & 
Michel, 2002;Gisbert et al, 2000;Kenny et a l, 1995;Buckner et a l, 1996). The 
predominance of the am-AR in the media of conductance arteries is consistent with the 
evidence that it regulates the contraction of these vessels (Kenny et a l, 1995;Leech & 
Faber, 1996;Maitinez L et a l, 1999). In addition, there is increasing evidence that the am- 
AR shows constitutive activity in conductance arteries of the rat (Gisbert et al, 
2000;McCune et a l, 2000). It has been suggested that this activity may occur to prevent 
abrupt changes to the response when an agonist is added (Ziani et al, 2002). Until 
recently there was no evidence for the am-AR contributing to the contraction of small 
resistance arteries (Stassen et al, 1998;Hedemann J & Michel, 2002). However, evidence 
to suggest that the am-AR has a minor contractile role in the first order mesenteric arteries 
of the mouse, in addition to the predominant am-AR, has now been reported (McBride et 
al Submitted for publication). In addition to a dominant role in vasoconstriction, there is 
also evidence that the am-AR may regulate the hypertrophie growth of the smooth muscle 
cells, as demonstrated in the rat aorta (Xin et a l, 1997).
1.6.3. ccib“AR
In contrast to the am-AR and am-AR, there is a lack of evidence for a dominant role of 
the am-AR in the contraction of any murine blood vessels. However, there is evidence 
that the am-AR may contiibute to the regulation of the rat mesenteric arteiy in addition to 
the am-AR (Piascik et a l, 1997). Furthermore, the am-AR may have a small contribution 
to contraction of the murine thoracic aorta and carotid artery (see section 1.7.1.1.). 
Nevertheless, it has become evident that a more prominent role of the am-AR may be the 
regulation of smooth muscle cell growth (Chen et a l, 1995;Milano et a l, 1994;Vecchione 
et al, 2002) or vascular modelling (McGrath et a l, 2002). Additionally, am-ARs have 
been associated with the regulation of cardiac growth and contractile function (Chalothom 
et a l, 2003), as well as the regulation of skeletal muscle venules (Leech & Faher, 1996).
There is evidence that the am-AR mediates the contiactile responses in the rabbit aorta 
(Muramatsu et al, 1990;Oshita et a l, 1993), carotid artery (Muramatsu, 1991) and 
mesenteric artery (Muramatsu et al, 1990;Van der Graaf et a l, 1997). However, evidence 
of the am-AR in the rat is limited to the mesenteric resistance arteries (Van der Graaf et
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al, 1996) and there is no evidence to suggest am-ARs mediate contraction in murine 
arteries.
1.6.4. The murine carotid artery
To date, the availability of literature characterising the ai-AR-mediated contractile 
response in the murine carotid artery is limited. In an earlier PhD thesis, Deighan (2002) 
characterised the ai-AR-mediated contractile response in the mouse carotid artery, using 
hoth WT mice and the am-KO. Based on the high potency of the selective am-AR 
antagonist, BMY 7378, against the contractile response to phenylephrine, it was found that 
the am-AR was the predominant contractile receptor in this vessel. An a^-A R  
component to the contractile response was excluded due to the low affinity of 5~ 
methylurapidil and it was, therefore, concluded that the am-AR was most likely to 
contribute to the ai-AR contractile response, in addition to the dominant aio-AR (Deighan 
C, 2002). Nevertheless, no am-AR antagonists are available, which are adequately 
selective over the aiA-AR and am-AR. Thus, there was no direct evidence that the am- 
AR contributed to the contraction in the WT mouse. At present, the contributions of the 
aiA-AR and am-AR in the murine carotid artery are not fully resolved. It should be noted 
that the findings of Deighan (2002) have been published with some of the results from 
Chapter Four of this thesis (Deighan C et al, 2005).
1.7. Genetically altered mice
In the last decade, the use of mice to study vascular tissues has markedly increased due to 
the development mice with either a deletion or overexpression of a specific gene. With the 
limited number of compounds selective between ai-AR subtypes, mice with alterations to 
the ai-AR genes were developed as an alternative approach to characterise aj-ARs.
In the knockout mouse, the normal expression pattern can be disrupted, or the gene of the 
relevant ai-AR subtype can be replaced with a modified gene (Rohrer & Kobilka, 1998). 
A knockout mouse can be utilised to study the pharmacology of a major subtype in 
isolation, or to study a minor subtype in the absence of the predominant subtype. Single 
ai-AR knockout mice have been developed for the aiA-AR (Rokosh & Simpson, 2002), 
am-AR (Cavalli et a l, 1997) and am-AR (Tanoue et a l, 2002c). For each strain, the ai- 
AR gene was disrupted using homologous recombination in embryonic stem cells 
(O’Connell et a l, 2003;Tanoue et a l, 2002c;Cavalli et al, 1997).
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1.7.1.1. oc-fQ-'KO
The aiB“KO was the first ai-AR knockout to be created (Cavalli et al, 1997). The first 
exon of the am-AR gene was replaced with a deoxyiibonucleic acid cassette containing the 
neomycin resistance gene. The gene was then electroporated into 129Sv embiyonic stem 
cells and microinjected into C57/B1/6 blastocytes before being transferred to 
pseudopregnant females. The disrupted gene was bred into C57/B1/6 mice creating am- 
KOs and corresponding WT mice with mixed genetic backgiounds.
Cavalli et al. (1997) reported that in the am-AR knockout, the pressor response to 
phenylephrine was reduced and phenylephrine was less potent in the thoracic aorta 
compared to WT mice. From these findings it was proposed that the am-AR had a role in 
the regulation of blood pressure and that there was evidence for am-AR mediated 
vasoconstiiction. A later study by Daly et al. (2002a) found that the phenylephrine- 
induced response in the thoracic aorta, first order mesenteric arteiy and tail artery of the 
am-KO was not reduced, while, the carotid artery of the am-KO was more sensitive to 
phenylephrine. This study did not lule out the possibility of the am-AR contributing to 
vasoconstriction but, in contrast to Cavalli et al. (1997), suggested that the contribution 
was relatively small. Deighan (2002;Deighan et a i, 2005) provided further evidence that 
the am-AR had a minor role in vasoconstriction as the am-AR antagonist BMY 7378 was 
more potent in the carotid artery of the am-KO than the WT mouse. The findings of 
Hosoda et al. (2005a) were also consistent with the role of the am-AR in vasoconstriction 
being minor. For instance, the potency of noradrenaline and phenyleplirine was slightly 
reduced in the thoracic aorta but there was no change in resting blood pressure in the am- 
KO compared to the WT mouse. The balance of evidence from the am-KO suggests that 
the am-AR has a minor role in vasoconstiiction.
Cavalli et al. (1997) also perfonned radioligand binding assays and found that, in the am- 
KO, ai-AR expression was decreased in the liver, heart, kidneys and brain (Cavalli et al,
1997). The presence of the am-AR in the murine liver was confirmed by a subsequent 
radioligand binding study, which compared the WT mouse with the am-KO (Deighan et 
al, 2004). These findings are consistent with the expression of the am-AR in these organs 
reported in previous studies (Yang et a l, 1998).
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1.7.1.2. ocia“KO
The aiA-KO was generated by Rokosh and Simpson (2002), who replaced the entire first 
exon of the aiA-AR gene with the Escherichia coli (3-galactosidase gene Lac Z and the 
neomycin-resistance gene. Mouse 129Sv embryonic stem cells were then electroporated, 
selected for neomycin resistance and injected into C57/B1/6 blastocytes. The modified 
gene was bred into mice with FVB/N and C57/B1/6 backgrounds. Several generations of 
aiA-KOs have now been back-crossed to ensure that the mice have a congenic C57/B1/6 
background, enabling the potential for phenotypic differences to be excluded (Simpson, 
2006).
In the aiA-KO, resting blood pressure and the pressor response to both phenylephrine and 
A-61603 were reduced (Rokosh & Simpson, 2002), demonstrating that the aiA-AR has a 
prominent role in the regulation of arterial blood pressure. The Lac Z gene encodes for |3- 
galactosidase production, therefore (3-galactosidase staining was used as a marker for aiA- 
AR expression. Thus, evidence of p-galactosidase staining was found in both the heart and 
kidney of aiA-KO mice and radioligand binding showed that ai-AR expression was 
reduced in the heart, kidney and brain (Rokosh & Simpson, 2002), supporting the 
expression of the aiA-AR in these organs reported by Yang et al. (1998). Furthermore, 
evidence indicative of aiA-AR expression was found in resistance arteries, including the 
celiac, mesenteric, hepatic, tail, femoral, iliac and renal arteries. However, in the thoracic 
aorta, carotid artery and the subclavian arteiy, the absence of (3-galactosidase opposed the 
expression of aiA-ARs. These findings are consistent with the predominance of œia-AR in 
resistance arteries described in earlier studies (Kong et a i, 1994).
1.7.1.3. cciD~KO
The aiD“KO was generated by Tanoue et al. (2002c), who also used targeted gene 
disruption. In this case the residues coding for the first 61 amino acids of the first exon of 
the aiD“AR gene were replaced with a deoxyribonucleic acid cassette containing the 
neomycin resistance gene. The targeting vector containing the modified gene was then 
electroporated into 129Sv embryonic stem cells and microinjected into C57/B1/6J 
blastocytes before being transferred to pseudopregnant females. The disrupted gene was 
bred into C57/B1/6 mice creating am-KOs and corresponding WT mice with mixed genetic 
backgrounds.
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Tanoue et al. (2002c) found that in the aiD-KO mean arterial blood pressure was reduced 
and the pressor response to both phenylephrine and noradrenaline was reduced. In 
addition, both phenylephrine and noradrenaline were less potent in the thoracic aorta of the 
aiD-KO. It therefore appeared that the am-AR regulated systemic arterial blood pressure 
by vasoconstriction (Tanoue et a l, 2002c). These findings were supported hy Hosoda et 
al. (2005a) who reported that systemic blood pressure was decreased in the am-KO and 
that mean arterial blood pressure was not markedly increased in response to noradrenaline. 
This study also found that the potency of noradrenaline and phenylephrine was decreased 
in the thoracic aorta. Thus, the am-KO provides evidence for a predominant role of the 
am -A R  in vasoconstriction and in the maintenance of resting blood pressure. In addition, 
it has been shown that in the thoracic aorta of the am -K O , the am -A R  mediates the 
contiactile response to both noradrenaline (Hosoda et a l, 2005a) and phenylephrine (Ali, 
2004). These studies in the am -K O  confirm a contractile role for the am -A R , but also 
suggest the am -A R  does have a role in vasoconstriction.
Radioligand binding studies in the am-KO revealed that ai-AR binding was reduced in the 
cerebral cortex (Tanoue et a l , 2002c) suggesting that the am-AR is present in the cerebral 
cortex of the WT mouse, in addition to the high levels of am-ARs and am-ARs detected in 
previous radioligand binding studies (Yang et al, 1998). Tanoue et al. (2002c) also found 
that ai-AR protein was absent in the thoracic aorta of the am-KO, which provides further 
evidence that this ai-AR is predominant in conductance arteries.
1.7.1.4. Double knockouts
Double knockout mice have recently been generated where only a single ai-AR population 
remains. At present only the aiA/n-KO (Turnbull et a l, 2003;McCloskey et a l, 
2003;0'Connell et a l, 2003) and am/o-KO (Hosoda et a l, 2005a;Hosoda et al, 2005b) 
have been characterised, although studies of the aiA/o-KO and a triple aiA/B/o-KO are 
ongoing. The double ai-AR knockout mice were generated by crossbreeding two of the 
single knockout mice.
The aiA/B-KO was generated by mating am-KO mice with am-KO mice (Turnbull et a l, 
2003). As a result of the mixed genetic backgiound of the breeding pairs, the aiA/e-KO 
had a mixed genetic backgiound of 129Sv, FVB/N and C57/B1/6. It has been shown that 
despite the loss of the am-AR and am-AR, blood pressure was unchanged in the aiA/s-KO
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compared to the WT mouse (O’Connell et al., 2000), which suggests that the aio-AR has a 
role in the maintenance of blood pressure. However, the majority of cuirent evidence of 
the aiA/B-AR double knockout mouse is limited to the heart.
The aiB/D-KO was generated by mating am-KO mice with am-KO mice (Hosoda et a l, 
2005a). The am-KO and am-KO had the genetic background of 129Sv and C57/B1/6, 
thus the am/D-KO had the same genetic background. In the am/o-KO resting blood 
pressure and mean arterial pressure were reduced compared to the WT mouse (Hosoda et 
al, 2005a). Furthermore, the pressor response to noradrenaline and phenylephrine was 
decreased, but the pressor response to A-61603 was comparable to the WT mouse. These 
findings suggest that the am-AR regulates arterial blood pressure, in agreement with the 
study in the am-KO (Rokosh & Simpson, 2002). In addition, Hosoda et al. (2005a) did 
not observe any contractile responses to ai-AR agonists in the thoracic aorta of the am/o- 
KO, which suggests that the am-AR does not mediate the contiactile response of this 
arteiy at all. This conclusion was also reached by Ali (2004), who failed to identify a 
contiactile response to phenylephrine in the thoracic aorta of the am/o-KO. Although, a 
subsequent study, Hosoda et al. (2005b) acknowledged that an am-AR-mediated 
contraction was present but was minimal. In the later study by Hosoda et al. (2005b) both 
the maximum response and sensitivity of noradrenaline was reduced in the mesenteric 
arteiy of the am/o-KO but was still detectable. This suggests that, in contiast to the 
thoracic aorta, the am-AR does mediate vasoconstriction in the mesenteric artery. Hosoda 
et al. (2005a) also examined ai-AR expression in the am/o-KO, using both real-time FOR 
and radioligand binding assays. The loss of am-AR and am-AR mRNA was confirmed in 
the brain, heart, aorta, kidney and liver, while total ai-AR binding was reduced in the 
brain, heart and kidney. Furthennore, ai-AR binding was abolished in the liver, which has 
been shown to express am-ARs (Deighan et al, 2004;Yang et al, 1998), and similarly in 
the aorta, which has been shown to express am-ARs (Hosoda et a l, 2005b), no ai-AR 
binding was detected.
1.7.1.5. Compensatory mechanisms
It has been proposed that knocking out an ai-AR may result in the other ai-ARs 
compensating for this loss of function, such as an up-regulation of another subtype (Rohier 
& Kobilka, 1998;Tanoue et a l, 2002c). It can be argued that, in the knockout, 
compensation for the loss of the receptor may occur as the animal develops. However,
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pharmacologically blocking the receptor enables the mouse to develop normally. Recent 
studies have shown that the pressor responses to phenylephrine and noradrenaline of the 
aiD-KO and am-KO were reduced, implying that the remaining subtypes did not appear to 
compensate for the loss of an ai-AR (Cavalli et a l, 1997;Daly et a l, 2002a;Ziani et a l, 
2002;Rolrrer & Kobilka, 1998). Furthennore, the loss of both the am-AR and am-AR did 
not appear to be compensated for in a functional study of the mesenteric artery in the 
otm/D"KO (McBride et al Submitted for Publication). However, a study in the mouse liver 
demonstrated that the normally homogeneous population of am-ARs was replaced by the 
am-AR in am-KO (Deighan et a l, 2004). Furthermore, the am-AR and am-AR are 
functional in the murine heart and when either the am-AR or am-AR was deleted, the 
other subtype compensated for the loss (O'Connell et al, 2003) but when both subtypes 
were deleted in the aiA/B-KO, the am-AR compensated (O'Connell et a l, 2003;Tumbull 
et a l, 2003). In addition, despite a lack of evidence for a role of the am-AR in the 
vasoconstriction of the murine thoracic aorta, there is evidence of an ajs-AR-mediated 
contractile response in the am-KO (Ali, 2004). It is, therefore, possible that the loss of the 
dominant receptor is required for a compensatory mechanism to occur.
1.7.1.6. Transgenic mice
Overexpression of an a i-A R  gene is also a valuable tool for studying a i-A R  subtypes. 
Transgenic mice have been generated for the am -A R  (Lin et a l, 2001) and am -A R  
(Milano et a l, 1994), under the a-myosin heavy chain promoter. Mice with a 
constitutively active am -A R  mutation enable the am -A R  to be studied, while the other a i -  
ARs remain inactivated (Milano et a l, 1994). This is a particularly useful tool to isolate 
the am -A R  response with the absence of am -A R  selective agonists. Zuscik et al. (2001) 
showed that mice with over-expression of the am -A R  were hypotensive but the a i-A R  
mediated contiactile response of the mesenteric arteiy was not different to the WT mouse 
(Zuscik et al, 2001). In agieement with studies using a i-A R  knockout mice (Daly et al, 
2002a), this suggests that the am-AR was not involved in vasoconstriction.
1.8. Role of the endothelium on ai-AR-meditated 
contraction
It is now known that the vascular endothelium has an important role in the control of 
vascular tone (Angus J et a l, 1986;Cocks T & Angus J, 1983;Furchgott RF & Zawadzki
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JV, 1980). Endothelial cells (EC) release endothelium-derived relaxing factors, such as 
nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarizing factor (EDHF), 
as well as endothelium-derived contracting factors, including endothelin-1, thromboxane 
Az, superoxide anions and endoperoxides (Furchgott RF & Vanhoutte, 1989). It has been 
shown that in large conductance arteries, NO has a major role, while the role of EDHF and 
prostacyclin is minimal (Shiniokawa H et al, 1996;Scotland RS et a l, 2005). 
Consequently, the role of NO on vascular contiuction will be of particular interest to this 
thesis.
NO was previously known as endothelium-derived relaxing factor and was first linked to 
the endothelium by Furchgott and Zawadski (1980). It was demonstrated that when the 
endothelium was present in the rabbit aorta a relaxatory response to acetylcholine was 
observed, but in the absence of the endothelium acetylcholine produced contractions. 
Shortly after EDHF was identified as NO (Palmer et a l, 1987), the pathways for NO 
synthesis and degradation were discovered (Palmer et a l, 1988). NO is produced by EC 
from L-arginine by endothelial NO synthase (eNOS), which is a constitutive, Ca^ "^ - 
dependent enzyme. Once released, NO diffuses into vascular SMCs and stimulates 
soluable guanylate cyclase, leading to vasodilation.
The involvement of NO on vascular contraction has been widely studied. It has been 
shown that using a denuded preparation or inhibitors of NOS, such as L-NMMA and L- 
NAME (Rees et a l, 1990), results in an increased contractile response to ai-AR agonists 
(Cocks & Angus, 1983;Kaneko & Sunano, 1993;Amerini S et a l, 1995). The release of 
NO can be constitutive or stimulated by agonists. Recently, an endothelium-dependent ai- 
AR-mediated relaxatory response was reported in the rat mesenteric artery (Filippi et al,
2001) and the rat carotid artery (de Andrade C et a l, 2006). It is, therefore, possible that 
ai-AR agonists can stimulate NO release through the direct activation of endothelial ai- 
ARs. Alternatively, it has been proposed that the activation of SMC ai-ARs indirectly 
stimulates NO release via myoendothelial connections (Dora K, 2001). These possibilities 
have been described in greater detail in Chapter Seven.
1.9. Aims and objectives
With the ambiguity concerning the contractile role of the am-AR and am-AR in large 
conductance arteries, such as the carotid arteiy, and the potential for ai-ARs existing on 
the endothelium, the main objectives of the following research were:
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(i). To establish whether there is an am-AR-mediated contractile response in the 
carotid artery of the WT mouse and also assess whether there is evidence of a 
functional am-AR. This was achieved by using the am-AR selective agonist A- 
61603 and range subtype selective antagonists, in addition to the ai-AR non- 
selective agonist phenylephrine.
(ii). To determine whether an am-AR-mediated contractile response could be identified 
in the carotid artery of aj-AR knockout mice and therefore aid the characterisation 
of ai-AR response in the WT mouse. This was achieved using a similar approach 
to (i) to isolate the am-AR in the am -K O , am -K O  and am /o-KO.
(iii). To investigate the role of NO on the vascular response to phenylephrine and A- 
61603 in the murine carotid arteiy. This was achieved by preventing NO release 
using the NOS inhibitor L-NAME.
(iv). To characterise the ai-AR subtypes present in the media of the carotid artery by 
using subtype selective antagonists to compete with the fluorescent ligand QAPB in 
the WT mouse and ai-AR knockout mice. In doing so, the distribution and cellular 
localisation of the ai-AR subtypes in SMC was examined.
(v). To establish whether ai-ARs exist on the endothelium of the murine carotid artery 
and to determine the ai-AR subtypes present in EC. This was achieved using the 
fluorescent ligand QAPB in the WT mouse and ai-AR knockout mice as well as 
subtype selective antagonists.
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Chapter 2 General Methods
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2.1. Mice
C57 Black mice were used as control (WT mouse) and for the breeding of colonies. Mice 
with a knockout of the am -A R gene (am -K O ), am -A R  gene (am -K O ) or both (am/o-KO) 
were bred at the University of Glasgow from breeding pairs kindly provided by Professor 
Susanna Cotecchia (University of Lausanne, Lausaime, Switzerland; am-KO) and 
Professor Gozoh Tsujimoto (National Children’s Medical Research Center, Tokyo, Japan; 
am -K O ). am o-K O  mice were generated by cross-breeding homozygous am -K O  with 
homozygous am -K O  at the University of Glasgow following the same protocol as Hosoda 
et al. (2005a). The generation and background of the knockouts have been described in 
detail (am-KO (Cavalli et a l, 1997;Tanoue et a l, 2002a); am /o-KO  (Hosoda et a l, 
2005a).
All mice were maintained on a 12:12-hour light/dark schedule at 22-25'^C with 45-65% 
humidity and fed ad-libitum on a standard chow diet and provided with distilled drinking 
water. All mice were killed by the schedule one method of carbon dioxide overdose.
All mice used for experimental protocols were four to five-month old males weighing 
between 25g and 54g (wild type (26g-44g); am-KO (25g-34g); am-KO (31g-46g); am/o- 
KO (32g-55g)).
2.2. Common carotid artery dissection
The murine carotid artery was used for all experiments described in this thesis. The 
dissection of both common carotid arteries was performed with the aid of a Zeiss 
dissecting microscope. The skin covering the area over trachea was removed. The two 
lobes of the exposed thyroid gland were separated and an incision was made into the 
carotid sheath to reveal the trachea. Both common carotid arteries were located within the 
carotid sheath formed by this incision, and were medial to the internal jugular vein and 
vagus nerve (Figure 2.1).
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Figure 2.1. Dissection of the common carotid artery.
The ieft common carotid artery is a direct branch of the aorta, while the right common 
carotid artery is a branch of the brachiocephalic artery. The left common carotid artery 
was gently gripped with forceps at the branch point with external carotid to avoid damage 
to the vessel. The artery was dissected free from any connective tissue and was cut at both 
ends and placed in Petri dish with cold physiological salt solution (PSS). This was 
repeated for the right common carotid artery. When placed in the Petri dish, the branch 
point was removed and the vessels were cleaned. Care was taken to remove blood from 
the lumen of the artery, which has been shown to limit damage to the endothelium 
(Horvath et al, 2005).
2.3. Myography
Wire myography was first developed by Sevan and Osher (1972) to enable small isolated 
vessels (<200 pm in diameter) to be studied. Mulvany and Halpern (1976) adapted this 
myograph design to permit isometric tension measurements to be made in vessels with a 
diameter as small as 100 pm. Consequently, wire myography is now a widely used in vitro 
technique. The murine carotid artery is a relatively small vessel (approximately 300 pm in 
diameter) and has been used for wire myography in a number of studies (Deighan C et al, 
2005;Daly et al, 2002a;Deighan C, 2002). This experimental technique has been used for 
the functional experiments in Chapters Three, Four and Five.
2.3.1. The wire myograph
The wire myograph consists of four stainless steel 5ml baths (Danish MyoTech, Aarhus, 
Denmark) (Figure 2.2). Each bath contains two detachable stainless steel heads. One of
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the heads was connected to a micrometer, to adjust the tension on the vessel, while the 
other head was attached to a force transducer, which measures the force in millinewtons 
generated by the vessel. Each bath contains fresh, gassed (95% O2 / 5% CO2 ) 
physiological salt solution (PSS: 119mM NaCl, 4.7mM KCl, 2.5mM CaCb, 1.2mM 
MgS0 4 -H2 0 , 1.2mM KH2PO4 , 24.9mM NaHCOg, and 11.1 mM glucose). A Perspex lid 
was used to maintain the temperature within the bath and prevent any evaporation o f PSS. 
Changes in tension were measured by the transducer head and sent to an ADI PowerLab 
(4/20), via the myograph interface, and the data was displayed and recorded in grams 
tension on a computer using Chart software. The equipment was calibrated on a regular 
basis using a 2g weight.
suction J r ^
gas
micrometer
transducer
5m 1 bath
Figure 2.2. The components of a myograph bath (Morton, 2006).
2.3.2. Vessel mounting
Following dissection and cleaning, each carotid artery was cut into two 2mm sections in a 
Petri-dish containing fresh, cold PSS. One 40pm stainless steel wire was threaded through 
the lumen of the vessel, with care being taken to minimise damage to the endothelium or 
smooth muscle cells. The sections were then transferred to individual myograph chambers 
(Figure 2.3(i)). The head attached to the micrometer was positioned so that the wire was 
trapped in between the two heads (Figure 2.3(ii)). The wire was attached to the transducer 
head by both ends o f the wire being screwed in place (Figure 2.3(iii)). The heads were 
then separated and a second wire threaded through the lumen o f the artery (Figure 2.3(iv)), 
trapped between the two heads (Figure 2.3(v)) and secured to the micrometer head (Figure 
2.3(vi)). The heads were opened until the wires were Just touching and the position o f the 
wires was adjusted to ensure that they were parallel.
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Figure 2.3. Vessel mounting procedure: (i) after being threaded through the lumen of the 
vessel, the wire was held between the two heads in the myograph bath; (ii) the head 
attached to the micrometer was positioned so that the wire was trapped between the heads; 
(iii) both ends of the wire were attached to the transducer head with small screws; (iv) the 
heads were separated and a second wire was threaded through the lumen of the artery; (v) 
the second wire was trapped between the two heads; (vi) both ends of the second wire were 
secured to the micrometer head by screws. Diagram from Morton (2006).
2.3.3. Equilibration period
The PSS in each bath was replaced immediately after vessel mounting and the myograph 
heated to 37°C with the vessels being allowed to acclimatise over a 30 minute period. 
Following this equilibration period, the arteries were set to a resting tension of 0.25g, 
which was determined in a previous study by a series of length tension experiments 
(Deighan C, 2002). The vessels were then equilibrated at this resting tension for a further 
45 minutes, with washes every 15 minutes. The tension was readjusted to ensure that each 
vessel was at the desired resting tension at the end of this period.
2.3.4. Wake-up procedure
To ensure that the vessels were functional following dissection and mounting, the vessels 
were exposed to three additions of a submaximal concentration of an agonist. Depending 
on the experimental protocol either phenylephrine 10 pM, A-61603 10 pM or 5-HT 1 pM 
was selected for the wake-up procedure. Once the response had reached a plateau the 
vessels were washed four times with PSS and rested for 10 minutes between additions. On
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the third contraction to the agonist, the ability of 3 pM acetylcholine (ACh) to relax the 
vessels was tested. Only vessels where at least 30% relaxation occnned in response to 
ACh were used for the experimental protocol. The vessels were then washed with PSS and 
allowed to rest for 30 minutes.
2.3.5. Experimental protocols
2.3.5.1. Agonist comparison
Cumulative concentration response cuiwes (CRC) to an agonist were produced using half­
log increments. The agonists used to constmct CRCs were: phenylephrine (1 nM -  0.1 
mM); A-61603 (1 iiM -  0.1 mM) or 5-HT (InM -  30pM). When a maximum response 
was achieved, the vessels were washed with PSS at five-minute intervals until resting tone 
resumed.
2.3.5 2. Antagonist affinity
In Chapters Three and Four, the affinity of ai-AR antagonists against an agonist response 
was estimated. Prior to a second CRC, the vessels were incubated with an antagonist for 
30 minutes. The antagonists tested during the sPidies were: the non-selective ai-AR 
antagonist prazosin (1 nM, 10 nM, 0.1 pM) (Hanft & Gross, 1989;Ford et a l, 1994) the 
aiA-AR selective antagonists 5-methylurapidil (10 nM, 0.1 pM, 0.3 pM, 1 pM) (Gross et 
al, 1988) and RS100329 (1 nM, 10 nM, 0.1 pM) (Williams et a l, 1999); the am-AR 
selective antagonist BMY7378 (1 nM, 10 nM, 0.1 pM) (Goetz et a l, 1995) and the ai-AR 
antagonist rauwolscine (Perry Sc U'Prichard, 1981;Weitzell et a l, 1979). A second CRC 
was produced in the presence of an antagonist, or in the absence of an antagonist acting as 
a time control.
In chapter six, the effect of L-NAME (Rees et a l, 1990) on the responses to phenylephrine 
and A-61603 (Knepper et a l, 1995) was tested. Following the first CRC, vessels were 
incubated with L-NAME 0.1 mM for 40 minutes, before a second CRC was produced.
2.3.6. Statistical analysis
All statistical analysis was performed using Graph Pad Prism (Version 4) and Microsoft 
Excel. Tests for statistical significance were performed on individual curves rather than
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mean data for improved accuracy. For all data analysis, statistical significance was 
established as p < 0.05.
2.3.6.1. Agonist responses
The raw data from the agonist responses were expressed as means ± SEM in grams 
tension. The maximum responses (or greatest response recorded within the concentration 
range used) were calculated for each agonist and compared using one-way ANOVA, 
followed by a Bonfeironi’s post test. CRCs were compared using a two-way-ANOVA 
with a Bonferroni’s post-test.
The percentage of the maximum response to the agonist was calculated for individual data 
sets using the maximum response of individual conti’ol CRC and pECso values were 
calculated for each agonist in each strain of mice. The pECso is defined as the negative 
logarithm of the concentration of agonist that produces half of the maximum response. 
Therefore, when a maximum response to an agonist was not obtained within the 
concentration range used a pECso could not be determined. pECso values were compared 
using one-way ANOVA, followed by a BonfeiToni’s post test.
Nonlinear regression was perfomied to fit sigmoidal-curves (variable slope) on mean data 
of responses in grams and percentage of the maximum response, using the equation: 
(Top -  Bottom)Y = Bottom + J _j_ jQ (H il ls lo p c ( lo g E C ; g -X ))
Where Bottom is the minimum value for Y in the absence of agonist. Top is the maximum 
value for Y at a high concentration of agonist, Hill slope is the steepness of the 
concentration-response cuiwe, X is the logaritlim of the molecular concentration of the 
agonist and Y is the response.
The analysis described above was also performed on the agonist responses in the absence 
and presence of L-NAME.
2.3.G.2. Antagonist data
The agonist CRCs in the presence of an antagonist were expressed as means ± SEM in 
grams tension or as a percentage of the maximum response of the first CRC. The 
maximum responses. Hill slopes and pECso values of the agonist response in the presence
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of an antagonist were calculated and compared using either a Student’s t-test or one-way 
ANOVA, followed by a Bonferroni’s post test.
The agonist concentr ation ratios were determined from the ratio of the EC50 of the agonist 
in the presence and absence of the antagonist. Concentration ratios were used for Schild 
analysis where the log of the antagonist concentration was plotted against log (DR-1). The 
pA% is defined as the negative logarithm of the molar concentration of an antagonist which 
reduces the effect of a dose of an agonist to that of half the dose. Following linear 
regression, the pAz was identified from the X-intercept of the Schild plot. A Schild slope 
not significantly different fr om unity indicated that an antagonist was acting competitively.
When a single concentration of antagonist had no effect or significantly reduced the 
maximum response, it was not appropriate to apply Schild analysis. A pKe is the negative 
logarithm of the dissociation equilibrium constant for an antagonist (Kb) and can be 
defined as the concentration of drug that occupies fifty percent of available receptors. A 
pKe was calculated from the effective concentrations of antagonist using the equation: 
pKn = log (DR-1) - log[B]. Where [B] is the concentration of antagonist.
2.4. Confocal microscopy
The confocal microscope was developed from the conventional light microscope by 
Minsky in 1955. The aim was to produce sharp images of thin cross sections, which had 
not been possible with conventional microscopy. The basic confocal microscope system 
has been improved upon over the years and confocal laser scanning microscopy (CLSM) is 
now a widely used technique. Several confocal studies have been performed on cells 
(Sugawara et al, 2002;Daly et a l, 2002b;Deighan et a l, 2004;Mackenzie et al, 2000) but 
recently this technique has been applied to whole vessels (Boumaza et al, 2001;Daly et a l, 
2002b;Coats et a l, 2003;McBride et al Submitted for Publication).
2.4.1. The confocal microscope
The confocal microscope consists of a photomultiplier tube (PMT), a detector pinhole, a 
source pinhole, a dichroic mirror and an objective (Figure 2.4.).
50
specimen
microscope
slide
coversiipf
spacer
microscope
objective
source
pinhole
dichroic
mirrorlaser
lens
detector
pinhole
photomultiplier
Figure 2.4. The confocal microscope. (Adapted! from Figure 1, Stelzer (1995).
An excitation light from a laser is focused into the source pinhole and the dichroic mirror 
reflects the light from the source and passes it through the objective to the sample. The 
excitation light fills a converging cone as it is focused through the specimen to the object 
plane, and all the excitation light passes out through a similar diverging cone. The 
fluorescent light from the fluorophore in the specimen is emitted in all directions. Light 
from the specimen passes through both the objective and dichroic mirrors and is focused 
into the detector pinhole, then measured by the PMT. The detector pinhole ensures that 
only light from the in-focus planes reach the PMT, and prevents the light scattered from 
out-of-focus planes reaching the PMT, so that the image produced is of a single plane. An 
image is built up from individual pixels using a computer with imaging software to 
visualise a complete image.
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Figure 2.5. Fluorescence generation. (Figure 1 Semwogerere & Weeks (2005).
Fluorescence occurs when a molecule absorbs light, resulting in the emission of light of a 
different colour (Figure 2.5). The lowest energy state of a molecule is the ground state. 
When stimulated, the molecule absorbs a photon of light, resulting in an increase in energy 
and an electron jumps to a higher energy state. The molecule disperses some of the 
absorbed energy and the electron drops to a lower energy state. The remaining energy is 
lost by the molecule emitting a photon of light with a longer wavelength and the electron 
drops back to the ground state.
In Chapters Six and Seven, CLSM was used to examine the distribution of ai-AR subtypes 
in the murine carotid artery using QAPB, a green fluorescent analogue of prazosin 
(nonselective ai-AR antagonist). A radioligand binding study, comparing specific 
antibodies to QAPB in rat fibroblasts, has shown that QAPB has 10-fold lower affinity 
than prazosin; but like prazosin, is not selective between ai-AR subtypes (Daly et al, 
1998;Mackenzie et ai, 2000). However, there is evidence that QAPB can bind a 2-ARs 
with moderate to low affinity (McGrath & Daly, 2005). Generally, QAPB fluoresces only 
when bound (Daly et al, 1998;Mackenzie et al, 2000). Thus, when bound to the ai-ARs 
in the carotid artery a fluorescent signal was generated by excitation of QAPB with a laser.
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2.4.2. Determination of incubation conditions
A series of experiments was caii'ied out to determine the optimum conditions for vessel 
incubation. The fluorescence and binding of l|.iM QAPB, 0.1 pM and lOnM QAPB were 
compared to assess the quality of QAPB binding at the lower concentrations (<1 pM), 
which are believed to be more specific to ai-ARs (Daly et al, 1998). Despite 
concentrations below lOnM being used successfully in studies on cells, in the intact carotid 
artery binding of QAPB lOnM was poor. QAPB 0.1 pM was selected for use for further 
experiments.
The most appropriate method of preparing the carotid artery for imaging was also 
established. The whole vessel; cross-sectional rings of carotid artery; and vessels which 
had been sliced longitudinally and opened out (Miquel RM et a l, 2005), were trialled. In 
the whole vessels, it was difficult to focus into the smooth muscle layers and endothelium 
due to the thick elastic wall of the carotid artery. In another attempt to use the whole intact 
vessel, the carotid artery was turned ‘inside out’ exposing the endothelium and stretching 
the elastic lamina. This preparation enabled the vessels to be imaged fiom the endothelium 
through to the media; however, severe endothelial cell damage occurred. In unfixed tissue 
damage was inflicted by slicing the cross-sectional rings, thus the use of this preparation 
was also discontinued. The open preparation was selected for use in the experimental 
protocols as it allowed imaging of the endothelium and smooth muscle cells with minimum 
damage. The live tissue was most appropriate for use in this study as the physiological 
processes for binding QAPB were preserved. Nevertheless, certain additional obstacles 
can arise from using a live tissue: the tissue is susceptible to damage due to changes in pH, 
temperature, oxidation, and glucose levels; and movements in the tissue can cause 
difficulties in focusing (Terasaki & Dailey, 1995). These factors were limited as much as 
practically possible for the duration of the experimentation.
In an attempt to keep incubation conditions as physiological as possible, initial 
experiments were canied out where the unfixed tissue was incubated in a water bath at 
37°C. However, when heated, the calcium in the PSS precipitated out of solution and the 
physiological pH was lost. As the total volume of the incubation solution was 200 pi it 
was not practical to continually bubble with 95% 02/5% CO2, which would have buffered 
the solution to maintain pH. Instead fieshly bubbled PSS solutions were replaced every 30 
minutes for the duration of the incubation period; however the problem still occurred at 
this temperature. A buffer that was not dependent on pH, such as HEPES, could have been 
used in the incubation solutions instead of PSS; however, as the confocal study would be
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examined in conjunction with the myography data, the use of PSS was continued. Thus, 
the incubations were performed at room temperature (21°C) and the solutions were 
changed every 30 minutes, which ensured the pH did not change during the incubation 
period. In addition to preventing the calcium precipitating out of solution, replacing the 
PSS also kept the living vessel supplied with glucose.
Once the concentration of QAPB, tissue preparation and temperature had been selected, 
vessels were imaged at a series of time-points (30 min, 60 min, 90 min, 120 min and 180 
min) in order to determine the optimum incubation time for 0.1 |.lM QAPB, which was 
found to be 120 minutes.
2.4.3. Incubations used for experimental protocol
5mm segments of carotid artery were incubated at room temperature with 0.1 pM QAPB, in 
a PSS solution at room temperature for 60 minutes. Incubating the vessels with QAPB 0.1 
pM prior to the addition of the selective antagonists ensured that QAPB binding was 
established and the antagonist competed with QAPB for ai-AR binding sites during the co­
incubation reaching equilibrium. The arteries were then incubated for a further 60 minutes 
with a 0.1 pM QAPB/PSS solution containing selected antagonist(s); prazosin 0.1 pM, 
(non-selective ai-AR antagonist); RSI00329 0.1 pM, (aiA-AR selective antagonist); 5- 
methylurapidil 1 pM (aiA-AR selective antagonist); BMY7378 0.1 pM (am-AR selective 
antagonist); both BMY 7378 0.1 pM and RS100329 0.1 pM; or rauwolscine 0.1 pM (az- 
AR antagonist). The concentrations of antagonist were based on the competitor’s affinity 
at the ai-AR subtypes, so that they would act with ten-times greater affinity than QAPB 
0.1 pM. The affinity estimates were based on the pKi values obtained in a radioligand 
binding study (Mackenzie et a l, 2000). The antagonist concentrations used in functional 
experiments were also taken into consideration when selecting the concentmtions used to 
compete with QAPB in confocal microscopy experiments. The same antagonists were 
used for CLSM studies of both the smooth muscle (Chapter Six) and endothelium (Chapter 
Seven).
Two sets of conbol vessels were used during the full incubation period: (i) controls for 
autofluorescence, which were incubated in PSS only, and (ii) QAPB control segments, 
which were incubated in a QAPB/PSS solution in the absence of antagonists. Throughout 
the incubation period all solutions were replaced eveiy 30 minutes to ensure the pH of the 
solution and glucose levels were maintained.
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A series o f experiments was carried out where the nuclear dye Syto 61 was co-incubated 
with QAPB 0.1 pM. The vessel was incubated with a 0.1 pM QAPB/PSS solution for 30 
minutes, followed by a 90 minute co-incubation o f QAPB 0.1 pM and Syto 61 1 pM, at 
room temperature, with solutions being replaced every 30 minutes.
2.4.4. Slide mounting
At the end o f the incubation period each carotid artery segment was sliced open with a 
single-edged razor blade and laid flat on a microscope slide with the endothelial side up 
(Miquel RM et al., 2005) (Figure 2.6).
Smooth 
muscle 
cell
Lume
Endothélia 
cell
Lumen
Figure 2.6. Vessel preparation (Miquel RM et al., 2005)
A small well was formed on the microscope slide using grease, which was filled with the 
solution that the vessel was incubated in. A coverslip thickness 1.5, suitable for the x40 
objective, was placed on top creating a seal. This closed chamber prevented loss of 
mounting media and stabilised the temperature during imaging.
2.4.5. Imaging
Initially, the specimen was viewed through the microscope eyepiece and the microscope 
(Nikon Eclipse TE300) used conventionally to focus on the specimen. Once focussed, the 
view was changed from the microscope eyepiece to the computer. The scanning settings 
for the confocal microscope were selected (see below) and an exploratory scan started, 
enabling the focus on the specimen to be finely adjusted under the objective, prior to data 
being recorded. It should be noted that prior to experimentation the objective was cleaned
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to remove any dust particles and a glass rod was used to drop oil onto the objective to 
prevent air bubbles forming in the immersion oil.
All arteries were visualised using the Bio-Rad Radiance 2100 Confocal Laser Scanning 
System. An argon-ion laser with an excitation wavelength of 488nm with an emission 
filter of 515nm was used for QAPB and a x40 oil immersion objective (NA 0.75) was used 
for all experiments. Two different settings were used to record images. For images 
recorded at zoom three, a laser intensity of 40; a gain of 12; offset 0.0; and pinhole setting 
of 1.4 were selected. For images recorded at zoom eight, a laser intensity of 20; gain 22; 
offset 0.0; and pinhole setting of 2.4 were chosen. At a higher magnitude, the rate at which 
photobleaching occurs is higher as the excitation light is focused over a smaller area, 
which increases the local intensity. To limit photobleaching at the high zoom setting, the 
laser intensity was reduced and the gain and exit pinhole size were also increased to 
increase the brightness. This increased the signal reaching the PMT at the lower laser 
intensity. The standard scan speed of 500 lines per second was used for all experiments. 
An image size of 512 x 512 pixels produced a field size of 289pm x 289pm.
During the co-staining experiments the settings for QAPB were as described above, while 
a red diode, with an excitation/emission wavelength of 628/645nm, was used for Syto 61. 
At a zoom of three, laser intensity was set to 30, with a gain of 12, offset 0.0 and an 
optimal pinhole of 1.4.
Each vessel was imaged from the internal elastic lamina through to the media, between the 
bands of elastic lamina (Figure 2,7). A minimum of three images was collected from 
random areas of the vessel. Care was taken not to image close to where the vessel had 
been cut. Each experiment was repeated four times for each strain of mice.
Folded lamina Endothelial cells
Optical slice at 
endothelium
MediaOptical slice 
at SMC
Figure 2.7. Illustration of Imaging of open vessels.
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Kalman (5 frames) was used to record individual 2D images. Averaging the data from 
several frames improved image quality. Z-series were also produced in stacks of 1 pm 
slices, starting at the last smooth muscle layer in focus and ending at the internal elastic 
lamina, producing a stack of approximately 30 pm.
2.4.6. Image analysis
8-bit images were produced and displayed spatially as pixels, where each pixel represents 
an intensity value between 0 (black) and 255 (white) from the Gray scale. Following 
image capture, Metamorph software (version 4) was used to analyse the 2D images 
collected at zoom eight to exclude any autofluorescence from the elastic lamina. Image 
histogram statistics were produced for each image to obtain the number of pixels at each 
intensity. The number of pixels was then used to calculate the total fluorescence at each 
intensity and the mean of replicate experiments was displayed in a histogram plot of 
fluorescence against intensity. Region statistics were used to generate integrated (total) 
intensity for each image and the mean data plotted in bar charts. Integrated intensity for 
QAPB was compared between all four stains of mice using one-way ANOVA. Integrated 
intensity of QAPB in presence of the selected antagonists was compared to QAPB alone 
using one-way ANOVA.
3D images were produced from a 3D projection of the stack of “optical sections”. 
Autofluorescence from elastic lamina can mask the fluorescence from QAPB when bound 
to receptors. As the fluorescence from the elastic lamina obstmcted the visualisation of 
smooth muscle cells, a series of adjacent planes was selected from the stack and used to 
create the 3D projectiorr.
The images produced from the colocalisation experiments with QAPB and Syto 61 were 
overlaid. Thus, the localisation of QAPB binding was directly compared with the nuclear 
binding of Syto 61.
2.5. Drugs and Solutions used
Physiological salt solution (PSS) composition (in rriM): 119 NaCl, 4.7 KCl, 1.2 
MgS0 4 .H2 0 , 1.2 KH2PO4, 24.9 NaHCOs, 2.5 CaCL, and 11.1 glucose.
The following stock solutions were made from crystalline form using distilled water 
(unless otherwise stated). All drug stock solutions used were prepared and diluted (1:10) in
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distilled water to give the concentrations used for experimental protocols (unless otherwise 
stated).
2.5.1. Agonist
Phenylephrine {(R)-(-)-l-(3-Hydroxyphenyl)-2-methylaminoethanol)\ lOOmM [SIGMA]
A61603 {N-[5-(4,5-Dihydro-lH-imidazol-2~yl)~2-hydroxy~5,6,7,8-tetrahydronaphthalen-l- 
yl]methanesulfonamide): lOOmM [TOCRIS]
5-hydroxytryptamine {3-[2-Aminoethyl]-5-hydroxyindole)'. lOmM [SIGMA]
Acetylcholine: lOmM [SIGMA]
2.5.2. Antagonists
Prazosin {1-(4-Amino-6, 7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine): 
ImM [SIGMA]
5-methylurapidil {5-Methyl-6[[3-[4-(2-methoxyphenyl)-l-piperazinyI]propyl]amino]-1,3- 
dimethyluracil)'. lOOpM [SIGMA]
RSI00-329 (N-[(2-trifliioroethoxy)phenyl],N'-(3-thyminylpropyl)piperazine 
hydrochloride)'. ImM [Roche]
BMY 7378 (8-[2~[4~(2-Methoxyphenyl)-l-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9- 
dione)'. ImM [Research Biochemicals]
Rauwolscine {17a-Hydroxy-20a-yohimban-l6fi-carboxylic acid methyl ester)'. lOOpM 
[Research Biochemicals]
L-NAME (Nco-Nitro-L-arginine methyl ester)'. lOOniM fresh daily [SIGMA]
QAPB (BODIPY FL-Prazosin or Quinazoline Piperazine Bodipy). 0. ImM in DSMO 
[Molecular Probes]. Diluted in freshly bubbled PSS to the required concentration. 
Photosensitive so prepared in a dark room and vials protected with aluminium foil.
Syto 61 : O.lmM, in DMSG [Molecular Probes]. Diluted in freshly bubbled PSS to the 
required concenfr ation.
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Chapter Three 
Characterisation of the WT mouse
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3.1. Introduction
To date, the availability of literature characterising the contractile response in the mouse 
carotid artery is limited. For this reason the pharmacology of the rat carotid artery and 
other mouse conductance arteries, such as the thoracic aorta, can provide an insight into the 
situation in the mouse carotid artery.
3.1.1. Mouse carotid artery
Deighan (2002) was the first in vitro study to determine the adrenoceptors mediating the 
contiaction of the mouse carotid arteiy. Based on the contractile responses to the ai-AR 
non-selective agonist, phenylephrine, it was reported that the dominant contractile response 
was mediated by ai-ARs. Furthermore, the lack of response to the ag-AR agonist, 
UK14304, and the p-AR agonist, isoprenaline, ruled out az-AR- or p-AR-mediated 
contractions. The study characterised the phenylephrine-induced response using selective 
antagonists and concluded that the am-AR was the predominant ai-AR subtype due to the 
affinity of the selective am-AR antagonist, BMY 7378. However, the Schild slope 
produced in the presence of BMY 7378 was shallow, raising the possibility that more than 
one subtype was contributing to the contractile response. The low potency of 5- 
methylurapidil against the phenylephrine-induced response failed to reveal any aiA-AR 
component to the contraction. By a process of elimination it was concluded that the aie- 
AR was most likely to mediate the secondary ai-AR contractile response (Deighan C, 
2002;Daly et a l, 2002a;Deighan et al., 2005). However, no am-AR antagonists are 
available that are adequately selective over the aiA-AR and aio-AR. Thus, there was no 
direct evidence that the am-AR contributed to the contraction of the carotid arteiy in the 
WT mouse.
3.1.2. Rat carotid artery
In contrast to the mouse carotid artery, the rat carotid artery has been widely used. It has 
been demonstrated that the am-AR is the predominant subtype, based on the potency of 
BMY 7378 (Villalobos-Molina & Ibarra, 1996;Chiba & Tsukada, 2002;Martinez L et al., 
1999). For instance, Villalobos-Molina & Ibarra (1996) reported a high pA% of 8.66 for 
BMY 7378 against the contractile response to methoxaniine in normotensive Wistar Kyoto 
rats. In addition, the high affinity values obtained for 5-methylurapidil (pAz 9.1), WB4101 
(pAz 10.7) and BMY 7378 (pAz 9.2) suggested that both the aiA-AR and am-AR mediate
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the contractile response to noradrenaline in the rat carotid artery (Naghadeh, 1996). This 
was supported by Chiba and Tsukada (2002) who reported that both WB4101 and BMY 
7378 inhibited changes in perfusion pressure in response to noradrenaline and 
phenylephrine, but no evidence of an aie-AR response was found. De Oliveria et al. 
(1998) reported that the phenylephrine -induced response in the rat carotid artery was 
mediated by the aiA-AR, but also reported an aig-AR-mediated component. However, this 
was based on the use of chloroethylclonidine, which does not show convincing selectivity 
for the aiB-AR (Perez et a l, 1994;Lomasney et ai, 1991;Schwinn et a l, 1990;Hirasawa et 
al, 1997). Furthermore, de Oliveria et al. (1998) concluded that there was no evidence of 
an aiD-AR response. However, it has been shown that their key antagonist WB4101 also 
has high affinity for the aio-AR and the analysis was canied out without the use of the 
aiD-AR selective antagonist. Nevertheless, the balance of evidence from studies in the rat 
carotid artery suggests that the predominant subtype is the am-AR, with a contribution 
from the aiA-AR and/or aiB-AR. This compares with the evidence obtained in the mouse 
carotid arteiy to date (Deighan C, 2002;Daly et a l, 2002a;Deighan et a l, 2005).
3.1.3. Mouse aorta
Studies in the mouse carotid artery and thoracic aorta suggest that the pharmacological 
profile of these conductance arteries is similar. For instance, it has been established that 
the aiD-AR has a main contractile function and there are several reports that the am-AR 
may have a minor contractile role in the aorta of the WT mouse (Daly et al, 2002a;Piascik 
& Perez, 2001;Garcia-Sainz et a l, 1999;Yamamoto & Koike, 200lb;Yamamoto & Koike, 
2001a;Hosoda et al, 2005a;Hosoda et a l, 2005b;Yamamoto & Koike, 2001b). However, 
the role of the aiA-AR and aiB-AR is unclear in this vessel (Tanoue et al, 
2002c;Yamamoto & Koike, 2001b;Tanaka et a l, 2004;Hosoda et a l, 2005b;Ali, 
2004;Hosoda et al, 2005a). Interestingly, like the thoracic aorta the upper abdominal aorta 
is predominantly aiD-AR-mediated, but a change in ai-AR subtypes occurs in the lower 
abdominal aorta, which is predominantly aiA-AR-mediated (Yamamoto & Koike, 2001a). 
Thus, the ai-AR population in the thoracic aorta may be unique, with a contractile 
response that is mediated by the am-AR and aiB-AR changing down the length of the 
aorta.
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3.1.4. Aims
It is clear from the studies in the conductance arteries of both mouse and rat that the am- 
AR is the predominant contractile ai-AR subtype. However, assessing the functional roles 
of the other ai-AR subtypes is complex. In the absence of selective am-AR compounds, 
the current study used the aiA-AR selective agonist A-61603 in an attempt to isolate an 
aiA“AR response. The aims of the study were:
• To compare the A-61603-induced response with the contractile response to 
phenylephrine in the mouse carotid artery.
• To use aiA-AR selective antagonists to further investigate the phenylephrine- 
induced response.
• To characterise the A-61603-induced response to ascertain whether an aiA-AR 
component to contraction exists in the mouse carotid artery.
3.2. Methods
The dissection, vessel mounting and acclimatisation period are described in detail in 
Chapter Two. In brief, four-five-month old male WT mice (C57 Black; 26g-44g) were 
killed by carbon dioxide overdose and both common carotid arteries were dissected. 
Following cleaning, vessels were mounted in a four-chamber wire myogiaph containing 
gassed (95% Oz / 5% COz) and heated (37°C) PSS. Vessels were allowed to acclimatise 
for 30 minutes before a resting tension of 0.25g was added to each vessel and a further 45 
minutes acclimatisation period prior to the start of the experimental protocol.
3.2.1. Characterisation of phenyiephrine-induced response
A  wake-up protocol for phenylephrine was performed as described in Chapter Two. The 
vessels were washed with PSS and allowed to rest for 30 minutes. CRCs to phenylephrine 
(1 nM -  0.1 niM) were produced using half-log increments. Prior to the second CRC, 
vessels were incubated for 30 minutes with the aiA-AR selective antagonist RSI00329 (1 
nM, 10 nM, 0.1 pM). A second phenylephrine CRC was then produced in the presence of 
the antagonist or in the absence of an antagonist acting as a time control.
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3.2.2. Characterisation of A-61603-induced response
A wake-up protocol for A-61603 was performed as described in Chapter Two. A CRC to 
A-61603 (1 nM -  0.1 mM) was constructed in half log increments. Vessels were incubated 
for 30 minutes with the aiA-AR selective antagonists 5-methylurapidil (10 nM, 0.1 pM, 
0.3 pM, 1 pM) and RSI00 329 (1 nM, 10 nM, 0.1 pM); or the am-AR selective antagonist 
BMY7378 (1 nM, 10 nM, 0.1 pM). A second CRC was produced in the presence of an 
antagonist, or in the absence of an antagonist acting as a time control.
3.2.3. Statistical analysis
Data were expressed as means ± standard eiTor in grams tension and percentage of the 
maximum response of the control CRC. The maximum responses obtained, pECso values 
of the agonist response in the absence or presence of an antagonist were compared using 
either a Student’s t-test or one-way ANOVA, followed by a Bonferroni’s post test. CRCs 
were compared using two-way-ANOVA with a Bonferroni post-test. Nonlinear regr ession 
was performed to fit sigmoidal-curves (variable slope) on mean data of responses in giams 
and percentage of the maximum response of the control CRC. Linear regression was 
performed to obtain the pAz which was identified from the X-intercept of the Schild plot. 
When a single concentration of antagonist had no effect, or the antagonist caused the 
maximum response obtained to be significantly reduced compared to the control CRC, a 
pKe was calculated from the remaining concentrations of antagonist.
3.3. Results
3.3.1. Comparison o f phenylephrine and A-61603 response
Phenylephrine produced concentration-dependent contractions in the WT mouse (Figure 
3.1; Table 3.1). No significant differences were obseiwed between the maximum response 
obtained or pEC^o values of the phenylephrine control and the phenyleplirine time control.
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Figure 3.1. WT mouse; Phenylephrine CRCs in the carotid artery (n=7) expressed as mean ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC.
Table 3.1. Comparison of phenylephrine CRCs in the WT mouse.
Agonist n pECso Maximum response
(s)
Hill slope (95% 
Cl)
PE control 7 6.6±0.05 0.27+0.03 0.6 (0.5-0.7)
PE time control 7 6.7±0.05‘^ 0.25+0.05' 0.7 (0.5-0.9)'"
 ^p>0.05 compared to PE control (Student’s t-test).
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A-61603 produced concenti’ation-dependent contractions in the WT mouse (Figure 3.2; 
Table 3.2). No significant differences were observed between the maximum response 
obtained or pECso values of the A-61603 control and the A-61603 time control.
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Figure 3.2. WT mouse: A-61603 CRC in the carotid artery (n=10) expressed as mean ± S.E. in 
(A) grams tension and (B) percentage of maximum response of the control CRC.
Table 3.2. Comparison of A-61603 CRCs in the WT mouse.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.0±0.06 0.2810.02 0.7(0.5~0.9)
A-61603 time 
control
10 6.0^0.03'" 0.2810.05"' 0.7 (0.4-0.9)'"
p>0.05 compared to A-61603 control (Student’s t-test).
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No significant difference was observed in the maximum response recorded between the 
phenylephrine control and A-61603 control, but sensitivity to phenylephrine was 
significantly higher than A-61603 (Figure 3.3; Table 3.3).
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Figure 3.3. WT mouse; Comparison of control CRCs to phenylephrine (n=7) and A-61603 
(n=1Q) in the carotid artery expressed in grams mean ± S.E.
Table 3.3. Comparison of control CRCs to phenylephrine and A-61603 in the WT mouse.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 7 6.6±0.05 0.27+0.03 0.6 (0.5-0.7)
A-61603 control 10 6.0±0.03" 0.28+0.05+ 0.7 (0.4~0.9)+
p>0.05; * p<0.05 compared to PE control (Student’s t-test).
Laura Methven, 2006
3.3.2. Antagonist data
Chapter 2, 66
3.3.2.1. Phenylephrine-induced response
Deighan (2002;Deighan et a l, 2005) calculated affinity estimates for prazosin, BMY 7378 
and 5-methylurapidil against the phenylephrine-induced response. These values have been 
included in Table 3.8 for completeness.
RS100 329
R S I00 329 produced a rightward displacement of the phenyleplri’ine response at 0.1 pM 
(Figure 3.4; Table 3.4), enabling a pKe of 7.9 to be calculated at this concentration.
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Figure 3.4. WT mouse: Phenylephrine CRCs in the presence of RSI 00 329 (n=6) expressed 
as mean ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC.
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Table 3.4. Phenylephrine CRCs in the presence of RS100 329 in the WT mouse
Agonist n pECso Maximum response (g) Hill slope (95% 
C l)
PE control 8 6.5±0.13 0.30±0.02 0.5 (0.5-0.6)
RSlOO 329 InM 6 6.7^0.07"" 0.28±0.08‘" 0.7 (0.6-0.9)"
RSlOO 329 lOnM 6 6.6±.26'" 0.32i0.04‘" 0.7 (0.6-0.8)^
RSlOO 329 0.1 pM 6 5.6±0.22" 0.30±0.04’" 0.9 (0.6-1.2)^
^p>0.05; *p<0.05 compared to PE control (one-way ANOVA, Bonferroni’s post test).
3.3.2.2. A-61603-induced response 
BMY 7378
The CRC produced in the presence of BMY 10 nM was biphasic. Only the highest 
concentration of BMY7378 used (0.1 pM) produced a significant rightward displacement 
of the A-61603 CRC (Figure 3.5; Table 3.5), enabling a pKe of 8.3 to be calculated at this 
concentration.
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Figure 3.5. WT mouse: A-61603 CRCs In the presence of BMY 7378 (n=6) expressed as mean 
± S.E. In (A) grams tension and (B) percentage of maximum response of the control CRC.
Table 3.5. A-61603 CRCs In the presence of BMY 7378 In the WT mouse.
Agonist n pECso Maximum response (g) Hill slope (95% Cl)
A-61603 control 6 5.74:0.05 0.274:0.02 0.7 (0.6-0.9)
BMY 7378 InM 6 5.3±0.18‘' 0.22±0.05^ 0.6 (0.3-0.9)'"
BMY 7378 lOnM 6 5.44=0.41^ 0.244=0.04"' 0.6 (0.4-0.7)'"
BMY 7378 0.1 pM 6 4.34L0.04' 0.224=0.04'" 0.8 (0.3-1.3)'"
 ^ p>0.05; p<0.05 compared to A-61603 control (one-way ANOVA, Bonferronl’s post test).
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5-methylurapidil
5-Methylurapidil caused a rightward displacement of the A-61603 CRC (Figure 3.6; Table
3.6). A pAz value of 8.3 was calculated with a slope of 1,0 (0.6-1.3), indicating 
competitive antagonism.
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Figure 3.6. WT mouse: A-61603 CRCs in the presence of 5-methylurapidil (n=6) expressed as 
mean ± S.E. in (A) grams tension, (B) percentage of maximum response of the control CRC 
and (C) Schild plot for 5-methylurapidil.
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Table 3.6. A-61603 CRCs in the presence of 5-methylurapidil in the WT mouse.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.03=0.08 0.223=0.02 0.9 (0.8-1.1)
5-MeU lOnM 7 5.23=0.05’ 0.183=0.03^ 1.1 (0.5-1.6)+
5-MeU 0.1 jiM 6 4.93=0.11’ 0.193=0.04"' 1.0 (0.7-1.4)^
5-MeU 0.3fiM 6 4.83:0.18’ 0.223=0.04^ 1.3 (0.7-1.9)""
S-MeU IpM 6 4.93=0.23" 0.19+-0.03"' 1.2 (0.5-2.0)^
* p>0.05; p<0.05 compared to A-61603 control (one-way ANOVA, Bonferroni’s post test). 
RSlOO 329
RSlOO 329 lOnM and 0.1 pM shifted the A-61603 CRC to the right (Figure 3.8; Table 
3.8). Due to the lack of effect of the lowest concentration of RSI00329 (InM), and a 
significant reduction in the maximum response recorded for phenyleplnine in the presence 
of RSI00-329 0.1 [xM a pKsof 8.7 was calculated for RSlOO 329 lOnM.
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Figure 3.7. WT mouse: A-61603 CRCs in the presence of RSlOO 329 (n=7) expressed as 
mean ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC.
Table 3.7. A-61603 CRCs in the presence and absence of RSlOO 329 In the WT mouse.
Agonist n pECso Maximum response (g) Hill slope (95% 
C l)
A-61603 control 8 5.8±0.n 0.28±0.03 0.9 (0.6-1.2)
RSlOO 329 InM 7 5.7±0.12'*’ 0.28±0.05"' 0.8 (0.6-1.0f
RSlOO 329 lOnM 8 5.3db0.14' 0.29±0.04"' 1.0 (0.9-1.I f
RSlOO 329 O.lpM 8 N.D. 0.17^=0.03' 1.2(0.4-1.9f
p>0.05; p<0.05 compared to A-61603 control (one-way ANOVA, Bonferroni’s post test).
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Table 3.8. Affinity estimates of selective arAR antagonists for phenylephrine and A-61603
Prazosin SMeU RSlOO-329 BMY7378
Agonist pAi /pKn Slope.
(95% C l)
pAi /pKn Slope 
(95% C l)
pAz /pKn Slope 
(95% C l)
pA i /pKg Slope 
(95% C l)
PE
9.6* 0.9
(0.8-1.1)
1.5* 1.1 
(0.7-1.5)
7.9 8.3*
A-61603
8.3 1.0 
(0.6-1.3)
8.7 8.3
* Denotes data from Deighan, University of Glasgow PhD Thesis (2002).
3.4. Discussion
The present study set out to further characterise the ai-AR-mediated contiactile response 
in the murine carotid arteiy by determining whether an aiA-AR response existed. Due to 
ai-AR heterogeneity, the characterisation of the ai~AR-mediated contractile response in 
the WT mouse is complex. In an attempt to isolate an aiA-AR response in the WT mouse, 
A-61603, an agonist with reported selectivity for the œia-AR (Knepper SM et a l, 
1995)(see Chapter One) was employed, in addition to the non-selective oci-AR agonist 
phenylephrine.
3.4.1. Agonist responses
Both phenylephrine and A-61603 produced concentiation-dependent contractions with no 
differences being observed between the control and time control, validating the use of 
these agonists for further analysis.
The maximum response recorded for phenylephrine and A-61603 were not significantly 
different. Phenylephrine has been shown to be 30-times more potent than A-61603 in the 
rat aorta (Knepper SM et a l, 1995), in which the aio-AR is predominant and there is no 
evidence of an a,A-AR response (Buckner et a l, 1996;Keimy et a l, 1995;Aboud et a l, 
1993). Like the rat aorta, the mouse carotid artery is predominantly aiD-AR-mediated. 
However, in the mouse carotid artery the potency for phenylephrine was only 4-fold higher 
than A-61603. This raises the possibility that the Œia-AR may contribute to the contractile 
response in the carotid artery. Nevertheless, this is markedly different from observations 
from tissues that are predominately aiA-AR (rat submaxillary gland (Michel et a l, 1989), 
rat vas deferens (Honner V & Docherty, 1999;Aboud et a l, 1993), canine prostate (Goetz 
et a l, 1994), in which A-61603 was at least 160-fold more potent than phenylephrine
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(Knepper SM et a l, 1995). Overall, the agonist responses alone provide further evidence 
in support of the aio-AR being the predominant ai-AR in the mouse carotid aitery and 
highlights that an aiA-AR-mediated response may exist.
3.4.2. aiD-AR antagonism
The pKb of 8.3 for BMY 7378 versus A-61603 is similar to that against phenylephrine and 
is in line with published values at the am-AR, so implicates the involvement of the aio- 
AR in the A-61603 response. However, the aio-AR selectivity of BMY 7378 may be lost 
at 0.1 pM and it is plausible that BMY 7378 was acting on the aiA-AR. Furthermore, a 
biphasic A-61603 CRC was obseiwed with BMY 7378 lOnM, highlighting the possible 
involvement of two subtypes in the A-61603 response: a low concentration effect resistant 
to BMY 7378 10 nM and a high concentration response that is susceptible to this 
concentration of BMY 7378. In the previous study of the WT mouse carotid artery, 
BMY7378 antagonised the phenylephrine-induced response only at the highest 
concentration used (0.1 pM) (Deighan C, 2002;Deighan et a l, 2005) but at this 
concentration a pKe of 8.3 was produced. This pKs was taken to be indicative of an ocm- 
AR-mediated response as it was consistent with published affinity estimates for BMY 7378 
at this subtype. In a recent study from our laboratory, All (2004) showed that neither A- 
61603 nor phenylephrine produced a contraction in the am/D-KO thoracic aorta arguing 
against an aiA-AR in that artery. However, it was also reported that phenylephrine but not 
A-61603 was potent and efficacious in the aio-KO, suggesting that phenylephrine, but not 
A-61603, acts on the aie-AR as well as the am-AR in the aorta. This absence of am-AR 
potency for A-61603 in the aorta suggests that the two components observed in the present 
study arise firam the am-AR and the a^-AR.
3.4.3. aiA~AR antagonism
In the cuiTent study, 5-methylurapidil acted with higher affinity against A-61603 than that 
reported for phenyleplirine, producing a pAi of 8.3, compared with 7.5 versus 
phenylephrine (Deighan C, 2002;Deighan et a l, 2005). According to the potency values 
from the literature, 8.3 is indicative of an aiA-AR-mediated response (See Chapter One). 
In contrast, in the previous sPidy the low potency of 5-methylurapidil against the 
phenylephrine-induced response was used to argue against an a^-A R  component to the 
contraction and it was concluded that the am-AR was most likely to contribute to the ai-
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AR contractile response to phenylephrine, in addition to the dominant am-AR (Deighan C, 
2002;Deighan et al, 2005). In the thoracic aorta of the WT mouse a relatively low pKs of 
7.7 was produced for 5-methylurapidil against the phenylephrine-induced response (Ali, 
2004). This affinity estimate is similar to that obtained for 5-methylurapidil against the 
phenylephrine-induced response in the study by Deighan (2002;Deighan et al, 2005) and 
does not support a functional role for the aiA-AR. However, an earlier study in the WT 
mouse aorta Daly et al. (2002a) reported that 5-methylurapidil antagonised the 
phenylephrine-induced response producing the higher pA% of 8.3. Despite acknowledging 
that the ajA-AR may be involved in the response, it was again concluded that the am-AR 
contributed to the contiactile response in addition to the am-AR. In the first order 
mesenteric arteiy of the mouse, in which the a^-A R  predominates, a pKe of 8.9 was 
produced for 5-methylurapidil against the A-61603-induced response (McBride et al 
Submitted for Publication). This higher pKe in the mesenteric artery may reflect the 
involvement of the am-AR in the A-61603-induced response in the carotid artery. 
Nevertheless, the relatively high pA% of 8.3 obtained in the present study versus A-61603 is 
more consistent with 5-methylurapidil acting at the am-AR rather than the am-AR or am- 
AR.
The aiA-AR selective antagonist, RSI00329 was used in the current study to consolidate 
the 5-methylurapidil data. RSI00329 0.1 pM competitively antagonised the phenylephrine 
response producing a pKe of 7.9. As the same affinity estimate value was obtained against 
the noradrenaline-induced response in the rat aorta (Williams et al, 1999), which is 
believed to be mediated by the am-AR, it seemed likely that this highest concentration of 
RSI00329 was antagonising the action of phenylephrine at the am-AR. A shallow Hill 
slope was obtained for the phenylephrine-induced response but in the presence of 0.1 pM 
RSI00329, a steeper Hill slope, not significantly different from 1.0, was produced. This 
suggests that the phenylephrine-induced response is mediated by the am-AR and another 
receptor. RS100329 antagonised the A-61603-induced response with higher affinity (pKe
8.7), which is closer to affinity estimates in am-AR tissues such as the human lower 
urinary tract (9.2) and rabbit bladder neck (9.2) reported by Williams et al. (1999). The 
high affinity of RSI00329 against the A-61603-induced response provides evidence that 
the am-AR is involved in the contractile response in the mouse carotid artery, reinforcing 
the less clear-cut 5-methylurapidil data. It is apparent that both an am-AR and am-AR- 
mediated response exists in the mouse carotid artery.
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3.4.4. Comparison with aorta
The aorta and carotid arteiy are considered to share similar pharmacological properties 
with the major contractile ai-AR of both being the am-AR (Daly et a t, 2002a;Piascik & 
Perez, 2001;Garcia-Sainz et a l, 1999;Yamamoto & Koike, 200lb;Yamamoto & Koike, 
2001a;Hosoda et a l, 2005a;Hosoda et al., 2005b;Yamamoto & Koike, 2001b;Deighan C, 
2002;Deighan et a l, 2005). However, there is no evidence of an aiA-AR-mediated 
response in the thoracic aorta of the WT mouse. Thus, the ai A-AR-mediated response in 
the carotid arteiy, described in the present study, may be a difference that exists between 
these vessels. Like the thoracic aorta, the upper abdominal aorta is am-AR-mediated, but 
the lower abdominal aorta is aiA-AR-mediated (Yamamoto & Koike, 2001a). This 
evidence of regional variations in the aj-AR subtypes in the same vessel suggests that, 
despite being considered pharmacologically similar, differences between the minor 
subtypes in the thoracic aorta and the carotid artery are entirely plausible. Furtheimore, 
differences exist in the ai-AR subtypes present in the branches of the aorta. For instance, 
this study has shown that the carotid arteiy is predominantly am-AR-mediated, with a 
contribution from the am-AR, while the iliac arteiy, a branch of the lower abdominal aorta 
is predominantly am-AR-mediated (Shibano et a l, 2002). It is plausible that as the 
distance fi'om the aortic arch increases the predominance of the am-AR may decrease, 
while the predominance of the am-AR may increase.
3.4.5. Comparison with rat
In addition to supporting evidence of the am-AR being predominant, the current study has 
provided evidence indicative of the am-AR having a functional role in the mouse carotid 
artery. The rat carotid arteiy has been more commonly studied and provides an insight to 
the mouse. The balance of evidence suggests that in the rat carotid arteiy the am-AR is 
also the dominant ai-AR (Villalobos-Molina & Ibarra, 1996;Martinez L et a l, 1999). The 
findings of the present study are similar to two studies in the rat carotid artery where both 
an am-AR and am-AR response was identified but no involvement from the am-AR was 
detected (Chiba & Tsukada, 2002;Naghadeh, 1996). However, there are still some 
discrepancies over the role of the am-AR in the rat carotid arteiy (de Oliveria et a l, 1998) 
and an am-AR-mediated response cannot be ruled out at present. The possible 
contribution of the a^-AR in the rat carotid artery raises the possibility that this ai-AR 
may contribute to the contiactile response in the mouse carotid artery.
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3.4.6. Conclusion
Without a doubt, the characterisation of ai-AR subtypes in vessels with apAR 
heterogeneity is restiicted by the availability of agonists and antagonists and a definite 
conclusion cannot be reached about the contribution of the am-AR and aiB-AR in the WT 
mouse. Fortunately, knockout mice of the ai-AR subtypes are available and have been 
used in Chapter Three to provide an insight into the situation in the WT mouse.
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Chapter Four 
Characterisation of the arAR knockout mice
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4.1. Introduction
Chapter Three has shown that the pharmacological analysis of the ai-AR subtypes is 
complex in the WT mouse, especially due to the limited numbers of selective agonists and 
antagonists. Consequently, mouse stiains with single and double knockout of the ai-AR 
subtypes have been developed and have been employed to assess ai-AR contractility.
4.1.1 ai-AR knockout mice
The aiB-KO was the first ai-AR knockout mouse to be generated, Cavalli et al. (1997) 
reported that the efficacy of phenylephrine was reduced in the thoracic aorta of the am-KO 
compared to the WT mouse, suggesting that the am-AR has a role in vasoconstiiction. A 
later study by Daly et al. (2002a) found that, in contrast to Cavalli et al. (1997), the 
efficacy of phenylephrine in the aorta was not significantly different to the WT mouse. 
However, this study found that the am-AR was the major ai-AR subtype in the aorta and 
carotid artery, while the am-AR was dominant in the first order mesenteric artery and tail 
artery. This study lent support to the conclusion of Cavalli et al. (1997) that the aiB-AR 
was involved in vasoconstriction, since some quantitative pharmacological differences 
existed in the am -KO, but added that this role was minor.
In the am-KO the contractile response in the aorta was markedly decreased in comparison 
with the WT mouse, providing evidence that the am-AR regulates vasoconstriction 
(Tanoue et a l, 2002c). Tire findings of two further studies (Ali, 2004;Yamamoto & Koike, 
2001b), supported both Tanoue et al. (2002a) and Daly et al. (2002a), as it was reported 
that the main contractile ai-AR in the mouse aorta was the am-AR. In addition, an am- 
AR-mediated contractile response to phenylephrine was present in the am-KO (Ali, 2004).
The am-KO revealed that the am-AR has a functional role in the maintenance of arterial 
blood pressure (Rokosh & Simpson, 2002) but, to date, in vitro studies have not been 
performed in this mouse. Similarly, there has not been an in vitro study of the vascular 
responses in the aiAB-KO (O'Connell et al, 2003).
In a recent study comparing ai-AR-mediated responses in the thoracic aorta of the am/D- 
KO, Hosoda et al. (2005a) reported that contractile responses to phenylephrine and 
noradrenaline were reduced in the am /o-KO , as well as the am -K O  and am -K O . In
79
particular, the aie/o-KO showed the response to noradrenaline or phenylephrine was 
abolished. Thus, it was concluded that the am-AR was the predominant ai-A R in the 
aorta, with a small contribution from the am-AR, which was consistent with the findings 
of the earlier studies in the single knockouts (Ali, 2004;Daly et a l,  2002a;Tanoue et a l, 
2002c). In a subsequent study, Hosoda et al. (2005b) characterised the noradrenaline- 
induced response in the thoracic aorta and mesenteric artery of the am/D-KO and compared 
this to the single knockouts of the am-AR and am-AR. In the thoracic aorta of the am/o- 
KO, the noradrenaline-induced response was almost abolished but was still detectable 
indicating that the role of the am-AR in the regulation of the thoracic aorta was minimal.
4.1.2. Carotid artery
Deighan (2002) undertook a detailed study of the carotid artery in the am-KO, in which a 
frinctional role of the am-AR was excluded due to the low affinity of 5-methylurapidil 
against the phenyleplrrine-induced response. BMY 7378 antagonised the phenylephiine 
response with high potency, which implicated that the am -AR mediated the contractile 
response in the am-KO. In addition, Deighan (2002) presented evidence indicative of a i-  
AR heterogeneity in the WT mouse carotid artery, raising the possibility that the am-AR 
may contribute to the contractile response in the WT mouse.
4.1.3. Aims
Wliile several research groups have examined the contractile ai-ARs in the aorta and 
resistance arteries in the ai-A R knockout mice, a comparative study of the carotid artery in 
the am-KO, am/o-KO or am/B-KO has not been performed. Furthermore, the am -AR has 
been characterised as the predominant ai-A R in the mouse carotid artery, but the roles of 
the am-AR and am-AR have not been resolved. The am-KO thus provides an 
opportunity to identify and study the other ai-A R subtypes.
The aims of the cun*ent study were:
• To characterise the phenylephrine-induced response in the am-KO carotid artery, 
enabling its profile to be studied when only the am -AR and am-AR can be present.
• To characterise the A-61603-induced response in the carotid artery of the am/o-KO 
in order to study its profile when only the am-AR can be present.
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To isolate an a i A-AR-mediated response in the carotid artery of the am-KO, using 
the aiA-AR selective agonist A-61603, and then determine whether the aiA-AR 
and/or am-AR are functional using selective antagonists.
To determine whether the contractile response in the carotid artery of the am-KO 
has an am-AR-mediated component.
• To carry out preliminaiy experiments in the ams-KO, in which only am-ARs can 
be present.
• To compare the findings in the knockouts with the WT mouse in order to further 
assess the subtype profile of the WT mouse in light of the findings in the knockout 
mice.
4.2. Methods
The dissection, vessel mounting and acclimatisation period are described in detail in 
Chapter Two. In brief, four-five-month old male knockout mice (am-KO (31-46g); am - 
KO (25-34g); am/D-KO (32-54g); ame-KO (29-3Ig)) were killed by carbon dioxide 
overdose and both common carotid arteries were dissected. Following cleaning, vessels 
were mounted in a four-chamber wire myograph containing gassed (95% O2 / 5% CO2) 
and heated (37°C) PSS. Vessels were allowed to acclimatise for 30 minutes before a 
resting tension of 0.25g was added to each vessel and a further 45 minutes acclimatisation 
period prior to the start o f the experimental protocol.
4.2.1. Comparison o f agonist responses in the double knockouts
In the aiA/B-KO and am /o -K O , the contractile response to phenylephiine, A-61603 and 5- 
HT were compared. A wake-up protocol for phenyleplirine was performed as described in 
Chapter Two. Following frirther PSS washes and ten minute rest period, a 5-HT wake-up 
protocol was also performed. Then the vessels were washed with PSS and allowed to rest 
for 30 minutes. CRCs to phenylepluine (1 nM -  0.1 mM), A-61603 (1 iiM -  0.1 inM) and 
5-HT (1 nM -  30 pM) were produced using half-log increments.
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4.2.2. Characterisation of phenylephrine-induced response
In the aiD-KO, the phenylephrine-indueed response was characterised. A phenylephrine 
wake-up protocol was performed as described in Chapter Two. Then the vessels were 
washed with PSS and allowed to rest for 30 minutes. CRCs to phenylephrine (1 nM -  0.1 
mM) were produced using half-log increments. Prior to the second CRC, vessels were 
incubated for 30 minutes with: the non-selective ai-AR antagonist prazosin (0.1 nM, 1 
nM, 10 nM); œia-AR selective antagonists 5-methylurapidil (lOnM, 0.1 pM, 0.3 pM, 1 
pM) and RSI00 329 (1 nM, 10 nM, 0.1 pM); or am-AR selective antagonist BMY 7378 
(InM, 10 nM, 0.1 pM). A second phenylephrine CRC was then produced in the presence 
of the antagonist or in the absence of an antagonist acting as a time control.
Following the same protocol, prazosin (10 nM) was tested against the phenylephrine- 
induced response in the am/D-KO, while BMY 7378 (10 nM) was tested against the 
phenylephrine-induced response in the aiA/e-KO.
4.2.3. Characterisation of A-61603-induced response
A  wake-up protocol for A-61603 was performed as described in Chapter Two. Following 
washing with PSS and a 30 minute rest period the first CRC to A-61603 (1 nM -  0.1 mM) 
was constructed in half-log increments. Prior to the second CRC the vessels were 
incubated for 30 minutes with an antagonist. The non-selective a i-A R  antagonist prazosin 
(1 nM, 10 nM, 0.1 pM) was used against the A-61603 CRC in the am -K O  and am /o-KO. 
The aiA-AR selective antagonists 5-methylurapidil (10 nM, 0.1 pM, 0.3 pM, 1 pM) and 
R S I00 329 (1 nM, 10 nM, 0.1 pM), as well as the am -A R  selective antagonist BMY 7378 
(1 nM, 10 nM, 0.1 pM), were tested in the am -K O  and am -K O . R S I00 329 (10 nM) and 
BMY 7378 (10 nM) were tested against the A -61603-induced response in both double 
knockouts, while 5-methylurapidil (0.1 pM) and the az-A R  antagonist rauwolscine (10 
nM) were also used in the am /o-KO. A  second CRC was produced in the presenee of an 
antagonist, or in the absence of an antagonist acting as a time control.
4.2.4. Statistical analysis
Data were expressed as means ± standard error in grams tension and percentage of the 
maximum response of the control CRC. The maximum responses recorded, pECso values 
of the agonist response in the absence or presence of an antagonist were compared using
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either a Student’s t-test or one-way ANOVA, followed by a Bonferroni’s post test CRCs 
were compared using two-way-ANOVA with a Bonferroni post-test. Nonlinear regression 
was performed to fit sigmoidal-curves (variable slope) on mean data of responses in grams 
and percentage of the maximum response of the control CRC. Linear regression was 
performed to detennine the pA% from the X-intercept of the Schild plot. When a single 
concentration of antagonist had no effect, or there was a significant reduction in the 
maximum response obtained, a pKs was calculated from the remaining concentration(s) of 
antagonist.
4.3. Results
4.3.1. Agonist responses
4.3.1.1. aiA/B "KO
In the aiAB-KO, the agonist responses to phenylephrine (oci-AR non selective agonist), A- 
61603 (aiA-AR selective agonist) and 5-HT were compared (Figure 4.1; Table 4.1). 
Concentration-dependent contractions were produced in response to both phenylephiine 
and 5-IiT. However, contractions to A-61603 were produced only at high eoncentrations.
Table 4.1. Comparison of agonist responses In aiA/B-KO.
Agonist 11 pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 3 7.6±0.11 0.23^=0.03 1.4 (1.3-1.4)
A-61603 control 3 5.5±0.17’"" 0.10±0.02"" 1.2(1.2-1.3)+
5-HT control 3 7.1±0.02'" 0.21±0.02'*' 2.5(1.1-3.9)"^
*p>0.05, p<0.01, p<0.001 compared to PE control (one-way ANOVA, Bonferroni’s post
test).
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Figure 4.1. Am-KO: Comparison of agonist responses expressed as means ± S.E. in (A) 
grams force and (B) percentage of maximum response of the control CRC (n=3). (C) 
Comparison of maximum response obtained in grams tension ± S.E. ** p<0.01 compared to 
PE control.
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4 . 3 . 1 . 2 .  a iB /D “K O
In the aiB/D-KO, contractions to phenylephrine were produced only at high concentrations 
(Figure 4.2; Table 4.2). Coneentiation-dependent contractions to A-61603 (Figure 4.3; 
Table 4.3) and 5-HT (Figure 4.4; Table 4.4) were observed. The responses in the am/D- 
KO varied between agonists (Figure 4.5; Table 4.5) and the potency series differed 
markedly from the aiA/B-KO (Figure 4.1; Table 4.1).
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Figure 4.2. aiB/o-KO: Comparison of the phenylephrine control and time control CRCs 
expressed as means ± S.E. in (A) grams force and (B) percentage of maximum response of 
the control CRC (nS7).
Table 4.2. Comparison of phenylephrine control and time control in aiB/o-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 8 5.2±0.04 0.06 ±0.02 1.3 (1.1-1.5)
PE time control 7 5.0±0.07^ 0.06 ±0.02’^ 1.1 (1.0-1.3)"^
p>0.05 compared to phenylephrine control (Student’s t-test).
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Figure 4.3. aiB/D“KO: CRC to A-61603 for control and time control expressed as means ± S.E. 
in (A) grams force and (B) percentage of maximum response of the control CRC (n=7).
Table 4.3. Comparison of A-61603 control and time control in aie/o-KO-
Agonist n pECso Maximum response (g) Hill slope (95% 
C l)
A-61603 control 7 6.6±0.07 0.10 ±0.03 0.6 (0.5-0.7)
A-61603 time 
control
7 6.5±0.22'" 0.10±0.03^ 0.6 (0.5-0.7)'"
p>0.05 compared to A-61603 control (Student’s t-test).
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Figure 4.4. aiem-KO: Comparison of 5-HT control and time controi expressed as means ± S.E 
in (A) grams force and (B) percentage of maximum response of the control CRC. (n=7).
Tabie 4.4. Comparison of 5-HT control and time control in ais/o-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
5-HT control 7 6.8±0.07 0.26+0.03 1.4(1.3-1.4)
5-HT time 
control
7 6.8i0.12^ 0.27+0.04"' 1.3 (1.2-1.4)^
'p>0.05 compared to 5-HT controi (Student’s t-test).
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Figure 4.5. aie/o-KO: Comparison of agonist responses expressed as means ± S.E in (A) 
grams force and (B) percentage of maximum response of the control CRC (nàlO). (C) 
Comparison of maximum response obtained in grams tension ± S.E, *** p<0.001 compared 
to PE control.
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Table 4.5. Comparison of agonist responses in the amm-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 8 5.2±0.04 0.06 ±0.02 1.3(1.1-1.5)
A-61603 control 7 6.6±0.07''' 0.10+0.03^ 0.6 (0.5-0.7)*
5-HT control 7 6.8±0.07'"' 0.26+0.03*** 1.4(1.3-1.4)'"
^p>0.05, * p<0.05, *** p<0.001 compared to PE control (one-way ANOVA, Bonferroni’s post 
test).
4.3.1.3. (Xid"KO
In the aiD-KO, reproducible concentration-dependent contractions were obtained in 
response to phenylephrine (Figure 4.6; Table 4.6) and A-61603 (Figure 4.7; Table 4.7). 
For both agonists no differences in the maximum response obtained or sensitivity were 
observed.
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Figure 4.6. aiD-KO: CRC to phenylephrine control and time control expressed as means + 
S.E. in (A) grams force and (B) percentage of maximum response of the control CRC (n=12).
Table 4.6. Comparison of phenyiephrine control and time control In am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 12 5.6±0.06 0.22±0.02 0.9 (0.7-1.2)
PE time control 12 5.6±0.13^ 0.21±0.02^ 0.8 (0.7-0.9)^
 ^p>0.05 compared to phenylephrine control (Student’s t-test).
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Figure 4.7. am-KO: CRC to A-61603 for control and time control expressed as means ± S.E. 
in (A) grams force and (B) percentage of maximum response of the control CRC (n=10).
Table 4.7. Comparison of A-61603 control and time control in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.94=0.06 0.13+0.01 0.5 (0.4-0.7)
A-61603 time 
control
10 e.OiO-iv"" 0.11+0.01^ 0.3 (0.3-0.3)'"
+ p>0.05 compared to A-61603 control (Student’s t-test).
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In the aiB“KO, concentration-dependent contractions were produced to phenylephrine 
(Figure 4.8; Table 4.8) and A-61603 (Figure 4.9; Table 4.9). For both agonists no 
differences in the maximum response obtained or sensitivity were observed.
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Figure 4.8. am-KO: CRC to phenylephrine for control and time control expressed as means ± 
S.E. in (A) grams force and (B) percentage of maximum response of the control CRC (n=9).
Table 4.8. Comparison of phenylephrine control and time control in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 9 6.9±0.09 0.32 ±0.02 0.6 (0.5-0.6)
PE time control 9 6.9±0.10^ 0.31±0.02'" Ô.6 (0.5-0.6)'*'
 ^p>0.05 compared to phenylephrine control (Student’s t-test).
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Figure 4.9. aiB-KO: CRC to A-61603 for control and time control expressed as means ± S.E. 
in (A) grams force and (B) percentage of maximum response of the controi CRC (n=7).
Tabie 4.9. Comparison of A-61603 controi and time controi in « ib-KO-
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 7 6.6±0.11 0.25 ±0.01 0.8(0.7-0.8)
A-61603 time 
control
7 6.7±0.2r 0.27±0.03^ 0.7 (0.7-0.7)'^
* p>0.05 compared to A-61603 controi (Student’s t-test).
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4.3.1.5. Comparison of agonist responses in WT mouse and knockouts 
Phenylephrine-induced response
Phenylephrine produced concentration-dependent conhactions in all mouse strains with the 
exception of the am/o-KO, where contractions were produced only in response to high 
concentrations of the agonist (Figure 4.10, Table 4.10). Compared to the WT mouse the 
maximum response obtained to phenylephrine was not significantly different in the am- 
KO and aiA/B-KG but was reduced in the am-KO. The phenylephrine-induced response 
was significantly smaller in the am/D-KO than in the other four strains of mice. The aiA/B- 
KO showed the highest sensitivity to phenylephrine followed by the am-KO and the WT 
mouse with the am-KO and the am/o-KO showing significantly lower sensitivity.
Table 4.10. Comparison of phenylephrine response In the WT mouse and knockouts.
Mouse u pECso Maximum respouse (g) Hill slope (95% 
Cl)
WT 7 6.6±0.05 0.27±0.03 0,6 (0.5-0.7)
aiB-KO 9 6.9±0.10^ 0.32±0.02^ 0.6 (0.5-0.6)^
am-KO 12 5.6±0.06^^^ 0.22±0.02" 0.9 (0.7-1.2)""
aiB/D“KO 8 5.0±0.07’^^ 0.06 ±0.02*" 1.3(1.1-1.5)'''
otiA/B-KO 3 7 .6 ± 0 .ir '' 0.23±0.03^ 1.4(1.3-1.4)'"
* p>0.05, ** p<0.01, *** p<0.Q01 compared to WT mouse (one-way ANOVA, Bonferronl’s post 
test).
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Figure 4.10. Comparison WT mouse and knockouts: phenylephrine response expressed as 
mean ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC (nàlO, with exception of aiA/e-KO (n=3)). (C) Comparison of maximum response obtained to phenylephrine in grams tension ± S.E. ** p<0.01 and *** p<0.001.
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A-61603-induced response
A-61603 produced concenti’ation-dependent contractions in all strains of mice, with the 
exception of the œia/b-KO, in which contractions were produced only at high 
concentrations of the agonist (Figure 4.11; Table 4.11). The maximum responses recorded 
for A-61603 were not significantly different in the WT mouse and aie-KO. Similarly, the 
maximum responses obtained to A-61603 were not significantly different in the am-KO, 
aiB/D-KO and aiA/B-KO, however, the efficacy in these strains was significantly reduced 
compared to the WT mouse and am-KO. Compared to the WT mouse the sensitivity to A- 
61603 was not significantly different in the aiA/B-KO but sensitivity was significantly 
higher in the am-KO, am-KO and am/n-KO.
Table 4.11. Comparison of the A-61603 response in the WT mouse and knockouts.
Mouse n pECso Maximum response (g) Hill slope (95% 
Cl)
WT 10 6.0±0.06 0.28±0.02 0.7 (0.5-0.9)
am-KO 7 6 . 6 ± 0 . i r ^ " 0.25 ±0.01'^ 0.8(0.7-0.8)'"
am-KO 10 6.9j:0.06'" 0.13±0.0f" 0.5 (0.4-0.7)"'
C t l B / D - K O 7 6.6±0.07''' 0.10+0.03*" 0.6 (0.5-0.7)^
O t l A / B - K O 3 5.5±0.17^ 0.10+0.02"* 1.2(1.2-1.3)"
 ^p>Q.05, ** p<0.01, *** p<0.001 compared to WT mouse (one-way ANOVA, Bonferroni’s post 
test).
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Figure 4.11. Comparison of WT mouse and knockouts: A-61603 response expressed as mean ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC. (C) Comparison of maximum response obtained to A-61603 in grams tension ± S.E. 
(n&IO, with exception of aiA/B"KO (n=3)) *** p<0.001.
97
4.3.2, Antagonist data
4.3.2.1. Phenylephrine-induced response
Deighan (2002;Deighan et a l ,  2005) obtained affinity estimates for prazosin, BMY 7378 
and 5-methylurapidil against the phenylephrine-induced response. These values have been 
included in Table 4.32. for completeness.
Prazosin
Prazosin potently antagonised the phenylephrine-induced response in the aiB/o-KO (Figure 
4.12; Table 4.12). Compared to the control CRC, the maximum response to phenylephrine 
was significantly reduced in the presence of prazosin 10 nM, therefore, it was not possible 
to calculate a pECso or a pKs.
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Figure 4.12. aiBo-KO: CRC to phenylephrine in the presence of prazosin expressed as 
means ± S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC (n=6).
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Table 4.12. Phenylephrine response In presence of prazosin in aiB/o-KO.
Agonist n pECso Maximnm response (g) Hill slope (95% 
Cl)
PE control 6 4.8 0.13±0,01 1.2(1,1-1.3)
Prazosin lOnM 6 N.D. 0.06±0.03^'* 0.9 (0.3-1.5)^
* p>0.05, *** p=0.001 compared to PE control (Student’s t-test).
In the aiD-KO, the phenylephrine-induced response was potently antagonised by prazosin 
(Figure 4.13; Table 4.13). The size of the response to phenylephrine was significantly 
reduced in the presence of prazosin 1 nM and 10 iiM, therefore pECso values could not be 
calculated. A pKe of 10.6 was calculated at prazosin 0. InM.
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Figure 4.13. am-KO: CRC to phenylephrine in the presence of prazosin expressed as means 
± S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n^7).
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Table 4.13. Phenylephrine response in presence of prazosin in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 11 5.1±0.07 0.12±0.02 1.1 (0.8-1.3)
Prazosin O.lnM 7 4.5±0.11” ^ 0.09±0.0r" (18 (0.5-1.1)^
Prazosin InM 7 N.D. 0 .0 7 ± 0 .0 f 0.6 (0.3-0.9)^
Prazosin lOnM 8 N.D. 0.04±0.0l'"" 0.6 (0.1-1.0)""
^p>0.05,** p<0.01, *** p<0.001 compared to PE control {one-way AN OVA, Bonferroni’s post 
test).
5-methy[urapidil
5-methylurapidil acted competitively against phenylephrine in the aio-KO (Figure 4,14; 
Table 4.14). Schild regression analysis was performed for 5-methylurapidil against 
phenylephrine and produced a pA% of 8.1, with a slope of 0,8 (0.4-1.3).
Table 4.14. Phenylephrine response in presence of 5-methylurapidil in aio-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 7 5.6±0.18 0.19±0.05 1.4 (1.2-1.6)
S-MeU 0.1 pM 7 5.1±0.14" 0.19±0.02^ 1.0 (0.5-1.7)""
5-MeU 0.3 pM 7 4.7±0.25' 0.153=0.03^ 1.3 (1.2-1.4)+
5-MeU 1 pM 7 4.6±0.12" 0.153=0.02"^ 1.3 (1.2-1.4)+
p>0.05, * p<0.05 compared to PE control (one-way AN OVA, Bonferroni’s post test).
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Figure 4.14. aiD-KO: CRC to phenylephrine in the presence of 5-methylurapidil expressed 
as means ± S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC (n=7).
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RS100 329
In the aiD“KO the phenylephrine-induced response was antagonised by RSlOO 329 lOnM 
and 0.1 jxM (Figure 4.15; Table 4.15). In the presence of RSI00 329 0.1 pM a maximum 
response was not obtained at the highest concentration of phenylephrine used, therefore a 
pECso was not calculated. A pKe of 9.1 was calculated at RSI00 329 10 nM.
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Figure 4.15. aip-KO: CRC to phenylephrine in the presence of RSI00 329 expressed as 
means ± S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC (n2:7).
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Table 4.15. Phenylephrine response in presence of RS100 329 in aio-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 8 5.4±0.09 0.20±0.03 1.2 (0.8-1.5)
RSlOO 329 InM 8 4.7±0.29'" 0.21±0.04'" 0.9 (0.7-1.2)^
RSlOO 329 lOnM 6 4.6±0.16 0.16±0.02"" 1.3(1.1-1.5)"
RSlOO 329 0.1 pM 8 N.D. 0.12±0.0r 6.8 (0.5-1.2)"
^p>0.05, * p<0.05 compared to PE control (one-way AN OVA, Bonferroni’s post test). 
BMY 7378
In the aiA/B-KO, BMY 7378 10 nM caused a rightward displacement of the phenylephrine- 
induced response (Figure 4.16; Table 4.16). A pKe of 9.0 was calculated for BMY 7378 
10 nM against the phenylephiine-induced response.
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Figure 4.16. aiA/s-KO: CRC to phenylephrine in the presence of BMY 7378 expressed as 
means ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC (n=3).
Table 4.16. Phenylephrine response in presence of BMY 7378 in «1A/B-K0.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 3 7.6±0.11 0.23i0.03 1.4 (1.3-1.4)
BMY 7378 lOnM 3 6.4±0.14"’ 0.22±0.03‘*' 1.5 (1.2-1.7)'"
+ p>0.05, *** p<0.001 compared to PE control (Student’s t-test).
In the am-KO a rightward shift in the phenylephrine CRC was observed in the presence of 
BMY 7378 0.1 pM (Figure 4.17; Table 4.17). A pKe of 7.0 was calculated for BMY 7378 
at 0.1 pM.
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Figure 4.17. am-KO: CRC to phenylephrine In the presence of BMY 7378 expressed as 
means ± S.E. In (A) grams tension and (B) percentage of maximum response of the control 
CRC (n>6).
Table 4.17. Phenylephrine response In presence of BMY 7378 in am-KO.
Agonist n pECso Maximum response 
(g)
Hill slope (95% 
Cl)
PE control 8 6.0±0.17 0.173=0.03 0.9(0.9-1.0)
BMY 7378 InM 7 5.6±0.32'" 0.153=0.01^ 0.7 (0.6-0.7)'"
BMY 7378 lOnM 6 5.6±0.49'" 0.153=0.01'" 0.8 (0.6-0.7)'"
BMY 7378 O.lpM 7 4.8±0.23"" 0.143=0.02^ 0.7 (0.6-0.7)'"
 ^p>0.05, p<0.01 compared to PE control (one-way ANOVA, Bonferronl’s post test).
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4.3.2.2. A-61603-induced response 
Prazosin
In the aiB/D-KO prazosin lOnM antagonised the A-61603-induced response (Figure 4.18; 
Table 4.18) producing a pKs of 9.1.
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Figure 4.18. cxibd-KO: CRC to A-61603 in the presence of prazosin expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=6).
Table 4.18. A-61603 response in presence of prazosin in oibd-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6 .6 i 0 .2 3 0 .1 2 ± 0 .0 1 0 .5  (G .3 -0 .5 )
Prazosin lOnM 6 5 . 4 ± 0 . i r " O .lO T O .O r 0 .5  (0 .2 -0 .8 )
p>0.05, p<0.01 compared to the A-61603 control (Student’s t-test).
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A rightward shift in the A-61603 CRC was produced by prazosin lOnM and 0.1 pM in the 
am-KO (Figure 4.19; Table 4,19) enabling a pKe of 8.9 to be calculated.
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Figure 4.19. am-KO : CRC to A-61603 in the presence of prazosin expressed as means ± S.E. 
in (A) grams tension and (B) percentage of maximum response of the controi CRC (n&7).
Tabie 4.19. A-61603 response in presence of prazosin in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 8 7.0±0.15 0.15±0.01 0.5 (0.5-0.6)
Prazosin InM 8 6.4±0.14'" 0.13±0.02^ 0.3 (0.2-0.4)’"
Prazosin lOnM 7 5.6±0.16” 0.13±0.02^ 0.4 (0.2-0.6)'
Prazosin 0.1 pM 7 5.1±0.35'^’ 0.13±0.02’^ 0.5(0.1-0.9)^
post test).
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Rauwolscine
In the aiB/D-KO rauwolscine lOnM did not produce a rightward shift in the A-61603- 
induced response (Figure 4.20; Table 4.20).
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Figure 4.20, aiBo-KO: CRC to A-61603 In the presence of rauwolscine expressed as means + 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=6).
Table 4.20. A-61603 response in presence of rauwolscine in aiBD-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6.5±0.14 0.13±0.02 0.9 (0.6-1.2)
Rauwolscine lOnM 6 6.2±0.24’^ O.lliO.02'" 0.8 (0.5-1.2)-"
*p>0.05 compared to A-61603 control (Student’s t-test).
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5-methyiurapîdil
In the aiB/D-KO, 5-methylurapidil caused a rightward displacement of the A-61603 CRC 
(Figure 4.21; Table 4.21), producing a pKs of 8.3.
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Figure 4.21. aiBo-KO: CRC to A-61603 In the presence of 5-methylurapidil expressed as 
means + S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC (n^7).
Table 4.21. A-61603 response in presence of 5-methylurapidil in aiBo“KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 8 6.5±0.13 0.11±0.04 0.8 (0.5-1.1)
5-MeU 0.1 pM 7 5.4±0.20"" O.lliO.04’*' 0.6 (0.1-1.1)"
p>0.05, ** p<0.01 compared to the A-61603 control (Student's t-test).
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Increasing concentrations of 5-Methylurapidil produced rightward shifts in the A-61603 
CRC in the aio-KO (Figure 4.22; Table 4.17). A pAz of 9.2 with a slope of 0.7 (0.4-1.0) 
was calculated for 5-methylurapidil in the aio-KO.
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Figure 4.22. aio-KO: A-61603 CRC in the presence of 5-methylurapldil expressed as means 
± S.E. In (A) grams tension and (B) percentage of maximum response of the controi CRC 
(n>6).
110
Table 4.22. A-61603 response In presence of 5-methylurapidil in am-KO
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.7±0.08 0.14±0.01 0.6 (0.5-0.6)’"
5-MeU lOnM 6 5 .8m  12"' 0.14±0.03^ 0.8 (0.7-1.0)""
5-MeU 0.1 pM 6 5 . im i2 " ' 0.12±0.02'" 0.7 (0.7-0.8)^
5-MeU 0.3 pM 6 5.1±0.12"' O.lOiO.Or 0.9 (0.8-1.0)""
5-MeU 1 pM 6 4.5±0.06"' 0.10±0.02^ 0.9 (0.7-1.1)^
 ^p>0.05, *** p<0.001 compared to the A-61603 controi {one-way ANOVA, Bonferroni’s post 
test).
In the presence of increasing concentrations of 5-Methylurapidil, a rightward displacement 
of the A-61603 CRC was observed in the aiB-KO (Figure 4.23; Table 4.23). A pA% of 8.1 
was produced, with a slope of 1.1 (0.6-1.6), indicating competitive antagonism.
Tabie 4.23. A-61603 response in presence of 5-methyiurapidil in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6 .7m  14 0.283=0.02 0.8 (0.5-1.2)
5-MeU lOnM 6 6.2±0.16'*' 0.323=0.02'" 0.8 (0.3-1.4)""
5-MeU 0.1 pM 6 5.2±0.20"' 0.273=0.05"" 0.8(0.4-1.2)""
5-MeU 0.3 pM 6 4.93=0.29"' 0.283=0.07"" 1.2(1.0-1.3)^
5-MeU 1 pM 6 4.23=0.20"' 0.233=0.04"" 1.1 (0.3-1.8)""
p>0.05, p<0.001 compared to A-61603 controi (one-way ANOVA, Bonferroni’s post test).
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Figure 4.23. aiB-KO; CRC to A-61603 in the presence of 5-methylurapidil expressed as 
means ± S.E. in (A) grams tension and (B) percentage of maximum response of the control 
CRC (n>6).
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RSlOO 329
RSlOO 329 10 nM did not antagonise the A-61603-induced response in the ajA/B-KO 
(Figure 4.24; Table 4.24).
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Figure 4.24. «lA/B-KO: CRC to A-61603 in the presence of RSlOO 329 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=2).
Table 4.24. A-61603 response in presence of RSlOO 329 in ai/vB-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 2 5.5±0.17 0.10±0.02 1.2 (1.2-1.3)
RSlOO 329 lOnM 2 5.6±0.05'" O.lOiO.05"" 3.0(2.1-3.9)'
 ^p>0.05, *p<0.05 compared to A-61603 control (Student's t-test).
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In the aiB/D-KO RSI00-329 lOnM caused a rightward shift in the A-61603 response 
(Figure 4.25; Table 4.25). A maximum response was not obtained at the highest 
concentration of A-61603 used, therefore, a pKs could not be estimated.
0.30-
0.25-
c 0.20
c  015-
0.10-
-8 "7 ”6 “5
[A-61603] (Log M)
Control 
RS lOnM
120-1
o
20 -
-10 -9 -8 -7 -6 ■5 -4 -3
Control 
RS lOnM
[A-61603] (Log M)
Figure 4.25. uibd-KO: CRC to A-61603 in the presence of RSlOO 329 expressed as means 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=6).
Table 4.25. A-61603 response in presence of RSlOO 329 in amo-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6.6±0.42 0.14d=0.04 0.8 (0.2-1.6)
RSlOO 329 lOnM 6 N.D. o.o7±o.or 0.6 (0.2-1.2)^
*  p>0.05, p<0.05 compared to A-61603 response (Student’s t-test).
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In the aiD-KO, increasing concentiations of RSlOO 329 caused rightward displacements of 
the A-61603 CRC (Figure 4.26; Table 4.26). At RSlOO 329 0.1 jiM, a maximum response 
to A-61603 was not obtained, therefore, a pKe of 10.0 was calculated at RSlOO 329 InM 
and lOnM.
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Figure 4.26. am-KO: CRC to A-61603 in the presence of RSlOO 329 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=7).
Table 4.26. A-61603 response in presence of RSlOO 329 in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.8±0.07 0.174=0.01 0.8(0.5-1.0)
RSlOO 329 InM 7 5.64=0.09"' 0.174=0.02'" 0.6 (0.5-0.7)^
RSlOO 329 lOnM 7 5.04=0.07"' 0.184=0.03^ 0.8 (0.3-1.2)"'
RSlOO 329 0.1 pM 7 N.D. 0.134=0.02' 1.3 (1.1-1.6)"
+p>0.05, * p<0.05, *** p<0.01 compared to A-61603 control (one-way ANOVA, Bonferroni’s
post test).
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In the aiB-KO, the presence of RSlOO 329 10 iiM and 0.1 jiM produced a significant 
rightward displacement of A-61603 CRC (Figure 4.27; Table 4.27), enabling a pKs of 8.5 
to be produced. With RSlOO 329 0.1 pM a biphasic CRC was produced.
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Figure 4.27. aiB-KO: CRC to A-61603 in the presence of RSlOO 329 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(nS6).
Table 4.27. A-61603 response in presence of RSlOO 329 in ais-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 6.4i0.05 0.25^=0.02 0.8 (0.7-0.8)
RSlOO 329 InM 6 6.0±0.23^ 0.28±0.05'" 0.8 (0.8-0.9)^
RSlOO 329 lOnM 6 5.8±0.71 0.24 =^0.03^ 1.0(0.8-1.3)""
RSlOO 329 0.1 iiM 6 5.7T0.37 0.25=L0.04"^ 1.0(0.5-1.9)'"
 ^p>0.05; * p<0.05 compared to A-61603 control (one-way ANOVA, Bonferroni's post test).
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BMY 7378
In the aiA7B-K.O, BMY 7378 10 nM produced a rightward shift to the A-61603 CRC 
(Figure 4.28; Table 4,28), enabling a pKn of 9.1 to be obtained.
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Figure 4.28. œia/b-KO: CRC to A-61603 in the presence of BMY 7378 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=2).
Table 4.28. A-61603 response In presence of BMY 7378 in aiA/s-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 2 5.5T0.17 0.104:0.02 1.2 (1.2-1.3)
BMY 7378 lOnM 2 4.7±0.06* 0.094:0.03"^ 1.2 (0.8-1.5)""
p>0.05, * p<0.05 compared to A-61603 controi (Student’s t-test)
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In the aiB/D"KO, BMY 7378 failed to produce a significant shift in the A-61603 response 
(Figure 4,29; Table 4.29).
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Figure 4.29. aiBD“KO: CRC to A-61603 In the presence of BMY 7378 expressed as means ± 
S.E. In (A) grams tension and (B) percentage of maximum response of the control CRC 
(n=6).
Table 4.29. A-61603 response in presence of BMY 7378 In amo-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6.2T0.33 0.09±0.02 0.4 (0.4-0.5)
BMY 7378 lOnM 6 6.1±0.16^ 0.10T0.03^ 0.5 (0.4-0.6)''
'^p>0.05 compared to A-61603 control (Student’s t-test).
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Increasing concentrations of BMY 7378 did not antagonise the A-61603 CRC in the aio- 
KO (Figure 4.30; Table 4.30).
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Figure 4.30. am-KO: CRC to A-61603 in the presence of BMY 7378 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the controi CRC 
(nS:6).
Tabie 4.30. A-61603 response in presence of BMY 7378 in am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 10 7.1±0.13 0.14±0.01 0.4 (0.4-0.5)
BMY 7378 InM 6 6.8±0.26'" 0.13±0.02'" 0.3 (0.2-0.3)'*’
BMY 7378 lOnM 6 6.5±0.40^ 0.14±0.03^ 0.3 (0.3-0.3)^
BMY 7378 0.1 pM 7 6.5 m  15^ 0.13±0.03'" 0.3 (0.2-0.3)'"
p>0.05 compared to A-61603 control (one-way ANOVA, Bonferroni’s post test).
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In the aiB-KO, BMY 7378 did not cause a rightward shift in the A-61603 CRC (Figure 
4.31; Table 4.31).
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Figure 4.31. ais-KO: CRC to A-61603 In the presence of BMY 7378 expressed as means ± 
S.E. in (A) grams tension and (B) percentage of maximum response of the control CRC 
(n>6).
Table 4.31. A-61603 response in presence of BMY 7378 in aiB“KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 8 6.2±0.10 0.20^=0.02 0.9 (0.7-1.1)
BMY 7378 InM 6 6.2±0.33^ 0.19=b0.07'' 0.6 (0.5-0.8)'*'
BMY 7378 lOnM 6 6.1±0.24'" 0.20=1=0.03'" 0.7(0.6-0.8)'"
BMY 7378 0.1 pM 6 5.8±0.37‘" 0.21=t0.02^ 0.6 (0.3-0.9)'"
 ^ p>0.05 compared to A-61603 control (one-way ANOVA, Bonferroni’s post test)
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4.4. Discussion
In the present study single and double knockouts of the ai-AR subtypes were employed to 
provide a valuable insight into the function of the ai-AR subtypes mediating the 
contractile response in the carotid artery of the WT mouse,
4.4.1. arA R  characterisation in the aiA/B-KO
Preliminary experiments were perfonned in the aiA/B-RO in order to gauge the ai-AR- 
mediated contractile response in this mouse. The a^-A R  is the only possible aj-AR 
subtype in the œia/b-KO and this mouse provided the opportunity to assess the actions of 
the agonists and antagonists used tlnoughout this study solely at the am-AR. It should be 
noted that no time controls for either phenylephrine or A-61603 were obtained in the aiA/B- 
KO due to the preliminary nature of the experiments in this strain. The phenylephrine- 
induced response was potent producitrg a large maximum response. In contrast, a 
contractile response was observed only at high concentrations of A-61603 and the response 
showed reduced efficacy compared to phenylephrine. The responses to the ai-AR agonists 
were compared with 5-HT to assess the contractile capability of the carotid artery in this 
mouse via a non-adrenergic mechanism. The contractile response to 5-HT was comparable 
to that reported in the WT mouse and single knockouts (Deighan C, 2002;Deighan et al, 
2005). It is, therefore, apparent that the reduction in the contractile response to A-61603 
was due to the loss of the two ai-AR subtypes, and not due to an overall reduction in the 
ability of the carotid artery to contract. From these early results, it was clear that 
phenylephrine does show some selectivity for the am-AR over the œia-AR and am-AR, 
supporting the findings of Knepper et al. (1995). Furthermore, high concentrations of A- 
61603 produced a contractile response. This suggests that A-61603 does have an action on 
the aiD-AR, but has reduced sensitivity and efficacy at this ai-AR subtype compared to the 
aiA-AR, which supports the findings of Knepper and colleagues (1995;Meyer et al, 1996). 
However, as a study of the pig carotid vasculatirre reported that A-61603 can act via a non- 
adrenergic mechanism (Willems et al., 2001), further pharmacological arralysis of the A- 
61603 contractile response was required.
BMY 7378 acted potently against phenylephrine (pA% 9.0) and A-61603 (pAi of 9.1). This 
is consistent with published affinity values for the am-AR (see Chapter Orre.), confirming 
that the aiD-AR was functional in this mouse. Furthermore, this confirms that A-61603
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also acts on the aio-AR. RSlOO 329 10 nM did not have an effect on the A-61603 CRC, 
indicating that RSlOO 329 has very low affinity for the am-AR. It has been reported that 
A-61603 acted through a non-adrenoceptor-mediated mechanism in the carotid 
arteriovenous anastomes of the pig (Willems et al, 2001). Therefore, the possibility that 
the A-61603-induced response in the aiA/B-KO is mediated by a non-adrenergic pathway 
does require further investigation. However, based on the evidence obtained in the aiA/B- 
KO at present the A-61603-induced response does appear to be ai-AR-mediated.
4.4.2. arA R  characterisation in the aiB/o~KO
In the aiB/D-KO, the aiA-AR is the only possible ai-AR subtype. In the aiB/D-KO the 
phenylephrine and A-61603 time controls were reproducible, validating their use for 
further pharmacological analysis. Phenylephrine showed lower sensitivity and efficacy, 
compared to A-61603, which contrasts with the aiA/B-KO and is consistent with 
phenylephrine being less potent at the aiA-AR, while the reverse holds for A-61603. This, 
together with the agonist data in the aiA/B-KO, provides good evidence that A-61603 is 
selective for the aiA-AR over the am-AR and that phenylephrine has some selectivity for 
the aiD“AR over the aiA-AR, which has been reported previously (Kirepper SM et al, 
1995;Meyer et al, 1996). The responses to phenylephrine and A-61603 were compared to 
a contractile response mediated through a non-adrenergic mechanism: 5-HT. The 5-HT 
CRCs were comparable to that reported in the WT mouse and single knockouts (Deighan 
C, 2002;Deighan et al, 2005), suggesting that the reduction in the contractile response to 
phenylephrine was due to the loss of two ai-AR subtypes and not due to an overall 
reduction in the contr actility of the carotid artery.
Prazosin acted with such high affinity against the contractile response to phenylephrine 
that the agonist response was almost completely abolished by a low concentration. This 
phenomenon was also reported by Hosoda et al. (2005b) for the noradrenaline-induced 
response in the aiB/o-KO in the thoracic aorta. Nevertheless, prazosin potently and 
competitively antagonised the A-61603-induced response in aie/o-KO (pKb 9.1), 
indicating that the A-61603 response was ai-AR-mediated. This was further supported by 
rauwolscine not having an effect on the A-61603 contractile response, opposing the 
possibility that the A-61603-induced response could be a 2-AR-mediated. The lack of 
effect of BMY 7378 lOnM on the A-61603 CRC suggested that BMY 7378 has very low 
affinity for the aiA-AR. This is supported by the low pAz of 6.5 obtained against the
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phenylephrine-induced response in the first order mesenteric artery of the mouse, which is 
predominantly aiA-AR-mediated (McBride et al Submitted for publication). The pKs of 
8.3 for 5-methylurapidil against the A-61603 response was lower than expected 
considering that the aiA-AR was the only ai-AR subtype present. However, RSI00 329 
was particularly potent in the aiB/o-KO, where the contiactile response to A-61603 was 
almost completely abolished. These findings suggest that the aiA-AR does mediate the 
contiactile response to phenylephrine and A-61603 in the ajB/D-KO-
4.4m 3. The cKfo-ACO
The aiD-KO provides an oppoitunity to study the ai-AR subtypes in the mouse carotid 
arteiy in the absence of the predominant contractile ai-AR. Potentially either the œia-AR 
or aiB-AR, or both of these ai-AR subtypes, could regulate the contractile response in the 
aiD-KO. The time controls for both phenylephrine and A-61603 were reproducible, 
validating the use of these ai-AR agonists for further phaiTnacological analysis. In the 
aiD-KO phenylephrine showed reduced sensitivity and efficacy, which can be accounted 
for by the loss of the am-AR. The efficacy of A-61603 was reduced in the aio-KO 
suggesting that the aio-AR may mediate a component of the A-61603 response.
Prazosin acted with high affinity against the phenylephrine-induced response in the am- 
KO, producing a high pKg (10.6) comparable to that obtained by Deighan (2002;Deighan 
et al, 2005) in the am-KO (pAz 10.3). However, in the aio-KO, the presence of prazosin 
caused nonparallel shifts and depressed the maximum response obtained to phenylephrine 
suggesting non-competitive antagonism. Deighan (2002) demonstrated that prazosin acted 
competitively against phenyleplirine in the WT mouse and ais-KG. It, therefore, appears 
that the difference in the nature of antagonism by prazosin is due to the absence of the aio- 
AR. Prazosin has been reported to act non-competitively against both phenylephrine and 
noradrenaline in the intact rat aorta, but competitively in the absence of the endothelium 
(Alosachie & Godfraind, 1988). Thus, the endothelium may account for the non­
competitive action of prazosin against phenylephrine in the am-KO and am/o-KO.
Further experiments to establish whether prazosin acts competitively in the aio-KO and 
ot!B/D“KO in the absence of the endothelium would confirm this hypothesis.
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Prazosin antagonised the A-61603-induced response (pKg 8.9) with lower affinity than the 
phenylephrine response but does still indicate a high affinity site, suggesting the response 
is ai-AR-mediated. As prazosin acted competitively against A-61603, this also suggests 
that the non-competitive nature of prazosin against phenylephrine is related to the aio-AR.
Only the highest concentration of BMY 7378 (0.1 pM) antagonised the phenylephrine 
response. Thus, a low pKe o f 7.0 was produced, which confirms that the am-AR is absent. 
The lack of effect of BMY 7378 10 nM on the A-61603 CRC suggested that this antagonist 
did not have an action at either the aiA-AR or aie-AR. In the aio-KO the high affinity of 
5-methylurapidil against both phenylephrine (pAi 8.1) and A-61603 (pA^ 9.2) suggested 
that the responses were aiA-AR-mediated. The affinity estimates for R S I00 329 against 
the A-61603-induced response in the aio-KO (pKe 10.0) was higher than the 
phenyleplirine response (pKe 9.1). Both of these affinity estimates are consistent with 
R S I00 329 acting at the Œia-AR. These affinity estimates for both selective aiA-AR 
antagonists are comparable to that obtained in the first order mesenteric artery of the WT 
mouse in which 5-methylurapidil showed higher affinity against phenyleplirine (pKe 8.3) 
than A-61603 (pKs 8.9) and R S I00 329 produced a high pKe of 10.1 (McBride et al. 
Submitted for publication). In the present study, the lower affinity against the 
phenylephrine-induced response may reflect that phenylephrine, but not A-61603, is acting 
on the aiB-AR. The findings suggest that the contractile response in the aio-KO is aiA- 
AR-mediated, but an aie-AR response may also exist.
4.4.4. The cxijErKO
In the aiB-KO, where the am-AR is present, the aiA-AR could potentially contribute to 
contraction. In the absence of any antagonists with suitable selectivity for the aiB-AR, the 
aiB-KO can be used as a substitute, hi the aiB-KO the phenylephrine and A-61603 time 
controls were reproducible, validating the use of these agonists for fuither pharmacological 
analysis. Both the phenyleplirine-induced response and A-61603-induced response were 
potent, with large maximum responses being produeed.
In the earlier study, BMY 7378 acted with high affinity (pKs 9.6) against the 
phenylephrine-induced response in the aiB-KO (Deighan C, 2002;Deighan et a l ,  2005), 
indicative of a aio-AR-mediated response. BMY 7378 did not antagonise the A-61603- 
induced response, implying that the aia-A R was mediating the response to A-61603, not 
the aiD-AR. Against phenylephrine, the estimated affinity for 5-methylurapidil reported
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by Deighan (2002) for the am-KO (pA2 7.6) was more indicative of an aio-AR-mediated 
response. When tested against A-61603, 5-methylurapidil showed higher affinity (pA2 
8.1), but this still did not clearly differentiate whether this was due to an aiA-AR- or aio- 
AR-mediated response. A pKs of 8.6 was obtained for R SI00 329 against A-61603, which 
is intermediate to the reported affinity o f R SI00 329 at the œia-AR and the aio-AR. The 
lower potency of the selective œia-AR antagonists in the aie-KO may be due to the 
dominant contractile response of the aio-AR masking the aiA-AR-mediated response. 
Collectively, these findings suggest that in the am-KO the am-AR is the predominant 
contractile ai-AR, although an aiA-AR-mediated response does appear to exist.
4.4.5. Comparison with the W T mouse
The data obtained from the WT mouse (Chapter Tliree) suggested that the a i a-AR may 
have a functional role in the carotid artery. This was compared to the data obtained in the 
single knockouts (aie-KO and aio-KO) and double knockouts (aiA/B-KO and aiB/o-KO) to 
highlight the functional ai-A R subtypes in the WT mouse.
It has been shown that phenylephrine has approximately ten-fold higher affinity at the am - 
AR than the aiA-AR and am-AR (Knepper et al., 1995), which is reflected in a higher 
efficacy, and is a plausible reason for the decreased potency of phenylephrine in the am - 
KO and am/o-KO. This was emphasised in the aiA/B-KO, where in the absence of the 
other ai-A R subtypes, sensitivity to phenylephrine was higher than in any other strain of 
mouse. The maximum response obtained to phenylephrine in the aiA/B-KO was not 
statistically different to that observed in the WT mouse suggesting that the phenylephrine- 
induced response was predominantly mediated by the am-AR. However, an additional 
component to the contractions at high concentrations of phenylephrine was observed in the 
WT mouse, presumably due to the aiA-AR and/or aiB-AR. This trend was also observed in 
the ŒiB-KO, indicating that this secondary contractile a]-AR was a i a-AR-mediated. 
However, comparison of the agonist responses in the knockout mice with the WT mouse 
suggested that the phenyleplnine-induced response may be mediated by all three ai-AR 
subtypes. Further evidence to suggest that an am-AR-mediated component to the 
phenylephr ine response existed was revealed by comparison of the phenylephrine-induced 
response in the am-KO and am/o-KO.
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Comparison of the A-61603-induced response demonstrated that the maximum response 
obtained to A-61603 in the am-KO, amo-KO and aiAm-KO was much lower than in the 
aiB-KO and WT mouse. The reduced efficacy in the am-KO could suggest that there was 
a non-aiA-AR component to the A-61603-induced response, which was present in the aig- 
KO, but eliminated in the am-KO. Therefore, at high concentrations A-61603 may have 
some action on the am-AR. This was supported by contractions to A-61603 being 
observed only at high concentrations in the aiA/s-KO. The potency of A-61603 was 
unchanged between strains of mice, with the exception of the aiA/B-KO, in which 
sensitivity to A-61603 was markedly reduced. This supports A-61603 having higher 
efficacy at the aiA-AR than the am-AR and am-AR.
The a i-A R  responses in the am/D-KO were more variable than the am -K O . A recent 
study reported that the am -A R  was involved in regulating the cell surface expression of 
the am -A R  (Hague et al, 2004b). It is, therefore, possible that the am -A R  has some 
regulatory role in mouse carotid artery, which would explain the difference in contraction 
between the am -K O  and am /o-KO. Alternatively, the am -A R may have a minor 
contractile role as suggested by Daly et al. (2002a). However, it seemed that if the A- 
61603-induced response in the aiA/s-KO was combined with the response in the am /o-KO 
the overall response would be equivalent to the response in the WT mouse, indicating that 
the aiA-AR and the am -A R , but not the am -A R , mediate the A-61603 response in the WT 
mouse.
In all knockouts where prazosin was tested, it antagonised the phenylephrine CRC, which 
suggests that the phenylephrine response was ai-AR-mediated. However, there is 
evidence from IP accumulation experiments that prazosin shows some selectivity for am- 
ARs and am-ARs over aiA-ARs (Williams et al., 1999). The affinity estimates do indicate 
a high affinity site, suggesting that the responses were a  i-AR-mediated. This was further 
supported by rauwolscine not having an effect on the A-61603 contractile response in the 
ctm/D-KO. In the absence of a suitably selective am-AR antagonist the identification of an 
a  IB-AR-mediated contraction is difficult. However, in the am-KO phenylephrine was 
more potent and had greater efficacy than in the am/o-KO, which may indicate a 
contractile role for the am-AR.
In the WT mouse, BMY 7378 antagonised the A-61603 response only at the highest 
concentration used (pKs 8.3). In all four knockouts the A-61603 response was unaffected 
by BMY 7378 0.1 pM, therefore, a pKs of at least 7.0 would be expected in the knockouts.
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It is unclear at present why BMY 7378 0.1 pM had an effect against A-61603 in the WT 
mouse but not in the ais-KO, in which the A-61603-induced response was expected to 
contain an am-AR-mediated component. Since BMY 7378 did not affect the A-61603- 
induced response in the am-KO, am-KO and am/o-KO, it seems plausible that A-61603 
has little or no action at the am-AR.
In the WT mouse, affinity estimates of 7.5 for 5-methylurapidil (Deighan C, 2002) and 7.9 
RSI00 329 were obtained against the phenylephrine-induced response, which did not 
suggest an aia-AR-mediated response. Both 5-methylurapidil and RSI00 329 showed 
higher affinity against the phenylephrine response in the am-KO (5-methylurapidil pAz 
8.1, RSI00 329 pKfi 9.1) compared to the WT mouse and am-KO (5-methylurapidil pAz 
7.6 (Deighan C, 2002;Deighan et al, 2005)). This suggests that, when present, the am-AR 
has influenced the affinity estimates of the aiA-AR selective compounds. RSI00 329 
antagonised the A-61603-induced response with higher affinity than the phenyleplirine 
response in the WT mouse (pAz 8.7). In the knockouts (excluding aiA/e-KO), both 5- 
methylurapidil (aiB-KO pAz 8.1; am-KO pAz 9.2; am/o-KO pKe 8.3) and RSI00 329 (a,B- 
KO pKb 8.6; am-KO 10.0; am/o-KO non-competitive block) acted with high affinity 
against A-61603. This was higher than that obtained against the phenylephrine-induced 
response, supporting obseiwations from the WT mouse. In the aiA/B-KO, contractions 
were produced in response to high concentrations of A-61603, which is indicative of an 
am-AR-mediated component to the A-61603 response or a non-adrenergic effect. Thus, 
A-61603 appears to have some action on the am-AR and binding to this lower affinity site 
would account for the affinity estimates of the aiA-AR selective antagonists being lower in 
the WT mouse and am-KO, where the am-AR is present. Taken together, this data 
suggests that an aiA-AR response does exist in the mouse carotid artery but is influenced 
by the dominant am-AR.
This study demonstrates that the aiA-AR is functional in the mouse carotid artery. The 
am -A R  is the predominant contractile a i-A R  in this vessel, but the aiA-AR does 
contribute to the contractile response. The aiA-AR-mediated response in the am -K O  has 
been published (Deighan et al, 2005). However, at the time of publication it was unclear 
whether the aiA-AR had been upregulated in the am -K O  to compensate for the loss of the 
main contiactile receptor. The evidence suggests that the aiA-AR is functional in the W T 
mouse, and the aiA-AR in the knockout mice is not due to a compensatory upregulation. 
This agrees with Hosoda et al. (2005b), who did not obseiwe any compensation for the loss
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of ai-AR subtypes in either the contractile responses or inRNA expression in both the aio- 
KO and aiB/D-KO.
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Figure 432? Summary of findings in the knockout mice leading to conclusion In WT mouse.
4.4.6. aiA-ARs in the mouse carotid
This is the first study to report the existence of the aiA-AR in the mouse carotid artery. In 
a study using p-galactosidase staining to identify aiA-AR expression Rokosh and Simpson 
(2002) did not find any evidence of aiA-AR in the carotid artery. Furthermore, in the only 
previous functional studies, the contribution of the aiA-AR to contraction in the mouse 
carotid artery was excluded due to the low affinity estimate calculated for 5-methylurapidil 
(Deighan C, 2002;Daly et a l ,  2002a). However, in these studies, 5-methylurapidil was 
tested only against the phenyleplirine-induced response. The present study has shown that 
phenyleplirine has some selectivity for the am-AR, which appears to mask the aia-AR- 
mediated response.
Evidence for heterogeneity of ai-A R subtypes in the mouse carotid artery has been 
previously reported (Deighan C, 2002): a shallow Schild slope was produced for BMY 
7378 against phenylephrine in the WT mouse, but a standard Schild slope was obtained in 
the ttiB-KO. This does imply that the a^-A R  may also contribute to the contractile 
response in the WT mouse. The current study demonstrated that comparison of the 
phenylephi'ine-induced response in the knockout mice with the WT mouse revealed an ais- 
AR-mediated component to contraction may exist. When considered with the findings of
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Deighan (2002), it is possible that all three ai-AR subtypes contiibute to the contractile 
response to phenyleplirine in the carotid artery of the WT mouse.
4.4.7. Cone fusion
The utilisation of ai-AR knockout mice enabled the contractile response in the mouse 
carotid arteiy to be studied in the absence of the dominant contiactile receptor. The 
investigation of the aiA-AR in the present study was enhanced by the use of the aiA-AR 
selective agonist A-61603 and ai-AR knockout mice. Evidence of an aia-AR-mediated 
contractile response was identified in all knockout mice (excluding the aiA/B-KO) and an 
aiB-AR-mediated response appears to exist in the am -K O . Thus, all three ai-AR subtypes 
are involved in the contractile response in the WT mouse.
130
Chapter Five 
The effect of NO on ai-AR-mediated contraction
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5.1. Introduction
NO is an endothelium derived relaxing factor, which is synthesized from L-arginine by the 
constitutive enzyme eNOS. The release of NO can be occur under basal conditions 
(Martin et al, 1986) or following agonist stimulation (Vanhoutte & Miller, 1989), which 
may occur through a direct or indirect action on ECs. There is also evidence to suggest 
that the release of NO can occur in response to the contraction of a vessel (Amerini S et al, 
1995). Regardless of the mechanism, once released, NO diffuses to vascular SMC where it 
stimulates soluble guanylate cyclase to release cyclic guanosine monophosphate. This 
second messenger leads to a decrease in smooth muscle tone, thereby modulating the 
contractile response.
5.1.1. Spontaneous NO release
Early evidence of spontaneous NO release was reported by Martin et al. (1986). This 
study demonstrated that in the denuded rat aorta the sensitivity to phenylephrine, 
noradrenaline, clonidine (selective a 2-AR agonist) and 5-HT was increased compared to 
intact vessels. In addition, in precontracted vessels in which the endothelium was intact no 
relaxations were observed in response to the a-AR agonists. These findings suggested that 
NO release was spontaneous and not in response to agonist stimulation. Subsequent 
studies have also demonstrated that basal NO release occurs in the rat aorta. For instance, 
at resting tone L-NAME has been shown to produce a contractile response indicating that 
NO was being released constitutively (Shimokawa H et al, 1996). NO also appears to be 
released basally in the mouse aorta, as the 5-HT contractile response was attenuated by L- 
NAME in a concentration-independent manner (Ali, 2004).
5.1.2. NO release via indirect stimulation
It has been proposed that NO release from the endothelium is indirectly triggered by the 
agonist-induced vasoconstriction (Dora K, 2001) (Figure 5.1 A). When ai-ARs in the 
SMC are activated [Ca^ ]^i is released and may diffuse to EC through myoendothelial gap 
junctions, increasing [Ca^ ]^i in EC. eNOS would be activated by this increase in [Ca^ j^i 
and, therefore, increase the release of NO from ECs. In this way, the agonist activation of 
SMCs regulates contraction by causing the release of relaxatoiy substances from the 
endothelium. It has been proposed that NO is released through the indirect stimulation of 
EC in the mesenteric arteiy of the rat (Dora et al, 2000). It was shown that the
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phenylephrine-induced response was significantly increased by L-NAME, but the lack of 
effect of phenylephrine on isolated EC opposed the stimulation of ai-AR on the 
endothelium. The findings of this study have been supported by the identification of 
myoendothelial gap junctions in this vessel (Dora, 2001;Gonzalez Unpublished 
observations).
eNOS eNOS L-CitrullineL-Citrulline
L-Arqinine NO L-Arqinine NO
diffusion !
PE
GC
GTP ► cGMP SfilC cGMPCa- G IF
Figure 5.1. Mechanisms of NO release from EC. (A) Indirect via the stimulation of Oi-AR on 
SMC causing an increase in [Ca^*]| and diffusion of Ca^  ^ to EC. (B) Direct through the 
stimulation ai-AR on EC. in both cases the increase in [Ca^ j^i in the EC activates eNOS, 
which produces NO from L-Arginine. NO then activates GC in SMC resulting in vascular 
relaxation, (adapted from Figure 1. Gornik and Creager (2004)).
5.1.3. NO release via direct stimulation
It is plausible that the release of NO fiom EC may be triggered by the direct agonist 
stimulation of receptors on the endothelium (Figure 5.1 B). In general, NO release, and the 
resultant vasodilation, is often associated with the stimulation of endothelial a 2-ARs 
(Vanhoutte & Miller, 1989;Malekzadeh Shafaroudi M et al, 2005). However, functional 
evidence of endothelial ai-ARs is increasingly being reported. Zschauer et al. (1997) 
reported the first evidence to implicate ai-ARs on the endothelium. In the rabbit bronchial 
arteries with an intact endothelium both L-NAME and indomethacin (a cyclooxygenase 
inhibitor) increased sensitivity to noradrenaline, indicating that NO and a prostanoid were 
being released and were suppressing vasoconstriction. In denuded arteries, sensitivity to 
phenylephiine and UK 14,304 (an a 2-AR agonist) was increased suggesting that both ai- 
ARs and aa-ARs may be involved in the release of the endothelium-derived relaxing 
factors. Furtheimore, in vessels with an intact endothelium, L-NAME markedly
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potentiated the contractile response to phenylephiine. The direct agonist stimulation of a j- 
ARs on the endothelium, triggering NO release, could account for these findings.
Further evidence that the direct stimulation of ai-AR on the endothelium leads to a 
relaxatory response was reported by Filippi et al. (2001). In the perfused rat mesenteric 
vascular bed, subnanomolar concentrations of phenyleplirine and noradrenaline produced 
relaxations, which were followed by a sustained contraction at higher agonist 
concentrations. In denuded vessels, no relaxations to the ai-A R agonists were obseiwed. 
Therefore, the relaxant responses mediated by ai-ARs appear to be a result of the direct 
stimulation of receptors on the endothelium. Although, the aiA-AR selective antagonist 
had no effect, the relaxant response was inhibited by the aio-AR selective antagonist BMY 
7378. It is, therefore, apparent that in the rat mesenteric vascular bed the response to 
phenylephrine involved an ai-AR-mediated contractile response in SMC and a relaxatory 
response tlu'ough the stimulation of aio-ARs in ECs.
In a recent study a phenylephiine-induced relaxatory response was obseiwed at 
subnanomolar concentrations in the rat carotid artery (de Andrade C et a l ,  2006). hi the 
absence of the endothelium, or in the presence of L-NAME, the relaxations to 
phenylephiine were not observed. This indicates that phenylephiine was stimulating an 
endothelium-dependent release of NO. Fuiihermore, prazosin and BMY 7378, but not 
yohimbine (a 2-AR antagonist), inhibited the relaxations. These findings suggest that the 
phenylephiine-induced relaxatory response in the rat carotid artery was induced by the 
stimulation of ai-ARs on endothelium, triggering NO release. In agreement with Filippi 
et al. (2001), the ai-ARs on the endothelium appeared to be predominantly am-ARs.
In addition, in a fluorescent ligand binding study investigating a 2-ARs in the thoracic 
aorta, binding to ECs was inhibited by prazosin (Malekzadeh Shafaroudi M et a l,  2005). 
This study in our laboratory provided preliminary evidence that ai-ARs may exist on the 
endothelium.
5.1 A. Conduit arteries
Previous studies have shown that EDHF is less important in conductance arteries than 
resistance arteries (Shimokawa H et a l ,  1996;Scotland RS et a l ,  2005). Furthermore, NO 
production by ECs is highest at the aortic arch and becomes low at the abdominal aorta 
(Balbatun et a l,  2003). These findings imply that NO is likely to be an important
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endothelial factor in the mouse carotid artery. Consequently, the role of NO in the 
contiaction of the mouse carotid artery was investigated in this chapter.
Several studies in rat and mouse aortae have revealed NO release from ECs as a result of 
stimulation with noradrenaline (Kaneko & Simano, 1993;Malekzadeh Shafaroudi M et al, 
2005), and phenylephrine (Tabemero et al, 1999;Kaneko & Sunano, 1993;Gurdal et al, 
2005). Although phenylephrine has been shown to result in NO release in the rat carotid 
artery (de Andrade C et al, 2006), the involvement of NO in relation to ai-AR-mediated 
contraction has not been investigated in the mouse carotid arteiy.
5.1.5. Aims
The present study evaluated the role of NO on ai-AR-mediated contraction in the carotid 
artery, by inhibiting the NO pathway using the L-arginine analogue L-NAME to inhibit 
NOS.
The aims of the present study were;
#
To assess the effect of L-NAME on the basal tone of the mouse carotid artery and, 
in doing so, establish whether NO release in this vessel was spontaneous or 
stimulated.
To investigate the effect of NO on a  i-AR-mediated contractions in the carotid 
arteiy.
5.2. Methods
The dissection, vessel mounting and acclimatisation period are described in detail in 
Chapter two. In brief, four-five-month old male WT mouse (C57 Black; 26g-44g), am- 
KO (25-34g) and aie/o-KO (32-54g) mice were killed by carbon dioxide overdose and 
both common carotid arteries were dissected. Following cleaning, vessels were mounted 
in a four-chamber wire myograph containing gassed (95% O2 / 5% CO2) and heated (37°C) 
PSS. Vessels were allowed to acclimatise for 30 minutes before a resting tension of 0.25g 
was added to each vessel and a further 45 minutes acclimatisation period prior to the start 
of the experimental protocol.
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5.2.1. Effect o f L-NAME on basal tone
The effect of L-NAME on basal tone was tested with and without prior stimulation with 
phenylephiine or A-61603. For the first set of experiments, without a wake-up procedure 
or agonist CRC, a NOS inhibitor, L-NAME 0.1 mM was added and the tone was observed 
for 40 minutes. This observation time was used as it would be used as the incubation time 
for L-NAME in subsequent experiments. For the second set of experiments, the wake-up 
procedure was perfonned for phenylephiine or A-61603 as described in Chapter Two. 
Following CRCs to phenylephrine (1 nM -  0.1 mM) or A-61603 (1 nM -  0.1 mM), vessels 
were washed with PSS and rested over a period of 30 minutes. L-NAME 0.1 mM was 
added and the tone was observed for 40 minutes.
5.2.2. The effect o f L-NAME on the response to ai-A R  agonists
After perfonning the wake-up procedure (as described in Chapter Two), CRCs to 
phenylephrine (1 iiM -  0.1 mM) or A-61603 (1 nM -  0.1 mM) were produced using half­
log increments. Prior to the second CRC, vessels were incubated for 40 minutes with L- 
NAME 0.1 mM. At the end of the protocol acetylcholine 3 pM was added to test whether 
the relaxation of the vessel had been inliibited. A second CRC to phenylephiine or A- 
61603 was produced in the absence of L-NAME, acting as a time control.
5.2.3. Statistical analysis
Data were expressed as means ± standard error in gi'ams tension and percentage of the 
maximum response of the control CRC. A Student’s t-test or one-way ANOVA, followed 
by a Bonferroni’s post test was used to compare the maximum responses, pECso values of 
the agonist response in the absence or presence of either L-NAME. CRCs were compared 
using two-way-ANOVA with a Bonferroni post-test. Nonlinear regression was perfonned 
to fit sigmoidal-curves (variable slope) on mean data of responses in grams and percentage 
of the maximum response.
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5,3. Results
5.3.1. Effect of L-NAME on basal tone
5.3.1.1. WT mouse
In the WT mouse, basal tone was unaltered by L-NAME when the vessels had not been 
previously stimulated but was significantly increased in the presence of L-NAME with 
prior stimulation to phenylephrine or A-61603 (Figure 5.2; Table 5.1).
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Figure 5.2. WT mouse: Effect of prior stimulation on the maximum response obtained to L- 
NAME 0.1 mM, expressed as mean ± S.E. in grams tension (n>6). ** p<0.01, *** p<0.001 
compared to maximum response without prior stimulation.
Tabie 5.1. Effect of prior stimulation on the maximum response to L-NAME 0.1 mM in the WT 
mouse.
Protocol n Maximum response to L-NAME (g)
No CRC 6 0.02±0.004
PE CRC 8 0.25±0.03***
A-61603 CRC 7 0.13±0.02**
** p<0.01; ***p<0.001 compared to maximum response without prior stimulation (one-way 
ANOVA, Bonferroni’s post test).
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5.3.1.2. CC1D-KO
In the aiD-KO, basal tone was unaltered by L-NAME when the vessels had not been 
previously stimulated (Figure 5.3; Table 5.2). Basal tone was not significantly increased 
in the presence of L-NAME with prior stimulation to phenylephrine but was significantly 
increased following stimulation with A-61603.
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Figure 5.3. am-KO: Effect of prior stimulation on the maximum response obtained to L- 
NAME 0.1 mM, expressed as mean ± S.E. in grams tension (n>5). ** p<0.01 compared to 
maximum response without prior stimulation.
Tabie 5.2. Effect of prior stimulation on the maximum response to L-NAME O.ImM in the 
am"KO.
Protocol n Maximum response to L-NAME 
(g)
No CRC 5 O.OliO.004
PE CRC 6 0.02±0.01***
A-61603 CRC 5 0.06+0.02**
**p<0.01; ***p<0.001 compared to maximum response without prior stimulation (one-way 
ANOVA, Bonferroni’s post test).
138
5.3.1.3. aiB/D“KO
In the aiB/D-KO, basal tone was unaltered by L-NAME when the vessels had not been 
previously stimulated (Figure 5.4; Table 5.3). A significant increase in basal tone was 
observed in the presence of L-NAME with prior stimulation to phenylephrine or A-61603.
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Figure 5.4. am/D-KO: Effect of prior stimulation on the maximum response to L-NAME 
O.ImM, expressed as mean ± S.E. in grams tension (n>5). * p<0.05 compared to maximum 
response obtained without prior stimulation.
Tabie 5.3. Effect of prior stimulation on the maximum response to L-NAME O.ImM in the(Xib/d"KO.
Protocol n Maximum response to L-NAME 
(g)No CRC 5 0.02+0.004
PE CRC 5 0.04+0.01*
A-61603 CRC 8 0.08+0.01*
*p<0.05 compared to maximum response without prior stimulation (one-way ANOVA, 
Bonferroni’s post test).
5.3.2. Effect of L-NAME in the WT mouse
5.3.2.1. Phenylephrine-induced response
In the WT mouse, phenylephrine produced concentiation-dependent contractions in the 
WT mouse in the presence of L-NAME (Figure 5.5; Table 5.4). L-NAME O.ImM 
significantly increased the average maximum response obtained to phenylephrine by 79% 
compared with the control CRC.
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Figure 5.5. WT mouse: Effect of L-NAME on phenylephrine CRC in (A) grams tension and 
(B) percentage of maximum response of the control CRC. (C) Effect of L-NAME on the 
maximum response obtained to phenylephrine in grams tension. Data expressed as mean ± 
S.E. (n=7). * p<0.05 compared to phenylephrine control (Student’s t-test).
Table 5.4. Comparison of phenylephrine CRCs in the presence of L-NAME O.ImM in the WT 
mouse.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 7 6.4±0.Q8 0.24±0.05 0.6 (0.5-0.6)
L-NAME 0.1 mM 7 7.1±0.43^ 0.43+0.05* 0.5 (0.5-0.6)'"
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5.3.2.2. A-GIGOS-induced response
In the presence of L-NAME O.ImM concentration-dependent contractions to A-61603 
were produced (Figure 5.6; Table 5.5). An increase of 37% in the average maximum 
response to A-61603 in the presence of L-NAME did not reach significance.
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Figure 5.6. WT mouse: The effect of L-NAME on the CRC to A-61603 In {A) grams tension 
and {B) percentage of maximum response of the control CRC. {C) Effect of L-NAME on the 
maximum response obtained to A-61603 in grams tension. Data expressed as means + S.E. 
(n=6).
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Table 5.5. Comparison of A-61603 CRCs In the presence of L-NAME O.ImM.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6.1±0.14 0.24+0.02 0.4 (0.4-0.5)
L-NAME 0.1 mM 6 6.8±0.4T^ 0.38+0.08"" 0.4 (0.4-0.4)^
+ p>0.05 compared to A-61603 control (Student’s t-test).
5.3.3. Effect of L-NAME in the aio-KO
5.3.3.1. Phenylephrine-induced response
In the aiD-KO, phenylephrine produced concentiation-dependent contractions in the am- 
KO in the presence of L-NAME (Figure 5.7; Table 5.6). An average increase of 60% was 
observed for the phenylephrine response in the presence of O.ImM L-NAME.
Table 5.6. Comparison of phenylephrine CRCs in presence of L-NAME O.ImM In the ctio-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 6 5.7+0.09 0.20+0.02 1.1 (0.0-1.1)
L-NAME 0.1 mM 6 5.9+0.08"* 0.32+0.04'* 1.0 (0.9-1.0)^
+ p>0.05, ** p<0.01 compared to phenylephrine control (Student’s t-test).
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Figure 5.7. am-KO: The effect of L-NAME on the CRC to phenylephrine in (A) grams tension 
and (B) percentage of maximum response of the control CRC. (C) Effect of L-NAME on the 
maximum response obtained to phenylephrine in grams tension. Data expressed as mean ± 
S.E. (n=6). ** p<0.01 compared to phenylephrine control (Student’s t-test).
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5.3.3.2. A-61603-induced response
Concentiation-dependent contractions to A-61603 were produced in the presence of L- 
NAME (Figure 5.8; Table 5.7). The maximum response obtained to A-61603 was 
increased by 62% in the presence of 0. ImM L-NAME.
B
0.5-t
0.4-
O)
0.3-C.2
g<u 0 ,2 -
0.0
10 ■9 ■8 ■7 ■6 ■5 ■4 ■3
[A-61603] {Log M)
~m~ Control 
□  L-NAME
350-1
<D 300- 
§  250-S'g  200- 
tS 150-E
w- 1 0 0 -o
5? 50-
-10 ■9 ■8 ■7 ■6 ■5 •4 •3
Control 
~B — L-NAME
[A-61603] (Log M)
c  0.2
Control 10-4M L-NAME
Figure 5.8. am-KO: The effect of L-NAME on the CRC to A-61603 In (A) grams tension and 
(B) percentage of maximum response of the control CRC. (C) Effect of L-NAME on the 
maximum response obtained to A-61603 in grams tension. Data expressed as means ± S.E. 
(n=6). ** p<0.01 compared to phenylephrine control (Student’s t-test).
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Table 5.7. Comparison of A-61603 CRCs in the presence of L-NAME O.ImM in the am-KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
A-61603 control 6 6.7±0.14 0.13±0.02 0.7 (0.7-0.8)
L-NAME 0.1 mM 6 7.3±0.17" 0.23+0.02*"* 0.7 (0.7-0.8)"
 ^p>0.05, * p<0.05, *** p<0.001 compared to phenylephrine control (Student’s t-test).
5.3.4. Effect of L-NAME in the am/o-KO
5.3.4.I. Phenylephrine-induced response
In the aiB/D“KO phenylephrine produced concentration-dependent contractions in the 
ocib/d-KO in the presence of L-NAME (Figure 5.9; Table 5.8). An average increase of 
233% in the maximum response obtained to phenylephrine was obseiwed in the presence of 
L-NAME.
Tabie 5.8. Comparison of phenylephrine CRCs in the presence of L-NAME 0.1 mM in theaiB/D"KO.
Agonist n pECso Maximum response (g) Hill slope (95% 
Cl)
PE control 6 5.0+0.12 0.06 ±0.01 1.1 (1.0-1.2)
L-NAME 0.1 niM 6 6.1+0.39" 0.20 ±0.06** 1.0 (0.9-1.2)^
p>0.05, ** p<0.01, *** p<0.001 compared to phenylephrine control (Student’s t-test).
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Figure 5,9. amm-KO: The effect of L-NAME on the CRC to phenylephrine in (A) grams 
tension and (B) percentage of maximum response of the control CRC. (C) Effect of L-NAME 
on maximum response obtained to phenylephrine In grams tension. Data expressed as 
means ± S.E. (n=6).** p<0.01 compared to phenylephrine control (Student’s t-test).
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5.3.4.2. A-61603-mduced response
A-61603 produced concentration-dependent contractions in the am/D-KO in the presence 
of L-NAME (Figure 5.10; Table 5.9). The maximum response obtained for the A-61603 
CRC showed an average increase of 69% in the presence of L-NAME.
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Figure 5.10. aiB/D-KO: The effect of L-NAME on the CRC to A-61603 in (A) grams tension 
and (B) percentage of maximum response of the control CRC. (C) Effect of L-NAME on 
maximum response obtained to A-61603 in grams tension. Data expressed as means + S.E. 
(n=6). ** p<0.01 compared to A-61603 control (Student’s t-test).
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Table 5.9. Comparison of A-61603 CRCs in the presence of L-NAME O.ImM in the aie/o-KO.
Agonist n pECso Maximum response (g) Hill slope (95% Cl)
A-61603 control 6 6.7±0.12 0.14+0.03 0.9(0.7-1.0)
L-NAME 0.1 mM 6 7.6±G.38'" 0.24 ±0.04'* 0.8 (0.4-1.1)^
* p>0.05, ** p<0.01 compared to A-61603 control (Student’s t-test).
S.3.4.3. 5-HT-induced response
In the a  IB/d- KO, 5-HT produced concentration-dependent contractions in the presence of 
L-NAME but the 5-HT CRC was unaffected by the presence of L-NAME (Figure 5.11; 
Table 5.10).
Table 5.10. Comparison of 5-HT CRCs in presence of L-NAME O.ImM in the aie/o-KO.
Agonist n pECso Maximum response (g) m u  slope (95% Cl)
5-HT control 6 6.7+0.06 0.30+0.02 2.6(1.7-3.5)
L-NAME 0.1 mM 6 7.0±0.14+ 0.32±0.04+ 2.4(1.1-3.6)-"
p>0.05 compared to A-61603 control (Student’s t-test).
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Figure 6.11. aiB/o-KO: The effect of L-NAME on the CRC to 5-HT In (A) grams tension and (B) percentage of maximum response of the control CRC. (C) Effect of L-NAME on the 
maximum response to 5-HT in grams tension. Data expressed as means ± S.E. (n=6).
149
5.3.5. Comparison of effect of L-NAME in the WT mouse and knockouts
5.3.5.1. Phenylephrine-induced response
In the presence of L-NAME, phenylephrine produced concentration-dependent 
conh'actions in the WT mouse, am-KO and aiB/o-KO (Figure 5.12; Table 5.11). The 
maximum response obtained to phenylephrine was significantly higher in the WT mouse in 
the presence of L-NAME than the aiB/o-KO but not the am-KO (0.32±0.04g). The pECso 
values for the phenylephrine-induced response in the presence of L-NAME were 
significantly different in the am-KO and aiB/o- KO compared to the WT mouse.
Table 5.11. Comparison of the WT mouse, am-KO and aig/o-KO: the effect of L-NAME on the 
phenylephrine-induced response.
pheny lephrine  alone pheny lephrine  + L-N A M E
pECso M axim um  
response (g)
H ill slope 
(95%  C l)
pECso M axim um  
response (g)
H ill slope 
(95%  C l)
W T  mouse 6.4±0.08 0.24+0.05 0.9 (0.5-1.3) 7.1+0.43 0.43+0.05 1.0 (0.6-1.4)
tXii)-KO 5.6±0.06” 0.22+0.02+ 1.2 (0.9-1.6)+ 5.9+0.08+ 0.32+0.04+ 1.1 (0.9-1.3)+
OtlB/D~KO 4.9±0.07"’’ 0.06+0.01*** 1.2 (0.6-1.9)+ 6.1+0.39+ 0.20 ±0.06* 0.8 (0.3-1.8)+
*p>0.05, * p<0.05, ** p<0.01, *** p<0.001 compared to WT mouse {one-way AN OVA, 
Bonferroni’s post test).
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Figure 5.12, Comparison of the WT mouse, aiD-KO and « ib/d-KO: the effect of L-NAME on 
CRCs to phenylephrine in (A) grams tension and (B) percentage of maximum response of 
the control CRC. (C) Effect of L-NAME on the maximum response obtained to 
phenylephrine In grams tension. Data expressed as means ± S.E. (n>6). * p<0.05, ** p<0.01 
(one-way AN OVA, Bonferroni’s post test).
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5.3.5.2. A-61603-induced response
In the presence of L-NAME, concentration-dependent contractions to A-61603 were 
observed in all three stiains of mice (Figure 5.13; Table 5.12). No significant differences 
were observed between stiains.
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Figure 5.13. Comparison of the WT mouse, aip-KO and aiB/o-KO: the effect of L-NAME on 
CRCs to A-61603 in in (A) grams tension and (B) percentage of maximum response of the 
control CRC. (C) Effect of L-NAME on the maximum response obtained to phenylephrine in 
grams tension expressed as means ± S.E. (n>6). *** p<0.01 compared to WT mouse (one­
way ANOVA, Bonferroni’s post test).
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Table 5.12. Comparison of the WT mouse, aio-KO and aiB/D"KO: the effect of L-NAME on the 
A-61603-induced response.
A-61603 alone A-61603 + L-NAME
pECso M aximum 
response (g)
Hill slope 
(95% Cl)
pECso M aximum 
response (g)
Hill slope 
(95% Cl)
WT mouse 6.0±0.06 0.27+0.05 0.6 (0.3-0.9) 6.8+0.41 0.38±0.08 0.5 (0.2-0.7)
ocii>-KO 6.9±d.Ô6"' o.14±o.oT 0.6 (0.2-0.9)^ 7.3+0.17^ 0.2310.02'' 0.7 (0 .3-1.2)'
0tlB/D"RO 6 .7± d .d7 ’^ 0.13+0.01* 0.9 (0.7-1.1)^ 7.6+0.38'' 0.24 +0.04'' 0.8 (0.4-1.!)^
1
^p>0.05, *p<0.05, * p<0.001 compared to WT mouse (one-way ANOVA, Bonferroni’s post 
test).
5.4. D iscussion
In the present study it was confirmed that NO had a functional role in the mouse carotid 
artery. The role of NO was further investigated by determining whether NO release was 
spontaneous, stimulated by ai-AR agonists indirectly through the activation of SMC ai- 
ARs, or tlirough the direct stimulation of a-ARs on the endothelium.
5.4.1. Spontaneous NO release
To assess whether NO was released constitutively, the direct effect of L-NAME on basal 
tone was investigated. No increase in basal tone was observed in response to L-NAME in 
the absence of prior ai-AR stimulation in any of the mouse strains. If spontaneous 
myogenic tone is suppressed by basal NO release, inhibition of NO results in an increase in 
tone (Rees et a l, 1990). Therefore, this possibility can be ruled out. It is possible that NO 
was being released spontaneously but did not have an effect in the mouse carotid artery, 
therefore, no increase was observed. Alternatively, it is possible that spontaneous NO 
release was simply not occurring in this vessel. From this data, neither scenario could be 
excluded. However, this was clarified with the subsequent experiments.
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5.4.2. Stimulated NO release
5.4.2.1. Effect of L-NAME on basal tone
In order to determine whether NO release was stimulated by ai-AR activation the effect of 
L-NAME with prior exposure to phenylephrine and A-61603 was investigated. In vessels 
which had been previously stimulated by the ai-AR agonists, contractions were observed 
in response to L-NAME, Firstly, this confirms that NO release was occurring in the mouse 
carotid aiteiy. Secondly, this increase in tone, indicates that NO release was stimulated by 
ai-AR activation, rather than spontaneous NO release. It is possible that the increase in 
tone was due to the ai-AR agonists activating SMC contraction and it was the contraction 
that caused NO release. However, this study has demonstrated that the 5-HT CRC was not 
affected by L-NAME (See section 5.4.2.2.), which opposes the possibility that the 
contraction itself was causing NO release. Alternatively, the agonist may have still been 
available to activate the receptors and, therefore, cause both contraction, through the 
stimulation of apARs on SMC, and relaxation, through the activation of endothelial 
receptors. It appears that NO release was suppressing contraction, which was removed in 
the presence of L-NAME and resulted in an increase in tone. This suggests that NO was 
released in response to ai-AR stimulation. The findings of the present study were 
consistent with previous studies showing ai-AR stimulation resulted in NO release (Filippi 
et al., 2001;Tabemero & Vila, 1995;Gurdal et al, 2005;Kaneko & Sunano, 1993;Zschauer 
A et al, 1997).
5.4.2.2. Effect of NO on ai-AR contractility
The effect of L-NAME on ai-AR-mediated contractility was assessed, using both 
phenylephrine and A-61603. The increase in contraction and/or sensitivity to 
phenylephrine and A-61603 in the presence of L-NAME is indicative of NO modulating 
the agonist-induced contiaction. In all mouse stiains, the effect of L-NAME obseiwed was 
gi'eater at higher concentrations of both phenylephrine and A-61603. This suggests that the 
observations were not due to the constitutive release of NO, suggested in section 5.4.1. 
Rather, it seems that the influence of NO increases with concentr ation of agonist, which is 
consistent with the effect being induced by the agonist.
154
To establish whether NO release could be stimulated by a non adrenoceptor-mediated 
pathway, the 5-HT contractile response was investigated with and without L-NAME in the 
aiB/D-KO. There is evidence that NO can modulate the contractile response to 5-HT in 
some arteries. For instance, an earlier study in the hovine pulmonary arter^^MacLean et al. 
(1994) demonstrated that the 5-HT contractile response was potentiated by L-NAME. 
Furtheimore, a recent study in the mouse aorta Ali (2004) reported that while the 
maximum response to 5-HT was unchanged, an increase in sensitivity was observed in the 
presence of L-NAME. However, in the present study, L-NAME did not affect the 
maximum response or sensitivity of 5-HT, suggesting that NO does not modulate the 
contractile response to 5-HT in the mouse carotid artery. This evidence rules out the 
possibility that an increase in vascular tone caused NO release, as reported by Amerini et 
al. (1995) in the rat mesenteric vascular bed. Furthermore, the lack of effect of L-NAME 
provides further evidence that there is no spontaneous NO release in the murine carotid 
artery and suggests that NO release is in response to ai-AR activation.
5.4.2.3. Mechanism of stimulated release
The effects o f NO on the phenyleplirine and A-61603 contractile response described in this 
chapter, suggest an ai-A R induced release of NO. NO release may result Rom either from 
the activation of ai-ARs on smooth muscle, which signal to the endothelium through myo- 
endothelial junctions (Dora K, 2001), or the direct activation of ai-ARs on the 
endothelium. Myoendothelial gap junctions have been identified in small arteries, such as 
the rat mesenteric artery (Dora K, 2001;Gonzalez Unpublished observations). Spagnoli et 
al. (1982) identified myoendothelial gap junctions in the carotid artery of the rabbit, 
demonstrating that they are not restricted to small arteries. However, to date there is no 
further evidence of myoendothelial gap junctions, either fi'om the literature or from 
visualisation studies in the carotid artery within our laboratory. Without positive evidence 
for the existence of myoendothelial gap junctions in the mouse carotid artery it cannot he 
concluded that NO release results fr om the activation of SMC ai-ARs and has an indirect 
action on the endothelium.
There is no functional evidence that NO is released thiough the direct activation of 
endothelial ai-ARs in the present study. However, increasingly, evidence of ai-ARs on 
the endothelium is being reported in several blood vessels (Boer et a l,  1999;Filippi et a l, 
2001;Zschauer A et a l, 1997;Tuttle & Falcone, 2001). For instance, Boer et al. (1999) 
reported that in response to ai-A R agonists, an endothelium-dependent relaxation occuiTed
155
in pulmonaiy arteries, which was mediated by NO. Furthermore, an earlier study in the rat 
mesenteric vascular bed showed that an endothelium-dependent relaxation occurred in 
response to phenylephrine. This relaxation was blocked by the selective am-AR 
antagonist BMY 7378, indicative of endothelial aio-ARs (Filippi et a l, 2001). 
Furthermore, preliminary eviderrce from a fluorescent ligarrd binding in our laboratory 
suggested that ai-ARs may exist on the endothelium. This has been further investigated in 
Chapter Seven. Thus, the direct stimulation of ai-ARs on the endothelium could result in 
NO release in the mouse carotid artery.
5A .3. Physiological relevance
It has been suggested that the relaxation resulting from NO preverrts arteries becoming 
over contracted, thus ensuring blood flow is maintained (Tuttle & Falcorre, 2001;Gurdal et 
al., 2005). The findings hr this chapter indicate that the response to ai-AR agonists 
consists of contraction and relaxation. When stimulated by an ai-AR agonist, ai-ARs on 
the smooth muscle contract aird NO release is stimulated to suppress the contractile 
respoirse. This balance of contractioir and relaxation would errsure blood flow was 
maintained during ai-AR-mediated contraction, which is crucial as the carotid artery 
supplies the brain.
5AA. Relevance to ai-AR subtypes in the mouse carotid artery 
Phenylephrine-induced response
The maximum response to phenylephrine was markedly increased in the presence of all 
mouse strains: an increase of 79%, 60% and 233% was observed in the WT mouse, am- 
KO and aiB/o-KO, respectively. The greater difference in maximum response and 
increased sensitivity to phenylephrine with L-NAME in the aie/o-KO appears to be due to 
the poor contractile response in the phenylephrine control. It is possible that due to the 
reduction in contractile ai-ARs, NO may be suppressirrg the phenylephriire response to a 
greater extent in the aiB/o-KG. This is consisteirt with an overall improvement in the 
contractile response to phenylephrine when NO release is inhibited in the am/o-KO. With 
the effect of NO removed, the maximum respoirse to phenylephrine was greater in the WT 
mouse tharr both knockouts, which corresponds to the pherryiephrine control data (Chapter 
Three). Similarly, in the presence of L-NAME, sensitivity to phenylephrine is 
approximately 10-fold higher in the WT mouse than the knockouts, which
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is similar to findings in the absence of L-NAME (Chapter Four). Thus, whether in the 
absence or presence of NO, the magnitude of the phenylephrine-induced response is 
dependent on the presence of the am-AR.
Filippi et al. (2001) demonstrated that aiD-ARs exist in the endothelium of rat mesenteric 
arteries. It was reported that phenylephrine acted on am-ARs on both smooth muscle cells 
and ECs producing contraction and relaxation, which resulted in the overall size of 
contraction being reduced. It is possible that a similar situation exists in the mouse carotid 
artery. If am-ARs were present on the endothelium of the carotid artery this could account 
for the greater increase in contractile response in the presence of L-NAME: the ai-AR- 
mediated relaxation would be greater in the WT mouse than in the am-KO. Thus, in the 
presence of L-NAME the loss of relaxation would be more substantial, in addition to the 
contraction by the am-AR in the smooth muscle cells.
A-61603-induced response
In the presence of L-NAM E, the maximum response to A-61603 was increased by 58% in 
the WT mouse, 77% in the am -K O  and 71%  in the am /o-KO. In agieement with control 
data (Chapters Three and Four), the A-61603 contractile response was greater in the WT 
mouse than the knockouts. This can be explained by the presence of the am -A R , which is 
appears to contribute to the A-61603 contractile response in WT mouse. Sensitivity to A- 
61603 was increased by L-NAM E in both the am -K O  and am /o-KO . In the presence of L- 
NAM E, no major difference in sensitivity to A-61603 was observed between strains. This 
contrasts with control data for A-61603 in which the WT mouse showed significantly 
reduced sensitivity. This suggests that NO is holding back the contractile response to A- 
61603 in the WT mouse, which is removed in the presence of L-NAM E. In addition, the 
increase in tone observed in the presence of L-NAM E following stimulation with A-61603 
suggests that a  ia-A R s may exist on the endothelium.
5.4.5. Conclusion
In summary, NO release appears to be triggered by the direct stimulation of ai-ARs most 
likely on the endothelium of the mouse carotid artery. Once released NO suppresses the 
ai-AR-mediated contiactile response.
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Chapter Six
ai-AR Distribution in the media of the mouse
carotid artery
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6.1. Introduction
6.1.1. Œi-AR subcellular distribution
QAPB is a fluorescent ligand with high affinity for ai-ARs and, therefore, can be used to 
study the distribution of ai-ARs in cells and tissues. QAPB has been used in several 
visualisation studies to examine the cellular distribution of ai-ARs in isolated cells (Daly 
et a l, 1998;Mackenzie et a l, 2000;McGrath et a l, 1999;Deighan et a l, 2004). Firstly, the 
existence of both diffuse and clustered binding of ai-ARs at intracellular sites was reported 
in transfected rat-1 fibroblasts (Daly et a l, 1998) and SMCs from the rat basilar artery 
(McGrath et a l, 1999). Further investigation revealed that ai-ARs were present on the cell 
membrane as well as at intracellular sites in live human SMCs (Mackenzie et a l, 2000). In 
contrast a recent study in mouse hepatocytes demonstrated that the total ai-A R population 
was intracellular (Deighan et a l, 2004). Clearly, differences in the location of ai-ARs 
within the cell exist and may vary between cell types.
The subcellular distribution of ai-ARs has also been examined visually using fluorescent 
antibodies and green fluorescent protein-tagged receptors in COS-7 transfected cells 
(Hirasawa et a l, 1997). This study found that aia-ARs were predominantly located at 
intracellular sites, while the am-AR was predominantly found on the cell surface. 
Subsequent studies in transfected rat fibroblasts (McCune et a l, 2000) and transfected 
COS-7 cells (Sugawara et al., 2002) also showed that the cell surface was the principal 
location of am-ARs, however, some intracellular am-ARs were detected. Furthemiore, 
Sugawara et al. (2002) identified punctate intracellular fluorescence in COS-7 cells 
transfected with aiA-ARs, which also confirms the findings of the previous study by this 
group (Hirasawa et a l, 1997). hi addition, McCune et al. (2000) went on to show that 
following the activation of the am-AR by an agonist the receptor internalised. 
Furtheimore, fibroblasts expressing am-ARs showed that the am-AR was predominantly 
located in perinuclear regions, although some am-ARs were detected on the cell surface 
(McCune et a l, 2000). Thus, collectively these studies have provided evidence that in 
isolated cells the am-AR is predominantly located on the cell surface and the aiA-AR and 
am-AR are predominantly located at intracellular sites.
It was recently proposed that the ai-A R subtypes can form dimers (Hague et a l, 
2004b;Uberti et a l, 2003). Using transfected HEK 293 cells Uberti et al. (2003)
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demonstrated that homodimers could be formed by the three ai-A R suhtypes, while 
heterodimers could only be fonned between the aiA-AR and am-AR or the am-AR and 
the aiD-AR. Both the homodimers and heterodimers appeared to be expressed on the cell 
surface (Uherti et a l, 2003). Both binding site density and protein expression of the aiA- 
AR and am-AR was increased when dimerised with the am-AR, implying that the am-AR 
had a functional role in cellular expression. Furtheimore, the cell surface expression of the 
am-AR was markedly increased when this subtype was coexpressed with the am-AR 
(Uberti et a l,  2003) and the am-AR was predominantly located on the cell surface rather 
than at intracellular sites(Hague et a l, 2004b). This also implies that the am-AR regulates 
the expression of the am-AR.
6.1.2. QAPB binding in intact vessels
Recently, two studies have used QAPB to examine ai-ARs in whole vessels. The first 
study to examine the ai-A R distribution visually compared the amount of QAPB binding 
in the fixed aorta of the am-KO and am-KO with the WT mouse (Miquel RM et a l,  2005). 
This study reported that fluorescence to QAPB was similar in the WT mouse and am-KO 
but reduced in the am-KO. It was concluded that the total number of a i-A R binding sites 
was reduced in the am-KO, which was consistent with the smaller contractile response in 
this mouse. However, the main purpose of the study was to develop a method to 
quantitatively analyse the amount of fluorescence in images produced by confocal 
microscopy, therefore this study did not fuither investigate the ai-A R subtypes present in 
each mouse strain nor did it concentrate on the tissue or subcellular distribution of 
fluorescence.
The second study examined the QAPB binding amount and distribution in unfixed 
mesenteric arteries of the WT mouse and am/D-KO to determine whether the distribution 
of the predominant contractile ai-A R subtype, the aia-AR, was influenced by the am-AR 
or am-AR (McBride et a l Submitted for publication). It was found that the aiA-AR was 
located on both the cell surface and inside the cell in punctate compartments and that the 
distribution of the QAPB binding in the am/o-KO was similar to the WT mouse. This 
suggests that the location of the aiA-AR was the same whether or not the subtypes were 
present. However, in the absence of the am-AR and am-AR a reduction in the intensity of 
fluorescence was ohseiwed. This study demonstrated that the subcellular distribution of 
ai-ARs could be examined in situ successfully. These two studies have shown that
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valuable information about the amount and distribution of ai-ARs can be obtained from 
the use of QAPB.
In the present study QAPB was used in conjunction with selective a-AR antagonists to 
undertake a detailed study of the distribution of ai-ARs in SMCs of the carotid artery in 
situ. In addition, single and double knockouts of am-AR, am-AR were employed to assess 
the effect of the loss of an ai-AR subtype on distribution. Thus, the aims of the present 
study were:
# To develop a protocol to examine the distribution of ai-ARs in the media of the 
carotid artery.
To compare the tissue distribution of ai-ARs in the smooth muscle layers of the 
carotid artery of the WT mouse and aj-AR knockout mice.
To subtype the ai-ARs in the smooth muscle layers of the carotid artery of the WT 
mouse and ai-AR knockout mice.
To examine the subcellular distribution of ai-ARs in SMCs of the WT mouse and 
ai-AR knockout mice.
6.2. Methods
6.2.1. Determination of incubation conditions
A series of experiments was earned out in the WT mouse to determine the optimum 
conditions for vessel incubation, which has been described in detail in Chapter Two. In 
brief, QAPB (1 nM, 10 nM, and 0.1 pM) was tested against the phenylephrine-induced 
contractile response to assess whether the ai-AR-mediated functional response was 
antagonised. The fluorescence and binding of QAPB IpM, 0.1 pM and lOnM were 
compared to assess the quality of QAPB binding at the different concentrations.
The most appropriate method of preparing the carotid artery for imaging was also 
established. The whole vessel; cross-sectional rings of carotid artery; and ‘opened out’ 
vessels (Miquel RM et al., 2005) were all considered. Unfixed vessels were used in this 
study to preserve the physiological processes for binding QAPB. Changes in pH,
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A series of experiments was earned out where the vessel was incubated with a 0.1 pM 
QAPB/PSS solution for 30 minutes, followed by a 90 minute co-incubation with either a 
QAPB 0.1 pM / PSS solution or a QAPB 0.1 pM / PSS solution containing a subtype 
selective antagonist. The nonfluorescent antagonists used for the protocol were: prazosin 
0.1 pM, (non-selective ai-AR antagonist); RSI00329 0.1 pM, (œia-AR selective 
antagonist); 5-methylurapidil 1 pM (aiA-AR selective antagonist); BMY7378 0.1 pM 
(aiD"AR selective antagonist); both BMY 7378 0.1 pM and RS100329 0.1 pM; or 
rauwolscine 0.1 pM (az-AR antagonist). Incubations were performed at room temperature 
(21°C) and solutions were replaced every 30 minutes.
At the end of the incubation period each carotid artery segment was sliced open with a 
single-edged razor blade and laid flat on a microscope slide with the endothelial side up 
(Miquel RM et a l, 2005) and coverslip (thickness 1.5) on top.
All arteries were visualised using the Bio-Rad Radiance 2100 Confocal Laser Scanning 
System. An argon-ion laser with an excitation wavelength of 488nm with an emission 
filter of 515nm was used for QAPB and a x40 oil immersion objective (NA 0.75) was used 
for all experiments. Two different settings were used to record images. For images
temperature, oxidation, and glucose levels were limited as much as practically possible for 
the duration of the experimentation (as described in Chapter Two).
Once the concentration of QAPB, tissue preparation and temperature had been selected, 
vessels were imaged at a series of time-points (30 min, 60 min, 90 min, 120 min and 180 
min) in order to determine the optimum incubation time for 0.1 pM QAPB, which was 
found to be 120 minutes.
6.2.2. Experimentai protocol
I
This protocol has been described in detail in Chapter Two. In brief, 5mm segments of
carotid artery were incubated at room temperature with 0.1 pM QAPB, in a PSS solution at
room temperature for 120 minutes. Two sets of control vessels were used during the
incubation period: (i) controls for autofluorescence, which were incubated in PSS only, and
(ii) QAPB control segments, which were incubated in a QAPB/PSS solution in the absence
of antagonists. Throughout the incubation period all solutions were replaced every 30
.minutes to ensure the pH of the solution and glucose levels were maintained.
5
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recorded at zoom tliree a laser intensity o f 40, a gain of 12, offset 0.0 and pinliole setting of 
1.4 was selected. While for images recorded at zoom eight a laser intensity of 20, gain 22, 
offset 0.0 and pinliole setting of 2.4 was used. The standard scan speed of 500 Ips was 
used for all experiments. An image size of 515 x 512 pixels produced a field size of 
289pm X 289pm.
During the co-staining experiments the settings for QAPB were as described above, while 
a red diode, with an excitation/emission wavelength of 628/645nm, was used for Syto 61. 
At a zoom of three, laser intensity was set to 30, with a gain o f 12, offset 0.0 and an 
optimal pinliole of 1.4.
Open vessels were imaged fiom the internal elastic lamina thi'ough to the media. At least 
thr ee images of the vessel were collected at random areas. Each experiment was repeated 
four times for each strain of mouse.
Kalman (5 frames) was used to record individual 2D images. Z-series were produced in 
stacks of 1 pM slices, starting at the last smooth muscle layer in focus and ending at the 
internal elastic lamina, producing a stack o f approximately 30pm.
6.2.3. Image analysis
Following image capture, the images produced from the colocalisation experiments with 
QAPB and Syto 61 were overlaid using Lasersharpe software. Thus, the distribution of 
QAPB binding was directly compared with the nuclear binding of Syto 61.
To ensure that the analysis was performed on images showing only SMCs the images 
collected at zoom eight were used for analysis using Metamorph software (version 4). 
Region statistics were generated for each image. Integi'ated intensity for QAPB was 
compared between all four strains of mice using one-way ANOVA. Integrated intensity of 
QAPB in presence of the selected antagonists was compared to QAPB alone using one­
way ANOVA and Bonferroni’s post test. For individual images the number of pixels at 
each intensity was obtained fr om image histogi'am statistics and used to calculate the total 
fluorescence at each intensity level. Mean data was displayed in histogi'am plots of 
fluorescence against intensity. These plots quantified the obseiwations made by eye and 
indicated how much fluorescence originated fi'om bright or dim pixels.
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6.3. R esults
6.3.1. Protocol development
6.3.1.1. Vessel preparation: Whole intact vessel
When imaging the whole intact vessel, it was difficult to focus into the smooth muscle 
layers and endothelium due to the thick elastic wall of the carotid artery. Consequently, an 
alternative approach was attempted in which the vessel was turned inside out to expose the 
endothelium and stretch the elastic lamina. This preparation did enable the vessels to be 
imaged from the endothelium tlirough to the media but unfortunately this approach resulted 
in severe damage to both the endothelium and the smooth muscle. Furthermore, it proved 
difficult to focus the microscope on the SMCs due to movement o f the vessel wall. The 
use of this preparation was not continued.
Cross-sectional rings
Cross-sectional rings can be easily sliced from fixed vessels. However, fr'esh tissue was 
used instead of fixed to enable the physiological processes for the ligand binding to be 
preserved. In the unfixed tissue slicing the cross-sectional rings caused unavoidable 
damage to the vessels.
Open vessel
The approach using an opened-out vessel enabled the vessel to be imaged from the 
endothelium thiough to the smooth muscle layers. This preparation was relatively easy to 
caiTy out and caused minimal damage to the vessel. Thus, the open vessel preparation was 
selected for use in the main experimental protocol.
6.3.1.2. Determination of optimal QAPB concentration
F unctiona l antagonism : The CRC to phenylephrine in the presence of QAPB 1 nM 
(maximum response obtained 0.26±0.02g; pECso 6.7±0.15) was not significantly different 
(p>0.05, one-way ANOVA, Bonferroni’s post test) to the phenylephiine control 
(maximum response obtained 0.21±0.06g; pECso 6.6±0.05). The maximum response 
obtained to phenylephrine was not significantly different (p>0.05, one-way ANOVA, 
BonfeiToni’s post test) in the presence of QAPB 10 nM (0.25±0.05g) or 0.1 pM
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(0.17±0.02g). A rightward displacement of the phenylephrine CRC (p<O.OI, one-way 
ANOVA, Bonferroni’s post test) was observed in the presence of QAPB 10 nM (PEC50 
5.7±0.35) and 0.1 pM (pECso 5.1±0,27). A mean pKo of 9.0 was obtained for QAPB.
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Figure 6. I . CRC to phenylephrine in the presence of QAPB expressed as percentage of the 
control CRC maximum as mean±S.E (n=6).
Binding: Using a standard incubation time of 120 minutes fluorescence progressively 
increased with increasing concentrations of QAPB (Figure 6.2). Evidence of QAPB 
binding was observed at 10 nM but binding was generally not intense with SMCs poorly 
defined. SMCs were clearly defined following incubation with QAPB 0.1 pM. With 
QAPB 1 pM SMCs were clearly defined and fluoresced brightly, however, some images 
showed evidence of saturation at this concentration. It was decided to use QAPB 0.1 pM 
for the experimental protocol as both the definition of the SMCs and fluorescence were 
sufficient at this concentration and the lower concentration is advantageous for using 
competitors to its binding.
10 nM 0.1 pM 1 pM
Figure 6 .Z  Determination of QAPB concentration in the WT mouse. Imaging settings: zoom 
three, laser 40, gain 12, iris 1.4.
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6.3.1.3. QAPB incubation time
Over the duration of the incubation period binding to QAPB 0.1 pM increased (Figure 
6.3). At zero minutes and 30 minutes only autofluorescence from the elastic lamina was 
visible. QAPB binding was detected at 60 minutes, which increased further at 90 minutes. 
Good evidence of QAPB binding was observed at both 120 minutes and 180 minutes, 
where SMCs were clearly defined. There was little difference between the QAPB staining 
at these two time points, which indicated that equilibrium had been reached. The shorter 
incubation time of 120 minutes was selected for use in the experimental protocol.
0 min
60 min
120 min
30 min
90 min
180 min
Figure 6.3L QAPB incubation times in WT mouse. Imaging settings: zoom three, laser 40, 
gain 12, iris 1.4.
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6.3.2. QAPB binding distribution
6.3.2.1. Controls
In the absence of QAPB, only autofluorescence from the elastic lamina was visualised and 
there was no evidence of fluorescence from the media in any of the mouse strains (Figure 
6.4).
WT mouse aiB“KO
a-iD"KO 0tiB/D"KO
Figure 6.4*- Low power view of SMCs in WT and knockout mice in the absence of QAPB. 
Imaging settings: zoom three, laser 40, gain 12, iris 1.4.
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6.5.2.2. WT mouse
QAPB binding was evenly distributed throughout the WT mouse vessels (Figure 6.5).
SMCs were clearly defined and fluoresced brightly. QAPB bound to both the cell surface 
and intracellular compartments (Figure 6.6). Intracellularly, evidence of both perinuclear 
binding and punctate binding was observed. There was no evidence of QAPB binding to 
nuclear sites.
6.3.2.3.
SMCs were clearly defined by QAPB binding and fluoresced brightly in the am-KO 
(Figure 6.5). QAPB binding to SMCs appeared evenly distributed tliroughout the vessel.
In addition to QAPB binding on the cell membrane, perinuclear and punctate binding were 
observed inside the cell (Figure 6.6). In general, QAPB binding in the am-KO resembled 
that obseiwed in the WT mouse, except that visual observations suggested that punctate 
binding was increased in the am -K O .
6.3.2.4. aiD"KO
QAPB binding to SMCs in the am-KO was variable. In some regions QAPB binding was 
markedly reduced and SMCs were less defined, while in other regions SMCs were clearly 
identified (Figure 6.5). Furthermore, the amount of fluorescence varied between individual 
cells. An overall reduction in SMCs stained with QAPB was evident compared to the WT 
mouse. The cells that QAPB bound showed both cell surface and perinuclear binding, and 
there was evidence of punctate binding in cells (Figure 6.6).
16.3.2.5. aiB/D"KO i
hi the a  1 B/D-KO QAPB binding to SMCs was variable. Overall, QAPB binding was 
markedly reduced but still detectable (Figure 6.5). Fluorescence varied between individual |
SMCs. Most SMCs were less defined with limited cell surface and perinuclear binding. 
However, most cells stained with QAPB showed evidence of punctate binding (Figure 
6 .6).
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At a zoom setting of three, QAPB binding to SMCs was observed between the grooves 
formed by the elastic lamina. At a zoom setting of eight, QAPB binding to SMCs to be 
imaged in greater detail due to the less exciting power and, therefore, a more sensitive 
detection. Furthermore, at this setting quantitative analysis could be performed in the 
absence of elastic lamina.
WT mouse otiB"KO
otiD"KO aiB/D"KO
Figure 6.5 . Low power view of SMCs in WT and knockout mice: QAPB binding. Imaging 
settings: zoom three, laser 40, gain 12, iris 1.4.
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WT mouse aiB"KO
a^ D-KO ai B/D-KO
Figure 6.6. High power view of SMCs in WT and knockout mice: QAPB binding. Imaging 
settings: zoom eight, laser 20, gain 22, iris 2.4.
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6.3.3. Comparison of QAPB intensity
Analysis o f  total amount o f  fluorescence: Fluorescence was reduced in the knockout 
mice compared to the WT mouse. This was shown by the leftward displacement of the 
histograms for the knockout mice, where the majority of fluorescence resulted from pixels 
of low intensity (Figure 6.7), and the significant decrease in total intensity in the knockouts 
compared to the WT mouse (Figure 6.8; Table 6.1).
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Figure 6.7. Comparison of integrated intensity to QAPB in the WT mouse and knockout mice 
expressed as mean ± S.E. (n=7).
150000001
s^  10000000"I 5000000-
WT 1BKO 1DK0 BDKO
Figure 6.8. Fluorescence against intensity to QAPB in the WT and knockout mice expressed 
as mean ± S.E. (n=7).
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Table 6.1. Integrated intensity to QAPB In the WT mouse and knockout mice
Mouse Strain Integrated Intensity % reduction
WT mouse 1.06x10^ ±2.9x10"
aiB“KO 5.84x10*' ±6.6x10" * 45%
aiD“K.O 3.43xl0"± 9.3x10"** 68%
ccib/d"KO 3.68x10*'±6.8x10" ** 65%
*p<0.05; **p<0.01 compared to WT mouse {one-way ANOVA, Bonferroni’s post test).
6.3.4. Pharmacological characterisation of QAPB binding to SMCs
6.3.4.1. WT mouse
No binding to QAPB was obsei-ved in the presence of prazosin (Figure 6.9; 6.10). A 
leftward shift in the histogram (Figure 6.11) and a significant reduction in integrated 
intensity (Figure 6.14; Table 6.2) demonstrated that prazosin caused a decrease in number 
high intensity pixels and, therefore, total fluorescence.
In the presence of rauwolscine no changes to QAPB binding were observed (Figure 6.9; 
6.10). The histogram produced for QAPB fluorescence in the presence of rauwolscine 
indicated that fluorescence was slightly decreased at low intensity pixels and increased at 
pixel intensities of 50 to 100 (Figure 6.11) but no significant difference in integiated 
intensity was observed compared to the QAPB control (Figure 6.14; Table 6.2).
QAPB binding appeared markedly reduced but not abolished by BMY 7378 and variations 
in binding between individual SMCs were obseiwed (Figure 6.9; 6.10). Fluorescence at 
high intensity pixels was reduced, as demonstrated by the leftward displacement of the 
histogram (Figure 6.12) and the significant reduction in integrated intensity (Figure 6.14; 
Table 6.2).
t'
Despite an apparent reduction in QAPB binding to SMCs in the presence of RSI00 329, 
both cell surface and intracellular staining remained (Figure 6.9; 6.10). A reduction in 
fluorescence to QAPB was detected at pixels of intensities of approximately 40 and above 
(Figure 6.12) and integrated intensity was significantly reduced (Figure 6.14; Table 6.2) in 
the presence of RSI 00 329.
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A reduction in fluorescence to QAPB occurred in the presence of 5-methylurapidil with 
SMCs being less defined (Figure 6.9; 6.10). There was less evidence o f cell surface and 
perinuclear binding to QAPB with 5-methylurapidil. However, punctate binding in 
intracellular compartments was still fi'equently observed. The histogram indicated that 
fluorescence was reduced at pixels of intensities of approximately 100 and above (Figure 
6.13) and a significant reduction in integrated intensity was detected (Figure 6.14; Table 
6 .2).
With the combination of BMY 7378 and R SI00 329 QAPB binding appeared markedly 
reduced but was still observed (Figure 6.9; 6.10). The definition of individual SMCs was 
lost in the presence of these antagonists, hi the presence of the combination of BMY 7378 
and R SI00 329 fluorescence was markedly reduced (Figure 6.12). The combination of 
BMY 7378 and R SI00 329 resulted in a significantly reduced integrated intensity (Figure 
6.14; Table 6.2).
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Control Prazosin
Rauwolscine
RS100 329
BMY 7378 + RSI 00 329
BMY 7378
5-methylurapldll
Figure 6.9. Low power view of SMGs in WT mouse: antagonists vs QAPB binding. Imaging
settings: zoom three, laser 40, gain 12, iris 1.4.
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Control Prazosin
Rauwolscine BMY 7378
RS100 329 5-methylurapidil
BMY 7378 + RS100 329
Figure 6.10. High power view of SMCs in WT mouse: antagonists vs QAPB binding.
Imaging settings: zoom eight, laser 20, gain 22, iris 2.4.
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Figure 6.11 . Fluorescence against intensity to QAPB in the WT mouse In the presence of 
prazosin and rauwolscine expressed as mean ± S.E. (n=4).
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Figure 6.12. Fluorescence against intensity to QAPB in the WT mouse in the presence of 
BMY 7378, R S I00 329 and BMY 7378/RS100 329 combination expressed as mean ± S.E. 
(n=4).
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Figure 6.13. Fluorescence against intensity to QAPB in the WT mouse in the presence of 5- 
methylurapidil and R S I00 329 expressed as mean ± S.E. (n=4).
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Figure 6.14. WT mouse: Integrated intensity of QAPB in the presence of antagonists (n=4).
Table 6.2. WT mouse: Comparison of integrated intensity for QAPB in the presence of 
antagonists.
Antagonist Integrated intensity (± S.E.)
QAPB control 1.06xl0'± 2.9x10"
QAPB + prazosin 1.53xlO"± 3.7x10"*"'
QAPB + BMY 7378 2.63xlO"± 1.5x10""
QAPB + RSlOO 329 4.79x10" ± 1.2x10""
QAPB + 5-methylurapidil 5.78x10" 1.3x10""
QAPB + BMY 7378 + RSlOO 329 2.97x10" ± 1.2x10^"'
QAPB + Rauwolscine 1.45xlO^± 2.4x10"''
+p>0.05; *p<0.05: **p<0.01; ***p<0.001 compared to QAPB control (one-way AN OVA, 
Bonferroni’s post test).
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6.3.4.2. aiB"KO
Like the WT mouse, in the aie-KO no QAPB binding was observed in the presence of 
prazosin (Figure 6.15; 6.16). With prazosin, the majority of QAPB fluorescence resulted 
from pixels of low intensity, thus the histogram for QAPB was displaced left (Figure 6.17) 
and integrated intensity was significantly reduced (Figure 6.20; Table 6.3).
In the presence of rauwolscine no change in fluorescence to QAPB was detected by eye 
(Figure 6.15; 6.16). The histogram mostly overlapped with that for QAPB alone although 
a small reduction in fluorescence was detected for pixels at intensities of approximately 30 
to 60 in the ais-KO (Figure 6.17). In the presence of rauwolscine integrated intensity was 
not significantly different to the QAPB control (Figure 6.20; Table 6.3).
In the presence of BMY 7378 QAPB binding appeared markedly reduced but was still 
detectable (Figure 6.15; 6.16). Variations in fluorescence were observed between 
individual SMCs. Like the WT mouse, the reduction in fluorescence was demonstrated by 
the decrease in high intensity pixels resulting in the leftward displacement of the histogram 
(Figure 6.18) and the significant reduction in integiated intensity (Figure 6.20; Table 6.3).
Despite an apparent reduction in fluorescence and QAPB binding to SMCs, in the presence 
of RSlOO 329, both cell surface and intracellular staining remained (Figure 6.15; Figure 
6.16). With RSlOO 329, a leftward shift in the histogram for QAPB was detected (Figure 
6.18) and integrated intensity was significantly reduced (Figure 6.20; Table 6.3), following 
a similar trend as the WT mouse.
The presence of 5-methylurapidil appeared to cause a decrease in fluorescence to QAPB 
and SMCs were less defined but both binding to the cell membrane and intracellular 
compartments was observed (Figure 6.15; 6.16). 5-methylurapidil reduced fluorescence 
between intensities o f approximately 25 to 50 but slightly increased fluorescence fi’om high 
intensity pixels (Figure 6.19), which was not detected in the WT mouse. A significant 
reduction in integrated intensity was detected (Figure 6.20; Table 6.3).
Unlike the WT mouse, with the combination of BMY 7378 and RSlOO 329 QAPB binding 
appeared to be abolished (Figure 6.15; 6.16). The reduction in fluorescence was 
demonstrated by the leftward displacement of the histogram for QAPB in the presence of 
BMY 7378 and RSlOO 329 (Figure 6.18) and a significant reduction in integrated intensity 
was detected (Figure 6.20; Table 6.3).
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Control
Rauwolscine
Prazosin
BMY 7378
RS100329 5-methylurapidil
BMY 7378 + RSlOO 329
Figure 6.15. Low power view of SMCs in oib-KO: QAPB vs antagonists. Imaging settings:
zoom three, laser 40, gain 12, iris 1.4.
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Control Prazosin
Rauwolscine
RS100 329
BMY 7378 + RS100 329
BMY 7378
5-methylurapidil
Figure 6.16. High power view of SMCs in Oib-KO: QAPB vs antagonists. Imaging settings;
zoom eight, laser 40, gain 22, iris 2.4.
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Figure 6.17 . Fluorescence against Intensity to QAPB in the aiB-KO in the presence of 
prazosin and rauwolscine expressed as mean ± S.E. (n=4).
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Figure 6.18. Fluorescence against intensity to QAPB in the ociB-KO In the presence of BMY 
7378, RSlOO 329 and BMY 7378/RSI00 329 combination expressed as mean ± S.E. (n=4).
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Figure 6.19. Fluorescence against intensity to QAPB in the am-KO in the presence of 5- 
methylurapidil and RSlOO 329 expressed as mean ± S.E. (n=4).
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Figure 6.20. ais'KO: Integrated intensity of QAPB in the presence of selective antagonists 
(n=4).
Table 6.3. aiB-KO: Comparison of integrated intensity for QAPB in the presence of selective 
antagonists.
Antagonist Integrated intensity (± S.E.)
QAPB control 5.84xl0"± 6.6x10'
QAPB + prazosin 1.42x10^ 3.5x10'
QAPB + BMY 7378 2.56xl0^± 3.7x10'"’'
QAPB + RSlOO 329 3.05x10" d: 4.1x10'"
QAPB + 5-methylurapidil 2.98xl0"± 2.9x10'""
QAPB + BMY 7378 + RSlOO 329 1.37xlO^± 2.3x10'"""
QAPB + Rauwolscine 5.21xi0^± 8.6x10''"
+p>0.05; *p<0.05; **p<0.01; ***p<0.001 compared to QAPB control (one-way ANOVA, 
Bonferroni’s post test).
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6 .3.4.3. 0C1D-KO
Like the WT mouse, in the am-KO in the presence of prazosin QAPB binding appeared to 
be abolished (Figure 6.21; 6.22). The histogram plot for QAPB in the presence of prazosin 
was shifted left showing the majority of fluorescence originating from pixels of low 
intensities (Figure 6.23) and integrated intensity was significantly reduced (Figure 6.26; 
Table 6.4).
In the presence o f rauwolscine QAPB binding did not appear to be changed (Figure 6.21, 
6.22). The histogram for QAPB with rauwolscine largely overlay the histogram for QAPB 
alone (Figure 6.23) and the increase in fluorescence detected in the WT mouse was not 
detected in the aiD-KO. Integrated intensity was not significantly different to the QAPB 
control (Figure 6.26; Table 6.4).
QAPB binding was unaffected by the presence of BMY 7378, with no detectable 
differences in fluorescence in SMCs or subcellular distribution (Figure 6.21; 6,22). Unlike 
the WT mouse, the presence of BMY 7378 had little effect on the QAPB histogram, with 
the exception of a small increase in fluorescence from pixels at intensities of 30 to 40 
(Figure 6.24). Integrated intensity was not significantly reduced compared to the QAPB 
control (Figure 6.26; Table 6.4).
No QAPB binding was observed in the presence of RSlOO 329 (Figure 6.21; 6.22). 
Following a similar trend to the WT mouse, RSlOO 329 caused fluorescence to decrease. 
This was shown by the leftward displacement of the histogram with the majority of 
fluorescence resulting from low intensity pixels (Figure 6.24), and a significant reduction 
in integrated intensity (Figure 6.26; Table 6.4).
In contrast to the WT mouse, in the presence of 5-methylurapidil no evidence of QAPB 
binding was obseiwed in the am-KO (Figure 6.21; 6.22). This was demonstrated by the 
leftward shift in intensity on the histogram (Figure 6.25) and the significant reduction in 
integi'ated intensity (Figure 6.26; Table 6.4).
Unlike the WT mouse, the combination of BMY 7378 and RSlOO 329 resulted in the 
abolition of QAPB binding (Figure 6.21; 6.22). The leftward displacement of the 
histogi'am (Figure 6.24) and the significant reduction in integrated intensity for QAPB 
(Figure 6.26; Table 6.4) demonstrated that fluorescence was decreased by the combination 
of BMY 7378 and RSlOO 329.
'T1
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Control Prazosin
Rauwolscine
RS100 329
BMY 7378 + RSlOO 329
BMY 7378
5-methylurapidil
Figure 6.21. Low power view of SMCs in aio-KO: QAPB vs antagonists. Imaging settings:
zoom three, laser 40, gain 12, iris 1.4.
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Control Prazosin
Rauwolscine BMY 7378
RS100 329 5-methylurapidil
BMY 7378 + RS100 329
Figure 6.22. High power view of SMCs in aio-KO: QAPB vs antagonists. Imaging settings:
zoom eight, laser 20, gain 22, iris 2.4.
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Figure 6.23 . Fluorescence against Intensity to QAPB In the ociD-KO In the presence of 
prazosin and rauwolscine expressed as mean ± S.E. (n=4).
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Figure 6.24. Fluorescence against intensity to QAPB in the am-KO in the presence of BMY 
7378, RSlOO 329 and BMY 7378/RSI00 329 combination expressed as mean ± S.E. (n=4).
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Figure 6.25. Fluorescence against intensity to QAPB in the aio-KO in the presence of 5- 
methylurapidil and RSlOO 329 expressed as mean ± S.E. (n=4).
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Figure 6.26. aïo-KO; Integrated Intensity of QAPB in the presence of selective antagonists 
(n=4).
Table 6.4. aio-KO: Comparison of integrated intensity for QAPB in the presence of selective 
antagonists.
Antagonist Integrated intensity (± S.E.)
QAPB control i43xl0^±  9.3x10^
QAPB + prazosin 8.53xlO"d= 5.1x10''"
QAPB + BMY 7378 4.46xlO"± 4.0x10'^
QAPB + RSlOO 329 1.43x1 O''± 1.9x10'"
QAPB + 5-methylurapidil 1.35x10" 2.5x10''
QAPB + BMY 7378 + RSlOO 329 1.43x10" ±1.9x10'
QAPB + Rauwolscine 4.08xl0"± 5.5x10^
+p>0.05; *p<0.05; **p<0.01 compared to QAPB control {one-way ANOVA, Bonferroni’s post 
test).
187
6.3.4.4. a-iB/D"KO
Like the WT mouse, in the aiB/o-KO prazosin abolished QAPB binding (Figures 6.27;
6.28). hi the presence of prazosin the leftward displacement o f the histogram, the high 
number of low intensity pixels (Figure 6.29), and the significant reduction in integrated 
intensity (Figure 6.32; Table 6.5) demonstrated that fluorescence was decreased.
In the presence of rauwolscine no differences in QAPB binding were observed compared 
to the QAPB control (Figure 3.27; 6.28). The histogram indicated that in the presence of 
rauwolscine fluorescence to QAPB was decreased at intensities of approximately 30 to 50 
but increased at intensities of 60 and above (Figure 6.29), following a similar trend to the 
WT mouse. Integrated intensity was not significantly different to the QAPB (Figure 6.32; 
Table 6.5).
Unlike the WT mouse, no changes to QAPB binding were obseiwed in the presence of 
BMY 7378 (Figure 6.27; 6.28). However, the histogram indicated fluorescence to QAPB 
was reduced slightly at pixel intensities greater than 40 (Figure 6.30), although no 
significant change in integrated intensity was observed (Figure 6.32; Table 6.5).
In the presence of RSlOO 329 QAPB binding was completely abolished (Figure 6.27;
6,28). The histogram indicated that fluorescence was reduced at pixel intensities of 25 and 
above (Figure 6.30) and integrated intensity was significantly reduced (Figure 6.32; Table 
6.5), following a similar trend as the WT mouse.
QAPB binding appeared markedly reduced and SMCs being less defined in the presence of 
5-methylurapidil (Figure 6.27; 6.28). The histogram was shifted left with a high number of 
low intensity pixels (Figure 6.31) and a significant reduction in integrated intensity was 
detected in the presence of 5-methylurapidil (Figure 6.32; Table 6.5), following a similar 
trend as the WT mouse.
Unlike the WT mouse, with the combination of BMY 7378 and RSlOO 329 no QAPB 
binding was detected in the aiB/o-KO (Figure 6.27; 6.28). The histogram was shifted left 
indicating that the majority o f fluorescence originated from low intensity pixels (Figure 
6.30). Integrated intensity was significantly reduced (Figure 6.32; Table 6.5).
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Figure 6.27. Low power view of SMCs in aie/o-KO: QAPB vs antagonists. Imaging settings:
zoom three, laser 40, gain 12, iris 1.4.
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Figure 6.28. High power view of SMCs in aiB/o-KO: QAPB vs antagonists. Imaging settings:
zoom eight, laser 20, gain 22, iris 2.4.
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Figure 6.29. Fluorescence against Intensity to QAPB In the aig/o-KO In the presence of 
prazosin and rauwolscine expressed as mean ± S.E. (n=4). -
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Figure 6.30. Fluorescence against Intensity to QAPB In the ais/o-KO In the presence of BMY 
7378, RSlOO 329 and BMY 7378/RSI00 329 combination expressed as mean ± S.E. (n=4).
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Figure 6.31. Fluorescence against intensity to QAPB In the aiB/D"KO In the presence of 5- 
methylurapldll and RSlOO 329 expressed as mean ± S.E. (n=4).
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Figure 6.32. aiB/D-KO: integrated intensity of QAPB In the presence of selective antagonists 
(n=4).
Table 6.5. aiB/D"KO: Comparison of integrated Intensity for QAPB in the presence of 
selective antagonists.
Antagonist Integrated intensity (± S.E.)
QAPB control 6.25xl0'’± 8.7x10^
QAPB + prazosin 1.24xl0"± 5.0x10'
QAPB + BMY 7378 4.40x10" ± 6.9x10'
QAPB + RSlOO 329 2.35xl0"± 6.3x10'
QAPB + 5-methyIurapidil 2.45xl0"± 3.7x10'""
QAPB + BMY 7378 + RSlOO 329 1.84x10" 2.0x10'""
QAPB + Rauwolscine 4.49x10" ±1.2x10"’"
+p>0.05; **p<0.01 compared to QAPB control (one-way ANOVA, Bonferroni’s post test).
192
6.4. D iscussion
6.4.1. Protocol development
At the onset of this study a series of preliminary experiments was carried out to determine 
the most suitable vessel preparation and incubation conditions for the experimental 
protocol. The use o f the open vessel preparation overcame the problems associated with 
the thick elastic wall of the carotid artery. Ideally QAPB incubations would have been 
performed at the physiological temperature of 37°C, but to prevent the calcium 
precipitating out of the PSS, incubations were earned out at room temperature (21 °C). 
QAPB binding was concentration-dependent but the intermediate concentration of QAPB 
0.1 pM was selected for use in the study due to insufficient definition at 10 nM and 
concerns over saturation and non-selectivity at QAPB 1 pM. In addition, QAPB 0.1 pM 
antagonised the ai-AR-mediated response to phenylepMne, which further validated the 
use of this concentration for the visualisation study of ai-ARs. The pKe of 8.5 obtained 
for QAPB 0.1 pM also conelates with the affinity of QAPB for the ai-A R subtypes (pKi 
aiA“AR 8.7, aiB"AR 8.4, am-AR 8.1) (Mackenzie et a l ,  2000). QAPB has been 
successfully used in previous studies on cells at concentrations below lOnM (Pediani et a l,  
2005;Woollhead, 2002). However, the present study has shown that in the intact vessel 
higher concentrations are required. This is supported by recent studies in the mouse 
mesenteric artery, which used QAPB 1 pM (McBride et a l  Submitted for publication). 
The binding of QAPB 0.1 pM was time-dependent. An incubation time of 120 minutes 
was selected for use in this study sinee SMCs were insufficiently defined at the eaidier 
time-points suggesting that QAPB had not reached equilibrium. This was surprising as 
incubations of 30 to 40 minutes are usually sufficient for an antagonist to reach equilibrium 
in functional experiments and previous studies using QAPB 1 pM have successfully 
imaged isolated cells and other vessels following an incubation of only 60-75 minutes 
(Pediani et a l ,  2005;McBride et a l  Submitted for publication). This suggests that the 
uptake of QAPB into the SMC is slower in the carotid artery than isolated SMCs or SMCs 
in the mouse first order mesenteric artery.
Control vessels were incubated in PSS alone to assess the fluorescence produced in the 
absence of QAPB. It has previously been demonstrated that QAPB was only fluorescent 
when bound to receptors (Daly et a l ,  1998;Mackenzie et a l ,  2000). This was confirmed in 
the present study by only autofluorescence fi'om the elastic lamina being obseiwed in the 
absence o f QAPB and no fluorescence was detected in the smooth muscle layers. For this
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reason the quantitative analysis was performed on the high power images, which excluded 
the elastic lamina.
6.4.2. Comparison o f QAPB binding in WT mouse and knockouts
Clear differences in the binding distribution of QAPB were observed between mouse 
strains, which were supported by the quantitative analysis. The even distribution of clearly 
defined SMCs and bright fluorescence observed in the WT mouse and am-KO contrasted 
with the variable binding pattern and reduced definition of SMCs in the aio-KO and aiB/o- 
KO. However, in all thi'ee knockouts a marked reduction in the fluorescence at high 
intensity pixels was detected. The reduction in the number of high intensity pixels in the 
aiB“KO suggests that the total ai-AR population in the carotid artery was reduced, thus in 
the WT mouse the aiB-AR appears to be present in SMCs. Fluorescence in the aio-KG 
was reduced more than in the aiB-KO, consistent with the expectation that the ocm-AR 
would be a major component of the ai~AR population. This suggests that a greater 
number of aio-ARs than ais-ARs are present in the media of the WT mouse. Like the 
aiD-KO, the marked reduction in QAPB binding in the am/o-KO compared to the aiB-KO 
confirms that a high proportion of the total ai-AR population in the WT mouse is aio- 
ARs. Furthennore, the reduction in fluorescence compared to the aio-KG supports 
findings in the aiB-KG that the am-AR does appear to comprise a component of the a i- 
AR population in the smooth muscle layers of the WT mouse carotid artery. It has been 
reported that when the aiB-AR is coexpressed with either the aiA-AR or aio-AR an 
increase in binding site density and protein expression is detected (Uberti et a l ,  2003). 
Thus, the absence of the Œib-AR may account for the decreased fluorescence in the aiB- 
KG and ais/o-KG by a reduction in the binding site density of the aiA-AR and/or aiD-AR., 
in addition to a reduction in the total ai~AR population
6.4.3. Competition with non-fiuorescent antagonists
The varying affinities of the non-fluorescent antagonists for the ai-ARs were taken into 
consideration while evaluating how effectively the antagonists competed with QAPB 
(Table 6.6). In addition, affinity estimates from binding experiments at the Œ2-AR 
subtypes (pK, 0C2A-AR 7.8; Œ2B-AR 7.3; a 2D-AR 7.8) (McGrath & Daly, 2005) were used 
to select the concentration of rauwolscine used. Generally, the concentration of each
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antagonist used was higher than indicated by the pKi but was selected to have 
approximately ten-fold higher affinity than QAPB 0.1 pM at the subtype.
Table 6.6. Comparison of affinity estimates from rat-1-fibroblasts expressing human a^-AR 
subtypes
Ligand aiA-AR pKi ajB-AR pKi a7Z)-ARpKi
QAPB 8.7 8.4 8.1
Prazosin 9.0 9.0 9.0
BMY 7378 7.1 6.8 10.5
RSlOO 329 9.7 8.0 8.0
5-methylurapidil 9.2 7.2 7.9
Data from Table 2, Mackenzie et al. (2000).
6.4.3.1. Prazosin
In all four mouse strains prazosin abolished QAPB binding, or at least reduced 
fluorescence below a detectable level. This confirmed that the ai-AR selectivity of QAPB 
was preserved at 0.1 pM. The observations were supported by the quantitative analysis, 
which showed prazosin caused a marked reduction in total intensity of QAPB. 
Furthermore, in the presence of prazosin the majority of fluorescence originated from low 
intensity pixels.
6.4.3.2. Rauwolscine
The a%-AR selective antagonist, rauwolscine did not appear to reduce fluorescence when 
examined visually in any of the mice stiains. However, the small reduction in low 
intensity pixels and the increase in high intensity pixels in both the WT mouse and aiB/o- 
KO indicated that caused an increase in fluorescence to QAPB. At present it is unclear 
why this would occur. In the am-KO a small reduction in fluorescence to QAPB from 
high intensity pixels was detected. This raises the possibility that QAPB 0.1 pM may be 
binding az-ARs. Alternatively, this could also reflect the binding of rauwolscine to ai- 
AR. However, in the am-KO rauwolscine did not have an effect on QAPB binding and 
the total intensity to QAPB in all four mouse strains was not significantly different in the
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presence of rauwolscine suggesting that QAPB binding was not gieatly affected by the 
antagonist.
6A3.3. BMY 7378
Based on the binding affinities at the a i-A R  subtypes (Table 6.6), BMY 7378 0.1 pM 
could have potentially bound to all three a i-A R  subtypes. However, a decrease in 
fluorescence to QAPB was observed in the presence of BMY 7378 in the WT mouse and 
aiB-KO, but not the am-KO or am/o-KO. These observations were sustained in the 
quantitative analysis: integrated intensity and fluorescence from high intensity pixels were 
reduced in the WT mouse and am-KO, but were largely unchanged in the am-KO and 
aiB/D-KO. These findings are consistent with a previous study in isolated SMCS from the 
carotid arteiy also reported that BMY 7378 blocked QAPB binding in the majority of 
SMCs in the WT mouse and am -K O . In agreement with the functional data in Chapters 
Three and Four, these findings suggest that the concentration of BMY 7378 used (0.1 pM) 
had higher affinity at the am -A R  than the aiA-AR or am -A R . The variations in 
fluorescence observed between individual SMCs in the presence of BMY 7378 in the WT 
mouse and am -K O  suggest that the am -A R  was not uniformly distributed throughout the 
media. Overall, these findings confimi that the am -A R  is present in the media of the WT 
mouse and am -K O  and is absent in the am -K O  and am/o-KO.
6A3.4. RS100 329
Relative to the binding affinity of RSlOO 329 at the ai-AR subtypes, at a concentration of 
0.1 pM, RSlOO 329 could prevent QAPB binding to all three aj-AR subtypes (Table 6.6). 
In the WT mouse and am -K O  a decrease in fluorescence to QAPB was obseived in the 
presence of RSlOO 329. This was supported by the significant reduction in integrated 
intensity and the reduction in the number of high intensity pixels. This suggested that the 
aiA-AR was present in both the WT mouse and am -K O . Some brighter cells remained 
stained, suggesting that the distribution of the aiA-AR was intennittent. This is in 
agreement with an earlier study in isolated SMCS from the carotid arteiy, in which RSlOO 
329 reduced QAPB binding in some cells in the WT mouse and am -K O  (Woollhead, 
2002). The cell surface and intiacellular binding observed in the presence of RSlOO 329 
indicated that populations of other ai-AR subtypes were present in these mice. In contrast, 
in the am -K O  and am /o-K O  QAPB binding appeared to be abolished by RSlOO 329. The 
observations were supported by the significant reduction in integrated intensity and the
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1majority of fluorescence being detected at low intensity pixels. This suggests that the aiA- 
AR was also present in the SMCs of the am-KO and the am/o-KO. In these two mouse 
strains, where it was shown that the ai-AR response is mediated by the aiA-AR (Chapter 
Four), the abolition of QAPB binding was consistent with RSlOO 329 showing higher 
binding affinity at the aiA-AR than the am-AR or am-AR. The residual QAPB binding 
detected in the WT mouse and am-KO, where the ai-AR response is predominantly am- 
AR-mediated, is in agreement with RSlOO 329 having lower affinity at the am-AR. There 
is no evidence from this data that am-ARs are present in the am-KO. This was 
unexpected since the am-AR appears to be present in the WT mouse. This may be due to 
either the absence of am-ARs in the am-KO or the am-ARs are present but are being 
blocked by RSlOO 329. This may be a difference that exists between the ai-AR 
populations in WT mouse and am-KO. Overall, these findings indicate that aiA-ARs are 
present in the media of the carotid artery of the four mice.
]'6.3.4.S. 5-methylurapidil i
Based on the binding affinities at the a i-A R  subtypes, 5-methylurapidil 0.1 pM could 
prevent QAPB binding to the am -A R  and am -A R  in addition to the a^-A R  (Table 6.6).
A marked reduction in QAPB binding was observed in the presence of 5-methylurapidil in 
the WT mouse, am-KO and am/o-KO, with SMCs being less defined. Furtheimore, in the 
am-KO QAPB binding was abolished. The reduction in QAPB binding observed was in 
agreement with the significant reduction in integrated intensity and the reduction in 
fluorescence from high intensity pixels at high intensities in all four mouse strains. 
However, the residual binding detected in the WT mouse and am-KO and the functional 
evidence in Chapters Three and Four suggest that at this concentration 5-methylurapidil 
has retained selectivity for the aiA-AR. The effect of 5-methylurapidil on QAPB binding 
is comparable to that observed in the presence of RSlOO 329 and suggests that aiA-ARs 
were present in the murine carotid arteiy of the four mouse strains, although there was no 
evidence of the am-AR in the am-KO.
G.3.4.6. BMY 7378 and RS100 329 combination
In the presence of both BMY 7378 and RSlOO 329 QAPB binding appeared markedly 
reduced in the WT mouse but was abolished in the am -K O , am -K O  and am /o-KO. 
Quantitative analysis revealed a marked reduction in total intensity in all four strains of 
mouse and in all mice there was no evidence of fluorescence at the higher intensities. The
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residual QAPB binding in the WT mouse suggests that all three ai-AR subtypes may exist 
in the smooth muscle of the carotid arteiy of the WT mouse. As no QAPB binding was 
observed in the am-KO, this may reflect that no am-ARs are present in this strain.
In summaiy, QAPB appears to have selectively bound to ai-ARs in the mouse carotid 
arteiy. In the am/o-KO the only possible ai-AR subtype, the aiA-AR, appears to be 
present. Evidence of the aiA-AR but not the am-AR was obseived in the am-KO. Both 
the aiA-AR and the am-AR appear to exist in the am-KO. In the WT mouse evidence of 
all three ai-AR subtypes was apparent. The findings in the WT mouse and am-KO are in 
agreement with those in isolated SMCs from the carotid arteiy, in which evidence of all 
three ai-ARs was reported in the WT and the aiA-AR and am-AR appeared to be present 
in the am-KO (Woollhead, 2002).
6.3.5. QAPB subcellular distribution
Comparison of the distribution of QAPB binding in individual SMCs indicated that 
differences between ai-AR subtypes may exist. In the WT mouse QAPB binding was 
obseived on the cell membrane and in intracellular compartments. Inside the cell, diffuse 
QAPB binding existed in the perinuclear regions, while clusters of QAPB binding were 
also identified. This is consistent with previous studies, which reported QAPB bound to 
the cell surface and in punctate intracellular sites in isolated cells (Daly et al, 
1998;McGrath et al, 1999;Mackenzie et al, 2000) and in SMCs in situ (McBride et al 
Submitted for publication). The subcellular distribution of QAPB binding in the am-KO 
was similar to the WT mouse but there appeared to be more clustered intracellular binding, 
although this was not reflected in the number of high intensity pixels measured. In 
contrast, there appeared to be less punctate binding in the am-KO and binding was 
generally more diffuse. However, in the am/n-KO, there was little evidence of difhise 
QAPB binding to the cell surface and perinuclear region and binding was mostly in 
punctate compartments. These differences in QAPB binding between the mouse strains 
suggest that the subcellular distiibution of ai-ARs may differ or at least that changes occur 
when an ai-AR subtype is not present.
Differences in a i-A R  subcellular distribution have been reported in previous studies. The 
aiA-AR was located mainly intiacellularly, while the am-AR was predominantly located 
on the cell surface (Hirasawa et al, 1997;Sugawara et al, 2002;McCune et al, 2000). In 
the present study in mice lacking the am -A R  (am -K O  and am /o-K O ), QAPB binding
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appeared to be more punctate. In contiast in the mice where the am-AR was present (WT 
mouse and am-KO), QAPB binding was more diffuse. This indicates that the am-AR 
may have a regulatoiy role within the cell. It was recently reported that the am-AR 
formed heterodimers with the aiA-AR and aio-AR (Uberti et al, 2003) and the am- 
AR/aiD-AR dimer was suggested to aid the h ansportation of the am-AR to the cell surface 
(Hague et ai, 2004b). Thus, the increase in punctate binding in the am-KO and aiB/o-KO 
may be due to a reduction in the transpoiiation of aiA-ARs or am-ARs to the cell surface. 
Furthemiore, the lack of intracellular clusters in the aio-KO could indicate that the a^-A R  
is predominantly located inside the cell, while the reduced binding on the cell surface of 
the aiB"KO and aiB/o-KO could point to the main location of the am-AR.
The evidence in the present study may support the hypothesis that a difference in the 
subcellular distribution of ai-ARs in the SMCs of the mouse carotid artery exists. In 
agreement with the studies of ai-AR distribution in isolated cells (Hirasawa et al, 
1997;Sugawara et al, 2002;McCune et al, 2000), the am-AR is mainly found at the cell 
surface, while in the absence of the am-ARs the aiA-AR and am-AR are predominantly 
located at intracellular sites.
6.3.6. ai‘AR distribution and function
In Chapters Three and Four the ai-AR-mediated contractile response of the mouse carotid 
artery was characterised pharmacologically. The am-AR was the predominant mediator of 
conhaction, supporting a previous study (Deighan C, 2002;Deighan C et al, 2005), and an 
aiA-AR-mediated secondary component to the contractile response was identified using a 
selective aiA-AR agonist. The present study has shown evidence which may provide an 
insight to the role of the am-AR in the mouse carotid artery. Despite the lack of evidence 
of am-ARs in the am-KO, the am-AR appeared to be present in the smooth muscle layers 
of the WT mouse. The presence of an ai-AR cannot be taken as evidence that it is 
functional. However, the presence of the am-AR is in agreement with the functional data 
in Chapters Three and Four, in which comparison of the phenylephrine-induced response 
in the WT and knockout mice indicated a contractile am-AR. Thus, the am-AR appears to 
contribute to the contraction of the carotid artery irr the WT mouse. In addition to a 
contractile role, the present study indicates that the am-AR may regulate the cellular 
expression of the aiA-AR and am-AR in the carotid artery.
199
6.3.7. Conclusion
The experimental protocol developed enabled the distribution of ai-ARs in the smooth 
muscle layers of the carotid artery to be examined. ai-ARs were evenly distributed in the 
WT mouse and am-KO but in the aio-KO and ate/o-KO the distribution of ai-ARs was 
variable. All three ai-A R subtypes appear' to exist in the WT mouse, while the œia-AR 
and aiD“AR were present in the am-KO and only the aiA-AR was identified in both the 
aiD-KO and aie/o-KO. In the absence of the am-AR (am-KO and am/D-KO) an increase 
in clustered binding was obsei*ved, while in the presence of the am-AR (WT mouse and 
aiD-KO) binding was more diffuse.
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Chapter Seven 
Visualisation of ai-ARs on the endothelium
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7.1. Introduction
7.1.1. Endothelial a-ARs
It is well established that az-ARs exist in both the media and the intima (Vanhoutte, 
2001;Cocks & Angus, 1983), while ai-ARs have been considered to be present only in the 
media due to the lack of positive evidence.
There is substantial functional evidence of endothelial ai-ARs in several arteries. For 
instance, Zschauer et al. (1997) proposed that noradrenaline acted on endothelial az-ARs 
to relax the rabbit brachial artery as no relaxation was observed in denuded vessels. It has 
also been demonstrated that the stimulation of a 2-ARs on the endothelium, with 
noradrenaline, induced the release of NO and the subsequent relaxation of the rat aorta 
(Kaneko & Sunano, 1993). Furthermore, Malekzadeh Shafaroudi et al. (2005) established 
that in the mouse aorta the activation of oc2A-ARs on the endothelium resulted in 
vasodilatation. It has also been shown that the stimulation of endothelial a 2-ARs 
accounted for the suppressed contractions to noradrenaline in the carotid artery of the pig 
(Ohgushi et al., 1993). Irr the mouse carotid artery L-NAME blocked relaxations to the a 2- 
AR agonist UK14304, indicating that a 2-ARs were involved in NO release (Malekzadeh 
Shafaroudi, 2005). Thus, in many studies the endothelium-dependent relaxations to 
catecholamines, or surrogates acting are their receptors, are attributed to a 2-ARs on the 
endothelium.
Functional evidence to suggest that ai-ARs exist on the endothelium is now emerging 
(Boer et al, 1999;Tuttle & Falcone, 2001;Zschauer et al, 1997;Kaneko & Sunano, 
1993;Filippi et al, 2001 ;de Andrade et al, 2006). The first study to demonstrate the 
existence of endothelial ai-ARs reported that in the presence of an aa-AR antagonist 
noradrenaline induced NO release in the rabbit bronchial artery (Zschauer et al, 1997). 
Furthermore, a study of the rat mesenteric vascular bed provided evidence of endothelium- 
dependent relaxations to phenylephrine (Filippi et al, 2001). It was also demonstrated that
The intima is the innermost layer of the arterial wall. It consists of a single layer of 
endothelial cells (EC), which are in direct contact with plasma, and is separated from the 
media by the internal elastic lamina. It is well documented that the vascular endothelium 
has an important role in the regulation of vascular tone, through the release of contractile 
or vasorelaxant substances from EC (see Chapter One).
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in the presence of the selective am-AR antagonist BMY 7378, no phenylephrine-induced 
relaxations were obseiwed, consistent with the response being mediated by endothelial am - 
ARs. Further evidence of an endothelium-dependent am-AR-mediated relaxation to 
phenyleplirine was recently reported in the rat carotid artery (de Andrade et a l ,  2006). At 
present, there is no evidence of the existence of ai-ARs on the endothelium of the mouse 
carotid artery.
7.1.2. Aims
It is clear that the role of ai-ARs on the endothelium is an area of research which is 
currently expanding. It is possible that attempts to obtain functional evidence of 
endothelial ai-ARs are hindered by the strong contractile response to ai~AR agonists in 
the carotid artery. However, endothelial a 2-ARs were recently visualised on the 
endothelium for the first time using a fluorescent ligand (Malekzadeh Shafaroudi et a l,  
2005). This demonstrated an alternative method to investigate the receptors present on the 
endothelium. Consequently, the aims of the present study were:
• To establish whether ai-ARs exist on the endothelium of the carotid artery of the 
WT mouse and ai-AR knockouts using visualisation teclmiques.
• To compare the proportion of EC with ai-ARs between mouse strains, and in doing 
so:
o Determine the ai-A R subtypes present on the endothelium of the WT 
mouse carotid artery by investigating the effect of subtype selective 
antagonists on the number of EC with ai-ARs.
o Investigate the ai-A R subtypes present on the endothelium of the am-KO, 
am-KO and am/o-KO by comparing the relative number of EC with a i- 
ARs, in the absence and presence of selective antagonists, in the knockouts 
with the WT mouse.
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7.2. Methods
7.2. Y. Incubation conditions
This protocol has been described in detail in Chapter Tliree. In brief, 5mm segments of 
carotid artery were incubated at room temperature (21°C) with QAPB 0.1 pM, in a PSS 
solution at room temperature for 30 minutes. The vessels were then co-incubated with the 
nuclear dye Syto 61 1 pM and QAPB 0.1 pM for 90 minutes. Syto 61 was used to identify 
the position of the EC.
In the WT mouse, additional experiments were carried out in which, following the QAPB i;
i
incubation period, vessels were incubated in a QAPB 0.1 pM /PSS solution containing Syto 
61 1 pM and a subtype selective antagonist(s): prazosin 0.1 pM, (non-selective ai-AR 
antagonist); R SI00329 0.1 pM, (œia-AR selective antagonist); 5-methylurapidil 1 pM 
(aiA-AR selective antagonist); BMY7378 0.1 pM (am-AR selective antagonist); both 
BMY 7378 0.1 pM and R SI00329 0.1 pM; or rauwolscine 0.1 pM (az-AR antagonist). 
Throughout the incubation period all solutions were replaced every 30 minutes to ensure 
the pH of the solution and glucose levels were maintained.
In all four mouse strains a series of experiments were also performed in which vessels 
were incubated with QAPB 0.1 pM for 60 minutes and then co-incubated for a further 60 
minutes with a 0.1 pM QAPB/PSS solution containing one of the subtype selective 
antagonists described above.
7.2.2. Siide mounting
At the end of the incubation period each carotid artery segment was sliced open with a 
single-edged razor blade and laid flat on a microscope slide with the endothelial side up 
(Miquel RM et a l ,  2005) and coverslip (thickness 1.5) on top. Care was taken to preserve 
the endothelium.
All arteries were visualised using the Bio-Rad Radiance 2100 Confocal Laser Scanning 
System. A x40 oil immersion objective (NA 0.75) was used for all experiments. An 
argon-ion laser with an excitation wavelength of 488nm with an emission filter of 515nm 
was used for QAPB. Images were recorded at zoom three a laser intensity of 40, a gain of 
12, offset 0.0 and pinhole setting of 1.4. A red diode, with an excitation/emission
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wavelength of 628/645mn, was used for Syto 61. At a zoom of three, laser intensity was 
set to 30, with a gain of 12, offset 0.0 and an optimal pinhole of 1.4. The standard scan 
speed of 500 lines per second was used for all experiments. An image size of 515 x 512 
pixels produced a field size of 289pm x 289pm.
Vessels were imaged from the internal elastic lamina thi'ough to the media. A minimum of 
tlu'ee images were collected from random areas of each vessel. Each experiment was 
repeated four times for each strain of mouse.
Kalman (5 frames) was used to record individual 2D images. Z-series were also produced 
in stacks of 1 pM slices, starting at the first smooth muscle layer and ending at the internal 
elastic lamina, producing a stack of approximately 15 pm.
7.2.3. Image analysis
Following image capture, the images produced from the colocalisation experiments with 
QAPB and Syto 61 were overlaid using Lasershaipe software. Thus, the localisation of 
QAPB binding was directly compared with the nuclear binding of Syto 61. In all four 
mouse strains, using Metamorph software, the numbers of EC showing QAPB binding 
were counted for individual 2D images produced in each experiment and a mean number 
of EC was calculated and expressed as mean ± standard error. This was repeated for the 
number of EC identified by Syto 61 binding. The number of EC with QAPB binding was 
expressed as a percentage of the total number of EC (as identified by Syto 61). The 
proportion of EC stained with QAPB out of the number of EC stained with Syto 61 was 
compared between mouse strains using Student’s t-test. hi addition, the number of EC 
stained with QAPB in the presence of the subtype selective antagonists in the WT mouse 
mice was compared with the knockout mice. It should be noted that this method of 
quantitative analysis was dependent on the ai-AR population varying among EC.
3D images were produced from a 3D projection of the stack of “optical sections” using 
Lasershaipe software.
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7.3. Results
7.3.1. QAPB and Syto 61 binding
7.3.1.1. WT mouse
The membrane dye Syto 61(1 pM) bound to the nucleus of cells on the endothelium of the 
carotid artery in the WT mouse. EC were located on the internal elastic lamina (Figure 
7.2) and within the grooves formed by folds in the internal elastic lamina (Figure 7.1). 
QAPB (0.1 |iM) bound to EC on the internal elastic lamina and within the folds of the 
internal elastic lamina in the WT mouse. QAPB binding on the endothelium overlapped 
with the Syto 61 binding as shown in the merged images. Evidence of both diffuse and 
clustered QAPB binding was observed on the cell membrane of the EC.
20 um
Figure 7.1. 2D image of EC in the WT mouse: EC attached to the folds in the internal elastic
lamina and smooth muscle cells within the bands of elastic lamina. (QAPB binding in green;
Syto 61 binding in red).
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Figure 7.2. 3D reconstruction of EC in the WT mouse; EC attached to the folds in the internal 
elastic lamina. (QAPB binding in green; Syto 61 binding in red).
7.3.1.2. aiB"KO
The nucleus of the EC in the carotid artery was stained with Syto 61 (Figure 7.3 and 7.4). 
EC were visualised on the surface of the internal elastic lamina as well as in the grooves 
formed by the folded internal elastic lamina. Evidence of co-staining with QAPB was 
observed on the cells stained with Syto 61. QAPB binding was observed on cells on the 
endothelium. Evidence of both diffuse and clustered QAPB binding was identified on the 
cell surface.
207
Figure 7.3. 2D image of EC in the aiB-KO; EC attached to the folds in the internal elastic 
lamina and smooth muscle cells within the bands of elastic lamina. (QAPB binding in 
green; Syto 61 binding in red).
Figure 7.4. 3D reconstruction of EC in the aiB-KO: EC attached to the folds in the internal
elastic lamina. (QAPB binding in green; Syto 61 binding in red).
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7.3.1.3. aiD“KO
Syto 61 bound to the nucleus of the EC in the carotid artery and enabled the location of 
individual cells to be revealed in the aio-KO. EC were attached to the internal elastic 
lamina surface and within the grooves formed by the folds in the lamina (Figure 7.5 and 
7.6). QAPB binding was observed on the EC in the aio-KO. Diffuse binding to the cell 
surface was visualised frequently, while punctate binding was observed on the cell surface 
occasionally.
Figure 7.5. 2D image of EC in the am-KO : EC attached to the folds in the internal elastic 
lamina and smooth muscle cells within the bands of elastic lamina. (QAPB binding in 
green; Syto 61 binding in red).
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Figure 7.6. 3D reconstruction of EC in the am-KO: EC attached to the folds in the internal 
elastic lamina. (QAPB binding in green; Syto 61 binding in red).
7 . 3 . 1 . 4 .  a iB /D " K O
In the aiB/D-KO the nucleus of the cells on the endothelium of the carotid artery was 
stained with Syto 61. EC were identified attached to the internal elastic lamina (Figure
7.8) including between the grooves created by the folds in the internal elastic lamina 
(Figure 7.7). Both diffuse and clustered QAPB binding was identified on the surface of the 
EC.
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Figure 7.7. 2D image of EC in the oi am-KO: EC attached to the foids in the internai eiaetic iamina and smooth muscle ceiia within the bands of elastic lamina. (QAPB binding in green; Syto 61 binding in red).
Figure 7.8. 30 reconstruction of EC in the aiam-KO: EC attached to the folds in the internal
elastic iamina. (QAPB binding in green; Syto 61 binding in red).
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7.3.2. Comparison of QAPB and Syto 61 binding in the wild type 
and knockout mice
In the WT mouse the mean number of EC showing QAPB binding was significantly lower 
than the total number of EC identified by nuclear staining (Table 7.1). The number of EC 
showing QAPB binding was 80.1% of the total number of EC.
In the am-KO the apparent reduction in the number of EC showing QAPB binding did not 
reach significance (Table 7.1). On average 55.8% of the total number of EC were stained 
with QAPB.
In the aiD-KO the number of EC identified with QAPB binding was significantly lower 
than the total number of EC identified by Syto 61 binding (Table 7.1). QAPB bound to 
68.9% of the total number of EC.
In the aiB/D-KO the apparent reduction in the number of EC with QAPB binding compared 
to the number of EC with Syto 61 binding did not reach significance (Table 7.1). QAPB 
bound to 46.0% of the total number of EC.
I
The number of EC with QAPB binding was highest in the WT mouse and the am -K O , 
which were not significantly different (Table 7.1). The number of EC with QAPB binding 
in both the am -K O  and am /o-K O  were significantly lower than the WT mouse.
Table 7.1, Comparison of number of EC bound with QAPB in the WT and knockout mice.
Mouse
strain
n Mean No. EC stained 
with QAPB
Mean No. EC 
stained with Syto 
61
% of EC stained 
with QAPB
WT
mouse
8 11.5±0.64 14.7±0.89" 80.1±2.34
am-KO 7 5.2±1.90-""‘ 9.1±0.98'" 55.8±18.4^^
am-KO 8 9.2±1.14- 13.6±1.43' 68.9i4.6M
CtlB/D"KO 8 7.0±1.73* 16.3±4.63^ 46.0±8.79"^*^
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7.3.3. Effect o f subtype selective antagonists in the WT mouse
In the absence of a subtype selective antagonist QAPB binding to EC was observed as 
described in section 7.3.2. The number of EC stained with QAPB was significantly lower 
than EC stained with Syto 61 (Table 7.2).
In the presence of prazosin 0.1 \xM, QAPB binding was abolished (Figui'e 7.9) with the 
exception of one experiment where QAPB binding to a limited number EC was observed. 
QAPB binding to EC in the presence of prazosin was significantly lower than the total 
number of EC identified by Syto 61 (Table 7.2). 14.3% of the total number of EC was 
stained with QAPB in the presence of prazosin.
QAPB binding to EC was obseiwed in the presence of rauwolscine 0.1 pM (Figure 7.9). 
The number o f EC with QAPB binding was not significantly different to the total number 
of EC observed with Syto 61 (Table 7.2). 86.9% of the total number of EC was stained 
with QAPB in the presence of rauwolscine.
A significant reduction in EC stained with QAPB was observed in the presence o f BMY 
7378 0.1 pM compared to EC identified by Syto 61 binding (Figure 7.9; Table 7.2). In the 
presence of BMY 7378 24.3% of the total number of EC were stained with QAPB.
In the presence of R SI00 329, QAPB binding to EC was observed but was limited (Figure
7.9). The number of EC cells identified by QAPB binding was not significantly different 
to the total number of EC identified by Syto 61 staining (Table 7.2). With R SI00 329 
62.0% of the total number of EC was stained with QAPB.
The combination o f BMY 7378 and RSI 00 329 markedly reduced the EC that were bound 
with QAPB compared to the number of EC identified with Syto 61 (Figure 7.9; Table 7.2). 
In the presence of both BMY 7378 and R SI00 329 24.4% of the total number of EC was 
stained with QAPB.
K.■ji
I
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Table 7.2. Number of EC bound with QAPB in the presence of subtype selective antagonists 
in the WT mouse.
n Mean No. EC stained 
with QAPB.
Mean No. EC stained 
with Syto 61
% of total EC
Control 8 11.5±0.64 14.7=1=0.89** 80.1=1=2.33
Prazosin 4 1.8±1.05*^^ 14.2±2.80'* 14.3±7.39
Rauwolscine 4 14.5^=1.61" 17.0=1=2.00'" 86.9±3.97
BMY 7378 4 1.5=1=0.50^^^ 6.0=1=1.00'' 24.3i=4.30
RSlOO 329 4 9.7=1=1.87" 15.8=1=2.89^ 62.0=1=7.79
BMY 7378 + RSlOO 329 4 3.2=hl.01^^^
12.9±1.36'"" 24.4±7.57
^p>0.05; **p<0.01; ***p<0.001 compared to EC stained with QAPB (Student’s t-test). "p>0.05; 
*^*p<0.001 compared to control (one-way ANOVA, Bonferroni’s post test).
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Control Prazosin
Rauwolscine BMY7378
RS100329 BMY7378 + RS100329
Figure 7.9. WT mouse: Effect of subtype selective antagonists on number of EC stained with QAPB (green) compared to the number of EC stained with Syto 61 (red).
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7.3.4. Comparison of effect of subtype selective antagonists in 
wild type and knockout mice
7.3.4.1. Prazosin
QAPB binding to EC was frequently abolished by prazosin 0.1 pM in all strains of mice 
(Figure 7.10). However, in some experiments isolated EC with QAPB staining were 
observed in the presence of prazosin (Table 7.3). In the WT mouse the number of EC 
showing QAPB binding was significantly reduced to 14.7% in the presence of prazosin. In 
the ociB-KO the number of EC stained with QAPB was significantly reduced by prazosin, 
which is 9.8% of the number of EC stained with QAPB. Prazosin significantly reduced the 
number of EC with QAPB binding from in the am-KO, which was 28.1% of the number of 
EC stained with QAPB. In the am/o-KO no QAPB binding to EC was detected in the 
presence of prazosin.
Table 7.3. Comparison of number of EC bound with QAPB in the presence of prazosin in the 
wild type and knockout mice.
Mouse
strain
n Mean No. EC Mean No. EC in 
presence prazosin
% EC in presence 
prazosin
WT mouse 4 12.5il.27 1.8±1.05'" 14.7
am-KO 4 6.1±1.05 0.6±0.6'" 9.8
aiD“KO 4 8.4±0.44 2.4±0.96''' 28.1
aiB/D-KO 4 4.2±0.79 O.OiO.OO 0.0
"p<0.001 compared to EC stained with QAPB (Student’s t-test).
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WT mouse
(Xid“KO
(Xib~KO
aiB/D"KO
Figure 7.10. Comparison the WT and knockout mice: number of EC bound with QAPB in the presence of prazosin.
7.3.4.2. Rauwolscine
In all four stains o f mouse the QAPB binding to EC was observed in the presence of 
rauwolscine 0.1 pM with evidence of both diffuse and punctate binding (Figure 7.11). In 
the WT mouse the number of EC stained with QAPB was not significantly different in the 
absence or presence of rauwolscine 0.1 pM. 93.5% of the number of EC stained with 
QAPB was identified in the presence of rauwolscine (Table 7.4). In the am-KO, in the 
presence of rauwolscine 127.6% of the EC were stained with QAPB, which was not 
significantly different. The number of EC showing QAPB binding was not significantly 
different in the presence of rauwolscine in the aio-KG with 83.2% of the number of EC 
stained with QAPB. In the am/D-KO, 167.0% of the number of EC showing QAPB 
binding was identified in the presence of rauwolscine in the presence of rauwolscine 
compared to QAPB alone, but this was not significantly different.
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Table 7.4. Comparison of the WT and knockout mice: number of EC bound with QAPB in the presence of rauwolscine.
Mouse
strain
Mean No. EC Mean No. EC in 
presence rauwolscine
% EC in presence 
rauwolscine
WT mouse 12.5±1.27 ll.6±l,24* 93.5
6.1±1.05 l . i ± \ . l T 127.6
ctiD“KO 8.4±0.44 7.0±1.72"‘ 83.2
0tlB/I3-KO 4.2±0.79 7.0±2.28"‘ 167.0
+ p>0.05 compared to EC stained with QAPB (Student’s t-test). 
WT mouse aiB-KO
otio'KO aiB/D"KO
Figure 7.11. Comparison of the WT and knockout mice: number of EC bound with QAPB in the presence of rauwolscine.
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7.3.4.3. BMY 7378
In both the WT mouse and am-KO a reduction in EC stained with QAPB was visible in 
the presence of BMY 7378 0.1 pM (Figure 7.12). Cells which had been stained showed 
diffuse QAPB binding to the cell surface but there was less evidence of punctate binding. 
BMY 7378 significantly reduced the number of EC stained with QAPB to 38.6% and 
35.5% of the number of EC stained with QAPB in the WT mouse and am-KO, 
respectively (Table 7.5). In the am-KO and am/o-KO, no difference in QAPB binding to 
EC was visible in the presence of BMY 7378 0.1 pM. However, in the am-KO 
quantitative analysis revealed a small but significant reduction in the number of cells 
stained with QAPB, with 60.9% of EC showing QAPB binding with BMY 7378. In the 
am/o-KO 131.2% of EC showed QAPB binding with BMY 7378, which was not 
significantly different.
Table 7.5. Comparison of number of the WT and knockout mice: EC bound with QAPB in the 
presence of BMY 7378.
Mouse strain n Mean No. EC Mean No. EC in 
presence RMF 7378
% EC in presence 
BMY 7378
WT mouse 4 12.5rbl.27 4.8±1.93" 38.6
a m - K O 4 6.1±1.05 2.24=0.95' 35.5
a m - K O 4 8.4±0.44 5.1±1.48' 60.9
OtlB/D-KO 4 4.2±0.79 5.5±0.56’" 131.2
+p>0.05; *p<0.05; **p<0.01 compared to EC stained with QAPB (Student’s t-test).
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WT mouse aiB~KO
(Xiq-KO o iib /d 'K O
Figure 7.12. Comparison of the WT and knockout mice: number of EC bound with QAPB in the presence of BMY 7378.
7.3.4.4. RS100 329
In the presence of RSlOO 329, QAPB binding to EC was observed but appeared to be 
reduced in the WT mouse, am-KO and aio-KG (Figure 7.13). QAPB binding to EC was 
largely diffuse but evidence of clustered binding was observed in some cells. In the WT 
mouse the number of EC showing QAPB binding was significantly in the presence of 
RSlOO 329, with 56.8% of EC showing QAPB binding with RSlOO 329 (Table 7.6). In the 
aiB-KO 32.7% of EC showed QAPB, which was significantly reduced. In the am-KO 
33.7% of EC stained with QAPB in the presence of RSlOO 329, which was significantly 
reduced. In the am /o -K O  QAPB binding to EC was not observed in the presence of RSlOO 
329, with the exception of one experiment in which isolated EC were observed. The 
number of EC showing QAPB binding was significantly reduced in the presence of RSlOO 
329, with 19.9% of EC showing QAPB binding with RSlOO 329.
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Table 7.6. Comparison of the WT and knockout mice: number of EC bound with QAPB in the 
presence of RS100 329.
Mouse strain Mean No. EC Mean No. EC in 
presence RSlOO 329
% EC in presence 
RSlOO 329
WT mouse 12.5±1.27 7.1±1.03' 56.8
(Xib"KO 6.1±1.05 2.0±0.62" 32.7
aiD"KO 8.4±0.44 2.8±0.70"' 33.7
ctiB/0"KO 4.2±0.79 0.83±0.40" 19.9
"p<0.05; **p<0.01; ***p<0.001 compared to EC stained with QAPB (Student’s t-test). 
WT mouse am-KO
aiD“KO OtlB/D'KO
Figure 7.13. Comparison of WT and knockout mice: number of EC bound with QAPB in the 
presence of RSlOO 329.
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7.3.4.5. BMY 7378 and RS100 329 combination
In the WT mouse and am-KO some evidence of QAPB binding to EC was visible in the 
presence of the combination of BMY 7378 and RSlOO 329 (Figure 7.14). The number of 
EC stained with QAPB was significantly reduced by BMY 7378 and RSlOO 329, with 
35.3% and 44.0% of EC showing QAPB binding for the WT mouse and am-KO, 
respectively (Table 7.7). In the am-KO and am/o-KO there was no evidence of QAPB 
binding to EC in the presence of the combination of BMY 7378 and RSlOO 329.
■
Table7.7. Comparison of the WT and knockout mice: number of EC bound with QAPB in the 
presence of a combination of BMY 7378 and RS100 329.
Mouse strain n Mean No. EC Mean No. EC in 
presence BMY 
7378 + RSlOO 329
% EC in presence 
BMY 7378 + RSlOO 
329
WT mouse 4 12.54=1.27 4.44=1.10'" 35.3
aiB-KO 4 6.1±1.05 0.04=0.00 0.0
am-KO 4 8.44=0.44 3.74=1.47" 44.0
aiB/D-KO 4 4.24=0.79 0.04=0.00 0.0
'’p<0.01; ***p<0.001 compared to EC stained with QAPB (Student’s t-test).
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WT mouse a iB ’KO
otiD”KO 0 tlB /D "K O
Figure 7.14. Comparison of the WT and knockout mice: number of EC bound with QAPB in 
the presence of BMY 7378 and RSlOO 329.
7.4. Discussion
7.4.1. ai-AR  subtypes on the endothelium
The nuclear membrane dye Syto 61 (1 pM) was used in the present study to confirm that 
the EC were preserved during slide mounting and to identify the position and shape of the 
EC. EC were attached to the surface of the internal elastic lamina, including within the 
grooves formed by the folds in the internal elastic lamina. In all four mouse strains, there 
was clear evidence that the position of the cells bound with QAPB, a fluorescent ai-AR  
ligand, matched that o f the EC identified by Syto 61. The binding of QAPB to cells on the 
endothelium indicated that ai-ARs were present in all four strains of mouse. QAPB bound 
to EC in both a diffuse and punctate manner, which was evident in all four mice strains.
The relative number of EC stained with QAPB was examined quantitatively. Firstly, the 
proportion of EC stained with QAPB relative to Syto 61 was examined in the WT mouse 
and knockouts. The number of EC bound with QAPB was 80.1%, 55.8%, 68.9% and
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46.0% of the total number of EC stained with Syto 61, for the WT mouse, am-KO, aio- 
KO and aiB/o-KO, respectively. This indicates that ai-ARs are not detectable in all EC. 
The reduction in the proportion of EC binding QAPB in the knockouts compared to the 
WT mouse is consistent with the loss of the entire ai-A R population fi'om a proportion of 
EC. Comparison of the number of EC identified with QAPB between the WT mouse and 
knockouts revealed a significant reduction in both the ais-KO and aiB/o-KO. This raises 
the possibility that endothelial ais-ARs are present in the WT mouse.
Secondly, in the WT mouse the effect of subtype selective antagonists on the number of 
endothelial apA Rs compared to the total number of EC (Syto 61 binding) was assessed. 
In the presence of prazosin (0.1 pM, nonselective apA R  antagonist) QAPB binding was 
detected in only 14.3% of the total number of EC. This marked reduction suggests that 
QAPB was binding apA Rs. The residual binding observed in some experiments may be 
due to QAPB binding ai-ARs. Particularly in light of the evidence that az-ARs exist on 
the endothelium of the mouse carotid artery (Malekzadeh Shafaroudi, 2005). However, in 
the present study rauwolscine (nonselective 0C2-AR antagonist) did not reduce the number 
of EC with QAPB binding, which opposes QAPB binding a 2-ARs at this concentration. 
The possibility o f QAPB binding to a 2-ARs was an important consideration as, in addition 
to showing high affinity at apARs, QAPB has been shown to have moderate affinity for 
0C2-ARS (McGrath & Daly, 2005). It should be noted that Malekzadeh et al. (2005) used 
QAPB 0.1 pM in the presence of apA R  subtype selective antagonists to study a 2-ARs on 
the endothelium of the mouse aorta. In contrast to the present study, QAPB binding to EC 
was absent in the presence of rauwolscine. This highlights a difference in the endothelial 
cell population between the carotid artery and aorta.
Out of the total number of EC, only 24.3% were stained with QAPB in the presence of 
BMY 7378 (0.1 pM), consistent with QAPB binding to endothelial aio-ARs being 
inhibited, or at least reduced to a level that was not detectable, hi the presence of R SI00 
329 the number of EC stained with QAPB was 62.0% of the total number of EC. This 
suggests that aiA-ARs may be present on the endothelium of the WT mouse. The 
combination of BMY 7378 and R SI00 329 reduced QAPB binding to only 24.4% of EC 
but QAPB binding was not completely abolished suggesting that endothelial am-ARs may 
exist. Thus, all tlu’ee apA R  subtypes may be present on the endothelium in the WT 
mouse.
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The final part of the present study compared the effect of subtype selective antagonists on 
QAPB binding in the wild type and knockout mice. In the knockouts, QAPB binding to 
EC was almost completely abolished by prazosin confirming that QAPB was binding a p  
ARs, consistent with the WT mouse. This was further supported by the failure of 
rauwolscine to displace QAPB in the knockouts, which suggests that QAPB was not 
binding ai-ARs on the endothelium at this concentiation.
Endothelial am-ARs were shown to exist in the am-KO as only 35.5% of EC showed 
QAPB binding in the presence of BMY 7378, which was comparable to the WT mouse. 
With RSI00 329, the number of EC with QAPB binding was 32.7%, 33.7% and 19.9% of 
the total number of apARs for the am-KO, am-KO and am/o-KO, respectively. This 
suggests that the aiA-AR is present on the endothelium of the knockouts, which supports 
the evidence in the WT mouse. There is also evidence to suggest that endothelial am-AR 
exist: in the presence of the combination of BMY 7378 and RSI00 329 EC were identified 
in the WT mouse (35.3%) but not the am-KO (0%). Comparison of the QAPB binding in 
the presence of subtype selective antagonists WT mouse and knockouts revealed that all 
three apAR subtypes appear to exist on the endothelium of the mouse carotid artery.
7.4.2. Physiological significance
The predominance of the apAR-mediated conhactile response in the mouse carotid artery 
means that any attempt to functionally investigate the potential of endothelial apARs 
proves difficult. However, evidence of an apAR stimulated release of NO has been 
shown in Chapter Five. As previously discussed it was unclear whether the release of NO 
was due to the direct stimulation of endothelial apARs or indirectly via the stimulation of 
apARs in the smooth muscle layers. The present study has shown that apARs do exist on 
endothelium of the mouse carotid artery. Therefore, it is likely that NO was released in 
response to the direct stimulation of endothelial apARs. This hypothesis is strengthened 
by other studies which have proposed that the activation of endothelial apARs induces NO 
release (Tuttle & Falcone, 2001;Zschauer et al, 1997).
7.4.3. Conclusions
apARs were identified on the endothelium of the WT mouse and knockout mice using 
visualisation techniques. The proportion of EC with apARs was reduced in the knockout 
mice compared to the WT mouse. All three apAR subtypes were present on the 
endothelium of the WT mouse.
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Chapter Eight 
General Discussion
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The main objectives of the experiments described in the previous chapters were:
(i). To establish whether there is an aiA-AR-mediated contmctile response in the 
carotid artery of the WT mouse and also assess whether there is evidence of a 
functional am-AR. This was achieved by using the aiA-AR selective agonist A- 
61603 and range subtype selective antagonists, in addition to the ai-AR non­
selective agonist phenylephrine.
(ii). To determine whether an aiA-AR-mediated contractile response could be identified 
in the carotid artery of apAR knockout mice and, therefore, aid the 
characterisation of the apAR response in the WT mouse. This was achieved using 
a similar approach to (i) to isolate the ajA-AR in the am-KO, am-KO and am/o- 
KO.
(hi). To investigate the role of NO on the vascular response to phenylephrine and A-
61603 in the mouse carotid artery. This was achieved by preventing NO release 
using the NOS inhibitor L-NAME.
(iv). To characterise the apAR subtypes present in the media of the carotid artery by 
using subtype selective antagonists to compete with the fluorescent ligand QAPB in 
the WT mouse and apAR knockout mice. In doing so, the distribution of the aj- 
AR subtypes in SMC was examined.
(v). To establish whether apARs exist on the endothelium of the mouse carotid arteiy 
and to determine the apAR subtypes present in EC. This was achieved using the 
fluorescent ligand QAPB in the WT mouse and apAR knockout mice, as well as 
subtype selective antagonists.
In this final chapter, the findings and general conclusions of the studies described in this
thesis are discussed.
8.1. ai-AR function
The functional studies described in Chapters Three and Four investigated the contribution
of the aiA-AR and am-AR to the apAR-mediated contractile response in the mouse
carotid artery, using a combination of pharmacological analysis and knockout technology.
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This method enabled an aiA-AR-mediated contractile response to be identified in the 
mouse carotid artery for the first time.
8.1.1. Phenylephrine and A~61603 seiectivity
hi general, the aiA-AR selective agonist, A-61603, has been used to study vessels where 
the aiA-AR is the predominant subtype, hi Chapters Tlu'ee and Four, A-61603 was used to 
isolate a minor am-AR response in an artery in which the am-AR is the main mediator of 
contraction: the mouse carotid artery. The agonist responses in the aiA/B-KO and am/o- 
KO provided good evidence that A-61603 is selective for the am-AR over the am-AR and 
am-AR, and that phenylephiine has selectivity for the am -AR over the am-AR, in 
agreement with the findings of Knepper and colleagues (Knepper SM et a l ,  1995;Meyer et 
al,  1996). However, it was also demonstrated that the A-61603-induced response 
consisted of two components: an am-AR-mediated component and an am-AR-mediated 
component, hi the murine thoracic aorta, A-61603 appeared to have an action on the am - 
AR on the basis that an ai-AR-mediated response was observed in the am-KO but not the 
am/D-KO. Thus, the findings presented in Chapter Four and those reported by Ali (2004) 
provide evidence indicative of an am-AR-mediated component to the A-61603-induced 
response.
8.1.2. am-AR in the mouse carotid artery
The findings described in Chapters Tliree and Four confirmed previous reports that the 
am-AR is the predominant contractile ai-A R in the mouse carotid aitery (Deighan C, 
2002;Deighan et a l ,  2005;Daly et a l ,  2002a). The predominant contribution of the am - 
AR in the WT mouse was illustrated by the limited phenylepluine-induced response in the 
am-KO and am/o-KO. In the earlier study of the mouse carotid artery by Deighan 
(2002;Deighan et a l ,  2005), a pKe of 8.3 was produced for BMY 7378 against the 
phenylephiine-induced response, which was indicative of an am-AR-mediated response in 
the WT mouse, hiterestingly, there was evidence of ai-A R heterogeneity in the WT 
mouse (Deighan C, 2002;Deighan et a l ,  2005). In the present study, the higher pKe of 9.1 
obtained for BMY 7378 against phenyleplmne, in preliminary results from the aiA/B-KO, 
appears to be representative of a ‘pure’ am-AR population. This agrees with BMY 7378 
acting on a low affinity site, in addition to the am-AR, in the WT mouse. However, 
Deighan (2002;Deighan et a l ,  2005) reported that in the am-KO an even higher pKb of
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9.6 was produced for BMY 7378 against phenylephrine. It is unclear why BMY 7378 is 
more potent in the am-KO than the aiAm-KO, though further experiments are required in 
the aiA/B-KO before any firm eonelusions can be drawn. The biphasic A-61603 CRC 
observed in the presence of BMY 7378 lOnM in the WT mouse suggested that the A- 
61603 response was mediated by two ai-AR subtypes. The pKe of 8.3 was consistent with 
published potency values for the am-AR and confirms the involvement of this subtype 
(see Chapter One). Together, these findings provide good evidence that the am-AR is the 
predominant ai-AR subtype and that the am-AR plus either the a^-A R  or am-AR 
mediate the contractile response to phenylephrine and A-61603 in the carotid artery of the 
WT mouse.
These conclusions fiom both studies in the murine carotid artery are reinforced by studies 
in other mouse arteries. For instance, in a previous study in the thoracic aorta, the lack of 
contraction to both phenylephrine and A-61603 in the am/o-KO argues against an am-AR- 
mediated response (Ali, 2004). Furtheimore, the high potency and efficacy of 
phenylephrine, but not A-61603, in the am-KO is consistent with phenylephrine acting on 
the am-AR, as well as the am-AR in the thoracic aorta. The absence of am-AR potency 
for A-61603 in the thoracic aorta suggests that the two components observed in the present 
study arise from the am-AR and the am-AR.
8.1.3. aiA-AR in the mouse carotid artery
Both 5-methylurapidil and RSI00 329 were used to distinguish the am-AR from the am- 
AR and the am-AR. The contractile role of the am-AR was clear in the am-KO and 
am/D-KO, in which both A-61603 and the am-AR selective antagonists were potent. In 
the WT mouse and am-KO, an am-AR-mediated response was not identified from the 
phenylephrine-induced response (Deighan C, 2002;Deighan et al, 2005); but 5- 
methylurapidil and RSI00 329 showed increased potency against A-61603. Thus, there is 
evidence to suggest a contractile role for the am-AR in these mice, although it appears to 
be masked by the predominant am-AR. In the am-KO, the reduced potency of RSI00 329 
against phenylephrine compared to A-61603 may be indicative of an am-AR component to 
the phenyleplirine-induced response. However, the use of the am-AR selective 
antagonists confirmed that the am-AR, but not the am-AR, was mediating the A-61603 
response.
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In a recent study of the mouse first order mesenteric artery, in which the am-AR is the 
predominant subtype, a biphasic phenylephrine CRC was obseiwed in the presence of 5- 
methylurapidil (McBride et a l  Submitted for publication). The 5-methylurapidil-resistant 
component to the response was lost in the presence of a combination of 5-methylurapidil 
and BMY 7378. This led to the conclusion that in addition to the predominant am-AR, the 
am-AR had a small contractile role in the mesenteric artery. Thus, evidence exists of a 
vessel, in which contraction is predominantly am-AR, having a contribution from the am - 
AR and now the present study has provided evidence of a vessel, which is predominantly 
am-AR, having a contribution from the am-AR.
8.1 A. aiB-AR in the mouse carotid artery
In the absence of any am-AR selective antagonists, there was no direct evidence of an am- 
AR-mediated response in the WT mouse. However, the am-KO could be used as a 
substitute for am-AR selective antagonists. The findings presented in Chapters Tluee and 
Four suggested that the am-AR may have a minor contractile role in mouse carotid artery, 
as proposed by Daly et al. (2002a). The existence of a small am-AR component to the 
phenylephrine-induced response was also suggested in the previous study in the mouse 
carotid artery (Deighan C, 2002;Deighan et a l,  2005), in which BMY 7378 had higher 
affinity in the am-KO than the WT mouse. An am-AR response would account for the 
difference in the phenylephrine-induced response between the am-KO and am/o-KO, 
identified in Chapter Four of this thesis. Comparison of the agonist responses in the 
knockout mice with the WT mouse suggested that the phenylephrine-induced response 
may be mediated by all three ai-A R subtypes. However, comparison of the A-61603- 
induced response in the aiA/B-KO and the am/o-KO with the WT mouse suggested that the 
aiA-AR and the am-AR, but not the am-AR, mediate the A-61603 response in the WT 
mouse. Furthermore, the visualisation study in Chapter Six provided evidence that the 
am-AR was present in the media of the mouse carotid artery, suggesting that an am-AR- 
mediated response is plausible. The findings presented in this thesis and those reported by 
Deighan and colleagues (Deighan C, 2002;Deighan et a l ,  2005;Daly et a l,  2002a) are in 
agreement that the am-AR does have a small contractile role in the mouse carotid artery.
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8.1.5. Comparison with the aorta
Both the carotid artery and thoracic aorta are conductance arteries and the am-AR is the 
predominant ai-A R subtype (Daly et al., 2002a;Ali, 2004;Yamamoto & Koike, 
2001b;Tanoue et a l ,  2002c;Tanaka et a l ,  2004;Hosoda et a l ,  2005a;Deighan C, 
2002;Deighan et a l ,  2005). The balance of evidence suggests that the mouse thoracic 
aorta has a contribution from the am-AR, but there is a lack o f evidence for a contractile 
aiA-AR, in contrast to the evidence presented in Chapters Three and Four in the mouse 
carotid artery. For instance, no contractile response to phenylephiine or A-61603 was 
obseiwed in the thoracic aorta of the am/o-KO (Ali, 2004). Furtheimore, receptor 
protection studies failed to find any evidence of either an aiA-AR or am-AR-mediated 
response (Ali, 2004). This suggests that an am-AR-mediated contractile response does not 
exist in the thoraeic aorta of the WT mouse. To date, however, two studies have reported 
that the am-AR has a functional role in the thoracic aorta in knockout mice. Firstly, 
Hosoda et al. (2005b) reported an ai-AR-mediated contractile response to noradrenaline in 
the aorta of the am/o-KO, based on the high potency of prazosin. The noradrenaline- 
induced contraction was very small (approximately 16% of the WT mouse response) and 
significantly less potent in comparison to that obtained in the WT mouse and single 
knockouts. Thus, the am/o-KO. infers that the contribution of the am-AR in the mouse 
thoracic aorta is very limited (Hosoda et al., 2005b) but may exist in the aorta of the WT 
mouse. This study in the aorta of the am/o-KO shares similarities with the findings in 
Chapter Four in the carotid artery of the am/o-KO. However, unlike the carotid artery, 
there is no evidence of an am-AR-mediated response in the WT mouse thoracic aorta. 
Secondly, Lazaro-Suarez et al. (2006) reported an am-AR-mediated response in the aorta 
of the am-KO. It should be noted that the conclusions of this receptor protection study 
were reached using the am-AR antagonist, A H llllO A , and the alkylating agent, 
chloroethylclonidine, and the reliability of both has been questioned (Eltze et a l ,  
2001;Hirasawa et a l ,  1997). Thus, the evidence to date suggesting that the am -AR has a 
role in the thoracic aorta of the mouse is less compelling than in the car otid artery.
Despite the contraction of both the thoracic aorta and carotid artery being predominantly 
am-AR-mediated, an am-AR-mediated response exists in the carotid artery, but is less 
likely to be present in the thoracic aoida. The ai-AR subtypes vary in the abdominal aorta: 
like the thoracic aortayhe upper abdominal aorta is predominantly am-AR-mediated, but 
contraction in the lower abdominal aorta is predominantly am-AR-mediated (Yamamoto
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& Koike, 2001a). Thus, differences between the minor subtypes in the thoracic aorta and 
the carotid artery are entirely plausible. Furthermore, differences exist in the ai-AR 
subtypes present in the branches of the aorta. For instance, this study has shown that the 
contraction of the carotid artery is predominantly aiD-AR-mediated, with a contribution 
from the am-AR, while in the iliac arteiy, a branch of the lower abdominal aorta, the am- 
AR is predominant (Shibano et a l, 2002). It is apparent that as the distance from the aortic 
arch increases the predominance of the aio-AR decreases and the predominance of the 
am-AR increases.
It is clear from the studies of conductance arteries that the characterisation of ai-AR 
subtypes other than the dominant am-AR is difficult. The utilisation of ai-AR knockout 
mice clearly aids the study of the ai-AR subtypes, particularly by enabling the contractile 
response to be studied in the absence of the dominant contractile receptor. Thus, the minor 
subtypes can be characterised without the dominant ai-AR subtype masking their function. 
The findings of Chapters Three and Four demonsfrate that it is not accurate to assign one 
ai-AR subtype to a specific vessel. Furthemiore, ai-AR heterogeneity is an important 
consideration when assessing the selectivity of ai-AR compounds, and would be of 
particular importance when testing potential clinical drugs.
8.2. Effect of NO
In Chapter Five, the final functional study examined the effect of NO on the contraction of 
mouse carotid artery and demonstrated that the a  i-AR-mediated contractile response was 
suppressed by NO. This was evident from the increase in conhaction and/or sensitivity to 
both phenylephrine and A-61603 in the presence of L-NAME.
There was no evidence that NO was being released spontaneously. For instance, it was 
demonstrated that without prior agonist stimulation basal tone was unaffected. At resting 
tone L-NAME has been shown to produce a contraction when spontaneous NO release is 
occurring (Shimokawa H et a l, 1996), which suggests that this was not the case in the 
mouse carotid arteiy. Furtheimore, the contractile response to 5-HT was unaffected by L- 
NAME. This is different to findings in the mouse thoracic aorta in which the 5-HT 
contractile response was attenuated by L-NAME in a concentration-independent manner 
and suggested that NO was released spontaneously (Ali, 2004). Thus, there was no 
positive evidence of spontaneous NO release in the mouse carotid artery.
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W ith prior stimulation to either phenylephrine or A-61603, L-NAME caused an increase in 
basal tone. In addition, it was evident from the phenylephrine and A-61603 CRCs in the 
presence of L-NAME that NO appeared to have a greater effect with increasing agonist 
concentrations. Thus, these findings suggest that NO was released in response to ai-AR 
stimulation, and are in agi’eement with those in the rat carotid artery (de Andrade C et a l,  
2006) and mouse thoracic aorta (Tabernero et a l,  1999;Kaneko & Sunano, 1993;Gurdal et 
a l ,  2005), in which NO release has been shown to he stimulated by phenylephrine.
It was not clear whether NO was released thi’ough the activation of smooth muscle cells 
and stimulation of EC via myo-endothelial junctions, or the direct activation of endothelial 
ai-ARs. To date, there is evidence of myo-endothelial junctions in small arteries such as 
the mesenteric artery of the rat (Dora K, 2001;Gonzalez Unpublished obseiwations), 
though they have been identified in the rabbit carotid artery (Spagnoli et a l ,  1982). 
However, there is no positive evidence that these structures exist in the carotid artery of 
other species or other conductance arteries. Nevertheless, phenylephrine-induced 
relaxatory responses were recently reported for the first time (Filippi et a l ,  2001) and have 
now also been obseiwed in the rat carotid artery (de Andrade C et a l ,  2006). The above 
functional evidence of ai-ARs on the endothelium, together with the identification of 
endothelial ai-ARs in the mouse carotid artery in Chapter Seven, suggests that NO release 
through the direct stimulation of ai-ARs on the endothelium is entirely plausible.
8.3. ai-AR distribution
The visualisation studies in Chapters Six and Seven examined the distribution of ai-AR 
subtypes in the media and SMC of the mouse carotid artery. These studies were intended 
to be analysed in conjunction with the findings of the ftmctional data in Chapters Thi'ee to 
Five.
8.3.1. Smooth muscle cells
In Chapter Six,the distribution of the ai-AR subtypes in the SMC were studied for the first 
time in the mouse carotid artery. A protocol was developed to enable the distribution of 
ai-ARs in the media o f the carotid artery to be examined at the tissue and subcellular level. 
Intact carotid arteries were incubated with QAPB 0.1 pM for 120 minutes at room 
temperature. Ideally, an even lower concentration of QAPB would be preferred as used in 
isolated cells (Pediani et a l ,  2005), but 0.1 pM was required for suitable definition of the
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SMC in the intact tissue. Incubations were performed at room temperature rather than 
physiological temperature due to pH problems associated with the PSS. A buffer that was 
not dependent on pH, such as HEPES, could have enabled a more physiological incubation 
temperature, but PSS was selected for use to complement the functional experiments.
SMC in both the WT mouse and am-KO were evenly dishibuted and clearly defined, but 
analysis revealed that the total ai-AR population in the am-KO was reduced. In the am- 
KO and am/o-KO, QAPB binding was reduced suggesting that a high proportion of the ai- 
AR population is am-AR. The detection of QAPB binding in the am/o-KO suggested the 
existence of the aiA-AR. Comparison of QAPB fluorescence in the am-KO and am/o-KO 
with the WT mouse indicated that the am-AR was present in the media of the carotid 
artery. This correlates with the functional data, in which a small am-AR-mediated 
contraction was apparent.
Non-fluorescent antagonists were used to compete for QAPB binding sites to obtain further 
information about the a i-A R  subtypes present in the media. The marked reduction or 
abolition of QAPB by the aiA-AR antagonist indicated that aiA-ARs were present in all 
mouse strains. This contrasts with a study in the aiA-KO, in which p-galactosidase 
staining was used to indicate aiA-AR expression, and was absent in the mouse carotid 
artery (Rokosh & Simpson, 2002). The inconsistencies in aiA-AR expression between the 
two studies may be due to the different methods employed. In the present study, the 
presence of the aiA-AR in the murine carotid artery was validated by the identification of 
the a  1 A -AR-mediated response in the WT mouse, am -K O , am -K O  and am /o-KO. The 
QAPB binding distiibution in the aiA-KO would provide valuable information to further 
investigate the presence of the aiA-AR in the carotid artery. The presence of the am-AR 
was confirmed in the WT mouse and am -K O  by the reduction in QAPB binding with the 
am -A R  selective antagonist. By blocking both the a ^ - A R  and am -A R  the presence of 
the am -A R  was confiimed, since QAPB binding was still detectable in the WT mouse but 
not the am -K O . Thus, it is evident that all tliree a i-A R  subtypes are present in the media 
of the carotid artery. The findings of the distribution study alone cannot be taken as 
evidence that the a i-A R s are functional, but the presence of the am -A R , am -A R  and a m - 
AR supports the functional data in Chapters Three and Four.
Consistent with previous studies in isolated cells (Daly et a l, 1998;McGrath et a l, 
1999;Mackenzie et a l, 2000), and in SMC s in situ (McBride et al Submitted for
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publication), QAPB binding was identified on the cell surface and in punctate intracellular 
sites. The differences in the cellular distribution of QAPB between the mouse strains 
suggest that the cellular distribution of a i-A R s may differ, or, at least, that changes occur 
when an a i-A R  subtype is not present. The lack of intracellular clusters in the am -K O  
could indicate that the am-AR is predominantly located inside the cell, while the reduced 
binding on the cell surface of the am -K O  and am /o-KO could point to the main location of 
the am -A R . Similar conclusions were reached using fluorescent antibodies and GFP- 
tagged receptors in isolated cells (McCune et a l, 2000;Sugawara et a l, 2002). It is 
possible that the am-AR may have a regulatoiy role as the increase in punctate binding 
observed in the am -K O  and am /o-K O  may be due to a reduction in the transportation of 
am -A R s or am -A R s to the cell surface. Thus, in the absence of the am -A R s, the am -A R  
and am-AR are predominantly located at intracellular sites.
8.3.2. Endothelial cells
Chapter Seven investigated whether ai-ARs were present on the endothelium of the mouse 
carotid artery. QAPB binding to EC was confiimed by the use of nuclear dye Syto 61. It 
was apparent that ai-ARs were present in all four mouse strains, but ai-ARs were not 
detected in all EC identified. The inhibition of QAPB binding to EC by prazosin but not 
rauwolscine verified the presence of ai-ARs.
The proportion of EC with ai-ARs was compared between mouse shains and subtype 
selective antagonists were used to investigate the ai-AR subtypes present on the 
endothelium of the WT mouse. The reduction of EC detected in the am-KO, am-KO and 
am/D-KO is consistent with loss of the respective ai-AR populations. The presence of 
endothelial am-ARs was suggested in the WT mouse and am-KO by the inhibitory effect 
of BMY 7378. RSI00 329 resulted in a reduction in the number of EC stained with QAPB 
in all four stiains, suggesting the presence of am-AR on the endothelium. The presence of 
am-ARs was also suggested by blocking both am-ARs and am-ARs; in the WT mouse, 
but not the am-KO, QAPB binding to EC was obseived. Thus, all three ai-ARs appear to 
exist on the endothelium of the mouse carotid artery.
Direct functional evidence of ai-ARs on the endothelium has recently been reported 
(Filippi et a l, 2001;de Andrade C et a l, 2006). However, the strong a,-AR-mediated 
contractile response makes it difficult to investigate an ai-AR-mediated relaxatory
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response in arteries, like the mouse carotid artery, and may account for the limited 
evidence of endothelial ai-A R  to date. It is possible that by following the protocol of 
Filippi et al. (2001) in the perfusion myograph, functional evidence of an ai-AR-mediated 
relaxatory response could be obtained in the mouse carotid artery and wan ants 
investigation. Despite no direct functional evidence, Chapter Seven demonstrates that a \-  
ARs can be identified on the endothelium visually.
The evidence from Chapters Five and Seven collectively suggest that the direct activation 
of endothelial ai-ARs triggers the release of NO. This is a more plausible explanation for 
NO release due to the existence of ai-ARs on the endothelium of the mouse carotid artery 
and the lack o f positive evidence for the presence of myo-endothelial jimctions in this 
vessel.
8.4. Future research
Detailed pharmacological analysis is required in the carotid artery of the aiA/B~KO to 
validate the preliminary results presented in Chapter Four. In doing so, further information 
about the subtype selectivity of the ai-A R antagonists employed in this thesis would be 
obtained. In the absence of any selective am-AR antagonists, the am -K O  and am /o -K O  
provided some evidence that the am-AR has a contractile role, but the aiA/o-KO would be 
the definitive test for an am-AR-mediated response. aiA/o-KO, as well as the other double 
knockout mice, are being generated and studied in our laboratory. In addition, studying the 
QAPB binding distribution in the aiA-KO would complete the examination of the three a i- 
AR knockout mice.
8.5. General conclusions
A number of conclusions can be drawn from the studies presented in the previous chapters.
(i). An a  1 A-AR-mediated contractile response was identified for the first time in the 
carotid artery of the WT mouse.
(ii). An a  1 A-AR-mediated contractile response and an am-AR-mediated response was 
identified in the carotid artery of ai-AR knockout mice, which provided valuable 
information for the characterisation of the ai-AR response in the WT mouse. The 
identification of all three ai-A R subtypes in the WT mouse highlights that ai-AR
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heterogeneity is an important consideration when assessing the selectivity of ai-AR 
compounds.
(iii). In the mouse carotid ai'tery, phenylephrine and A-61603 induced NO release, which 
had a suppressant action on the contractile response to these ai-AR agonists.
(iv). Evidence of all tlu*ee ai-A R subtypes was observed in the media of the earotid 
ai'tery. The presence of the subtypes is consistent with their contractile roles 
identified in this vessel, though the am-AR may also have a role in the regulation 
o f the aiA-AR and am-AR.
(v). All three ai-ARs exist on the endothelium of the mouse carotid artery. This unique 
evidence suggests that the mechanism of NO release in (iii) was through the direct 
stimulation of endothelial ai-ARs.
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